ROBERTORLOWSKIROBERT ORLOWSKI9449ORLOWSKI, ROBERTProfessorprns:coAuthorOfcoauthor ofFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:similarTosimilar toprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierAddressvivo:address1address line 1vivo:addressCitycityvivo:addressPostalCodepostal codevivo:addressStatestate or provincevivo:authorInAuthorshipselected publicationsvivo:authorRankauthor rank in publicationAuthorshipDepartmentDivisionvivo:hasResearchArearesearch areasvivo:hrJobTitleHR job titleInformation Resourcevivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcevivo:mailingAddressmailing addressvivo:personInPositionpositionsPositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPerson1400 Holcombe BlvdHouston77030-4008TXAuthorship 1640502Authorship 1703371Authorship 1720821Authorship 1733821Authorship 1737641Authorship 17764511Authorship 1780797Authorship 1785757Authorship 17995627Authorship 1803767Authorship 1815896Authorship 1838107Authorship 1864415Authorship 1875179Authorship 1877148Authorship 1880354Authorship 18848417Authorship 1885939Authorship 19024523Authorship 1903444Authorship 1906292Authorship 19080115Authorship 190849Authorship 1923503Authorship 19296614Authorship 1948567Authorship 19612136150434Orlowski M, Orlowski R, Chang JC, Wilk E, Lesser MMolecular and cellular biochemistryA sensitive procedure for determination of cathepsin D: activity in alveolar and peritoneal macrophages. Mol Cell Biochem. 1984 Sep; 64(2):155-62.Mol Cell Biochem1984-09-01T00:00:001984A sensitive procedure for determination of cathepsin D: activity in alveolar and peritoneal macrophages.12127724Orlowski RZ, Baldwin ASTrends in molecular medicineNF-kappaB as a therapeutic target in cancer. Trends Mol Med. 2002 Aug; 8(8):385-9.Trends Mol Med2002-08-01T00:00:002002NF-kappaB as a therapeutic target in cancer.12559038Orlowski RZ, Dees ECBreast cancer research : BCRThe role of the ubiquitination-proteasome pathway in breast cancer: applying drugs that affect the ubiquitin-proteasome pathway to the therapy of breast cancer. Breast Cancer Res. 2003; 5(1):1-7.Breast Cancer Res2002-08-14T00:00:002002The role of the ubiquitination-proteasome pathway in breast cancer: applying drugs that affect the ubiquitin-proteasome pathway to the therapy of breast cancer.15056047Orlowski RZExpert review of anticancer therapyBortezomib and its role in the management of patients with multiple myeloma. Expert Rev Anticancer Ther. 2004 Apr; 4(2):171-9.Expert Rev Anticancer Ther2004-04-01T00:00:002004Bortezomib and its role in the management of patients with multiple myeloma.15626743Orlowski RZ, Voorhees PM, Garcia RA, Hall MD, Kudrik FJ, Allred T, Johri AR, Jones PE, Ivanova A, Van Deventer HW, Gabriel DA, Shea TC, Mitchell BS, Adams J, Esseltine DL, Trehu EG, Green M, Lehman MJ, Natoli S, Collins JM, Lindley CM, Dees ECBloodPhase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood. 2005 Apr 15; 105(8):3058-65.Blood2004-12-30T00:00:002004Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies.17146676Biehn SE, Moore DT, Voorhees PM, Garcia RA, Lehman MJ, Dees EC, Orlowski RZAnnals of hematologyExtended follow-up of outcome measures in multiple myeloma patients treated on a phase I study with bortezomib and pegylated liposomal doxorubicin. Ann Hematol. 2007 Mar; 86(3):211-6.Ann Hematol2006-12-05T00:00:002006Extended follow-up of outcome measures in multiple myeloma patients treated on a phase I study with bortezomib and pegylated liposomal doxorubicin.17515569Kyle RA, Yee GC, Somerfield MR, Flynn PJ, Halabi S, Jagannath S, Orlowski RZ, Roodman DG, Twilde P, Anderson K, American Society of Clinical OncologyJournal of clinical oncology : official journal of the American Society of Clinical OncologyAmerican Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol. 2007 Jun 10; 25(17):2464-72.J Clin Oncol2007-05-21T00:00:002007American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma.17591945Kuhn DJ, Chen Q, Voorhees PM, Strader JS, Shenk KD, Sun CM, Demo SD, Bennett MK, van Leeuwen FW, Chanan-Khan AA, Orlowski RZBloodPotent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood. 2007 Nov 01; 110(9):3281-90.Blood2007-06-25T00:00:002007Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma.18765533Jones RJ, Chen Q, Voorhees PM, Young KH, Bruey-Sedano N, Yang D, Orlowski RZClinical cancer research : an official journal of the American Association for Cancer ResearchInhibition of the p53 E3 ligase HDM-2 induces apoptosis and DNA damage--independent p53 phosphorylation in mantle cell lymphoma. Clin Cancer Res. 2008 Sep 01; 14(17):5416-25.Clin Cancer Res2008-09-01T00:00:002008Inhibition of the p53 E3 ligase HDM-2 induces apoptosis and DNA damage--independent p53 phosphorylation in mantle cell lymphoma.19903785O'Connor OA, Stewart AK, Vallone M, Molineaux CJ, Kunkel LA, Gerecitano JF, Orlowski RZClinical cancer research : an official journal of the American Association for Cancer ResearchA phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies. Clin Cancer Res. 2009 Nov 15; 15(22):7085-91.Clin Cancer Res2009-11-10T00:00:002009A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies.21057542Yang L, Wang H, Kornblau SM, Graber DA, Zhang N, Matthews JA, Wang M, Weber DM, Thomas SK, Shah JJ, Zhang L, Lu G, Zhao M, Muddasani R, Yoo SY, Baggerly KA, Orlowski RZOncogeneEvidence of a role for the novel zinc-finger transcription factor ZKSCAN3 in modulating Cyclin D2 expression in multiple myeloma. Oncogene. 2011 Mar 17; 30(11):1329-40.Oncogene2010-11-08T00:00:002010Evidence of a role for the novel zinc-finger transcription factor ZKSCAN3 in modulating Cyclin D2 expression in multiple myeloma.21062912Wen J, Feng Y, Bjorklund CC, Wang M, Orlowski RZ, Shi ZZ, Liao B, O'Hare J, Zu Y, Schally AV, Chang CCMolecular cancer therapeuticsLuteinizing Hormone-Releasing Hormone (LHRH)-I antagonist cetrorelix inhibits myeloma cell growth in vitro and in vivo. Mol Cancer Ther. 2011 Jan; 10(1):148-58.Mol Cancer Ther2010-11-09T00:00:002010Luteinizing Hormone-Releasing Hormone (LHRH)-I antagonist cetrorelix inhibits myeloma cell growth in vitro and in vivo.21292775Rajkumar SV, Harousseau JL, Durie B, Anderson KC, Dimopoulos M, Kyle R, Blade J, Richardson P, Orlowski R, Siegel D, Jagannath S, Facon T, Avet-Loiseau H, Lonial S, Palumbo A, Zonder J, Ludwig H, Vesole D, Sezer O, Munshi NC, San Miguel J, International Myeloma Workshop Consensus Panel 1BloodConsensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011 May 05; 117(18):4691-5.Blood2011-02-03T00:00:002011Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1.21844567Jones RJ, Baladandayuthapani V, Neelapu S, Fayad LE, Romaguera JE, Wang M, Sharma R, Yang D, Orlowski RZBloodHDM-2 inhibition suppresses expression of ribonucleotide reductase subunit M2, and synergistically enhances gemcitabine-induced cytotoxicity in mantle cell lymphoma. Blood. 2011 Oct 13; 118(15):4140-9.Blood2011-08-15T00:00:002011HDM-2 inhibition suppresses expression of ribonucleotide reductase subunit M2, and synergistically enhances gemcitabine-induced cytotoxicity in mantle cell lymphoma.22193964Richardson PG, Delforge M, Beksac M, Wen P, Jongen JL, Sezer O, Terpos E, Munshi N, Palumbo A, Rajkumar SV, Harousseau JL, Moreau P, Avet-Loiseau H, Lee JH, Cavo M, Merlini G, Voorhees P, Chng WJ, Mazumder A, Usmani S, Einsele H, Comenzo R, Orlowski R, Vesole D, Lahuerta JJ, Niesvizky R, Siegel D, Mateos MV, Dimopoulos M, Lonial S, Jagannath S, Blad? J, Miguel JS, Morgan G, Anderson KC, Durie BG, Sonneveld PLeukemiaManagement of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia. 2012 Apr; 26(4):595-608.Leukemia2011-12-23T00:00:002011Management of treatment-emergent peripheral neuropathy in multiple myeloma.22275381Xu-Monette ZY, Medeiros LJ, Li Y, Orlowski RZ, Andreeff M, Bueso-Ramos CE, Greiner TC, McDonnell TJ, Young KHBloodDysfunction of the TP53 tumor suppressor gene in lymphoid malignancies. Blood. 2012 Apr 19; 119(16):3668-83.Blood2012-01-24T00:00:002012Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies.22645181Moreau P, Richardson PG, Cavo M, Orlowski RZ, San Miguel JF, Palumbo A, Harousseau JLBloodProteasome inhibitors in multiple myeloma: 10 years later. Blood. 2012 Aug 02; 120(5):947-59.Blood2012-05-29T00:00:002012Proteasome inhibitors in multiple myeloma: 10 years later.22726549Kuhn DJ, Orlowski RZSeminars in hematologyThe immunoproteasome as a target in hematologic malignancies. Semin Hematol. 2012 Jul; 49(3):258-62.Semin Hematol2012-07-01T00:00:002012The immunoproteasome as a target in hematologic malignancies.22845873Vij R, Siegel DS, Jagannath S, Jakubowiak AJ, Stewart AK, McDonagh K, Bahlis N, Belch A, Kunkel LA, Wear S, Wong AF, Wang MBritish journal of haematologyAn open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib. Br J Haematol. 2012 Sep; 158(6):739-48.Br J Haematol2012-07-30T00:00:002012An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib.24117234Oki Y, Westin JR, Vega F, Chuang H, Fowler N, Neelapu S, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale M, Younes A, Rodriguez MA, Orlowski RZ, Wang M, Ouzounian ST, Samaniego F, Fayad LBritish journal of haematologyProspective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma. Br J Haematol. 2013 Dec; 163(5):611-20.Br J Haematol2013-10-01T00:00:002013Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma.24423611Wang XS, Shi Q, Shah ND, Heijnen CJ, Cohen EN, Reuben JM, Orlowski RZ, Qazilbash MH, Johnson VE, Williams LA, Mendoza TR, Cleeland CSClinical cancer research : an official journal of the American Association for Cancer ResearchInflammatory markers and development of symptom burden in patients with multiple myeloma during autologous stem cell transplantation. Clin Cancer Res. 2014 Mar 01; 20(5):1366-74.Clin Cancer Res2014-01-14T00:00:002014Inflammatory markers and development of symptom burden in patients with multiple myeloma during autologous stem cell transplantation.LeukemiaLymphoma-MyelomaStem Cell TransplantationMD AndersonRICHARD ECHAMPLINRICHARD E CHAMPLIN8508CHAMPLIN, RICHARD EProfessorJORGE ECORTESJORGE E CORTES8637CORTES, JORGE EProfessorQAISERBASHIRQAISER BASHIR9601BASHIR, QAISERAssociate ProfessorHAGOP MKANTARJIANHAGOP M KANTARJIAN8501KANTARJIAN, HAGOP MProfessorDONNA MWEBERDONNA M WEBER8507WEBER, DONNA MProfessorKRINAPATELKRINA PATEL9538PATEL, KRINAAssistant ProfessorSHEEBA KOSHYTHOMASSHEEBA KOSHY THOMAS9017THOMAS, SHEEBA KOSHYAssociate ProfessorMUZAFFAR HQAZILBASHMUZAFFAR H QAZILBASH9055QAZILBASH, MUZAFFAR HProfessor24.96660.00177647829research areas7.952140.0271583150coauthor of603.44968.709660similar to11407selected publicationsAuthorship 2163041Authorship 21944712Authorship 2199406Authorship 2199684Authorship 2210156Authorship 22180912Authorship 2220962Authorship 2225341Authorship 2228792Authorship 2229771Authorship 2229811Authorship 2232536Authorship 22344716Authorship 2243552Authorship 2243834Authorship 22468710Authorship 2255678Authorship 22609810Authorship 22682010Authorship 2268291Authorship 2279982Authorship 2298377Authorship 2299332Authorship 23020810Authorship 2305164Authorship 23071519Authorship 2312775Authorship 23137311Authorship 23158423Authorship 23185923Authorship 23250712Authorship 23265022Authorship 23278412Authorship 23284611Authorship 23322312Authorship 2335301Authorship 23373421Authorship 2337739Authorship 2338933Authorship 2341026Authorship 23422220Authorship 2346078Authorship 2347783Authorship 23514217Authorship 23521219766662Orlowski RZ, Eswara JR, Lafond-Walker A, Grever MR, Orlowski M, Dang CVCancer researchTumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor. Cancer Res. 1998 Oct 01; 58(19):4342-8.Cancer Res1998-10-01T00:00:001998Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor.12097302Somasundaram S, Edmund NA, Moore DT, Small GW, Shi YY, Orlowski RZCancer researchDietary curcumin inhibits chemotherapy-induced apoptosis in models of human breast cancer. Cancer Res. 2002 Jul 01; 62(13):3868-75.Cancer Res2002-07-01T00:00:002002Dietary curcumin inhibits chemotherapy-induced apoptosis in models of human breast cancer.12826635Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP, Anderson KCThe New England journal of medicineA phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003 Jun 26; 348(26):2609-17.N Engl J Med2003-06-26T00:00:002003A phase 2 study of bortezomib in relapsed, refractory myeloma.14695130Voorhees PM, Dees EC, O'Neil B, Orlowski RZClinical cancer research : an official journal of the American Association for Cancer ResearchThe proteasome as a target for cancer therapy. Clin Cancer Res. 2003 Dec 15; 9(17):6316-25.Clin Cancer Res2003-12-15T00:00:002003The proteasome as a target for cancer therapy.15448190Small GW, Shi YY, Edmund NA, Somasundaram S, Moore DT, Orlowski RZMolecular pharmacologyEvidence that mitogen-activated protein kinase phosphatase-1 induction by proteasome inhibitors plays an antiapoptotic role. Mol Pharmacol. 2004 Dec; 66(6):1478-90.Mol Pharmacol2004-09-24T00:00:002004Evidence that mitogen-activated protein kinase phosphatase-1 induction by proteasome inhibitors plays an antiapoptotic role.15917644Orlowski RZMethods in molecular biology (Clifton, N.J.)Proteasome inhibitors in cancer therapy. Methods Mol Biol. 2005; 301:339-50.Methods Mol Biol2005-01-01T00:00:002005Proteasome inhibitors in cancer therapy.16184461Ramaswamy B, Povoski SP, Rhoades C, Allen J, Hauger M, Young D, Burak W, Farrar W, Yee L, Kendra K, Somasundaram S, Orlowski RZ, Shapiro CLBreast cancer research and treatmentPhase II trial of neoadjuvant chemotherapy with docetaxel followed by epirubicin in stage II/III breast cancer. Breast Cancer Res Treat. 2005 Sep; 93(1):67-74.Breast Cancer Res Treat2005-09-01T00:00:002005Phase II trial of neoadjuvant chemotherapy with docetaxel followed by epirubicin in stage II/III breast cancer.16402903Voorhees PM, Orlowski RZAnnual review of pharmacology and toxicologyThe proteasome and proteasome inhibitors in cancer therapy. Annu Rev Pharmacol Toxicol. 2006; 46:189-213.Annu Rev Pharmacol Toxicol2006-01-01T00:00:002006The proteasome and proteasome inhibitors in cancer therapy.16407873Orlowski RZNature clinical practice. OncologyIs bortezomib superior to high-dose dexamethasone for the treatment of relapsed multiple myeloma? Nat Clin Pract Oncol. 2006 Jan; 3(1):16-7.Nat Clin Pract Oncol2006-01-01T00:00:002006Is bortezomib superior to high-dose dexamethasone for the treatment of relapsed multiple myeloma?16433592Orlowski RZ, Zeger ELExpert opinion on investigational drugsTargeting the proteasome as a therapeutic strategy against haematological malignancies. Expert Opin Investig Drugs. 2006 Feb; 15(2):117-30.Expert Opin Investig Drugs2006-02-01T00:00:002006Targeting the proteasome as a therapeutic strategy against haematological malignancies.16556079Dees EC, Orlowski RZFuture oncology (London, England)Targeting the ubiquitin-proteasome pathway in breast cancer therapy. Future Oncol. 2006 Feb; 2(1):121-35.Future Oncol2006-02-01T00:00:002006Targeting the ubiquitin-proteasome pathway in breast cancer therapy.16754936Richardson PG, Briemberg H, Jagannath S, Wen PY, Barlogie B, Berenson J, Singhal S, Siegel DS, Irwin D, Schuster M, Srkalovic G, Alexanian R, Rajkumar SV, Limentani S, Alsina M, Orlowski RZ, Najarian K, Esseltine D, Anderson KC, Amato AAJournal of clinical oncology : official journal of the American Society of Clinical OncologyFrequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol. 2006 Jul 01; 24(19):3113-20.J Clin Oncol2006-06-05T00:00:002006Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib.16948177Biehn SE, Kirk D, Rivera MP, Martinez AE, Khandani AH, Orlowski RZHematological oncologyBronchiolitis obliterans with organizing pneumonia after rituximab therapy for non-Hodgkin's lymphoma. Hematol Oncol. 2006 Dec; 24(4):234-7.Hematol Oncol2006-12-01T00:00:002006Bronchiolitis obliterans with organizing pneumonia after rituximab therapy for non-Hodgkin's lymphoma.17483361Small GW, Shi YY, Higgins LS, Orlowski RZCancer researchMitogen-activated protein kinase phosphatase-1 is a mediator of breast cancer chemoresistance. Cancer Res. 2007 May 01; 67(9):4459-66.Cancer Res2007-05-01T00:00:002007Mitogen-activated protein kinase phosphatase-1 is a mediator of breast cancer chemoresistance.17562254Voorhees PM, Orlowski RZClinical lymphoma & myelomaEmerging data on the use of anthracyclines in combination with bortezomib in multiple myeloma. Clin Lymphoma Myeloma. 2007 Apr; 7 Suppl 4:S156-62.Clin Lymphoma Myeloma2007-04-01T00:00:002007Emerging data on the use of anthracyclines in combination with bortezomib in multiple myeloma.17975159Voorhees PM, Chen Q, Kuhn DJ, Small GW, Hunsucker SA, Strader JS, Corringham RE, Zaki MH, Nemeth JA, Orlowski RZClinical cancer research : an official journal of the American Association for Cancer ResearchInhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma. Clin Cancer Res. 2007 Nov 01; 13(21):6469-78.Clin Cancer Res2007-11-01T00:00:002007Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma.18300257Sonneveld P, Hajek R, Nagler A, Spencer A, Blad? J, Robak T, Zhuang SH, Harousseau JL, Orlowski RZ, DOXIL-MMY-3001 Study InvestigatorsCancerCombined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy. Cancer. 2008 Apr 01; 112(7):1529-37.Cancer2008-04-01T00:00:002008Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy.18327587Dees EC, O'Neil BH, Lindley CM, Collichio F, Carey LA, Collins J, Riordan WJ, Ivanova A, Esseltine D, Orlowski RZCancer chemotherapy and pharmacologyA phase I and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumors. Cancer Chemother Pharmacol. 2008 Dec; 63(1):99-107.Cancer Chemother Pharmacol2008-03-08T00:00:002008A phase I and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumors.18347166Orlowski RZ, Kuhn DJClinical cancer research : an official journal of the American Association for Cancer ResearchProteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res. 2008 Mar 15; 14(6):1649-57.Clin Cancer Res2008-03-15T00:00:002008Proteasome inhibitors in cancer therapy: lessons from the first decade.19064400Blad? J, Sonneveld P, San Miguel JF, Sutherland HJ, Hajek R, Nagler A, Spencer A, Robak T, Cibeira MT, Zhuang SH, Harousseau JL, Orlowski RZ, DOXIL-MMY-3001 Study InvestigatorsClinical lymphoma & myelomaPegylated liposomal doxorubicin plus bortezomib in relapsed or refractory multiple myeloma: efficacy and safety in patients with renal function impairment. Clin Lymphoma Myeloma. 2008 Dec; 8(6):352-5.Clin Lymphoma Myeloma2008-12-01T00:00:002008Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory multiple myeloma: efficacy and safety in patients with renal function impairment.19741722Shah JJ, Orlowski RZLeukemiaProteasome inhibitors in the treatment of multiple myeloma. Leukemia. 2009 Nov; 23(11):1964-79.Leukemia2009-09-10T00:00:002009Proteasome inhibitors in the treatment of multiple myeloma.21147690Irvin WJ, Orlowski RZ, Chiu WK, Carey LA, Collichio FA, Bernard PS, Stijleman IJ, Perou C, Ivanova A, Dees ECClinical breast cancerPhase II study of bortezomib and pegylated liposomal doxorubicin in the treatment of metastatic breast cancer. Clin Breast Cancer. 2010 Dec 01; 10(6):465-70.Clin Breast Cancer2010-12-01T00:00:002010Phase II study of bortezomib and pegylated liposomal doxorubicin in the treatment of metastatic breast cancer.21328327Shah J, Blad? J, Sonneveld P, Harousseau JL, Lantz K, Londhe A, Lowery C, Orlowski RZCancerRapid early monoclonal protein reduction after therapy with bortezomib or bortezomib and pegylated liposomal doxorubicin in relapsed/refractory myeloma is associated with a longer time to progression. Cancer. 2011 Aug 15; 117(16):3758-62.Cancer2011-02-15T00:00:002011Rapid early monoclonal protein reduction after therapy with bortezomib or bortezomib and pegylated liposomal doxorubicin in relapsed/refractory myeloma is associated with a longer time to progression.21454189Blad? J, Sonneveld P, San Miguel JF, Sutherland HJ, Hajek R, Nagler A, Spencer A, Robak T, Lantz KC, Zhuang SH, Harousseau JL, Orlowski RZ, DOXIL-MMY-3001 Study InvestigatorsClinical lymphoma, myeloma & leukemiaEfficacy and safety of pegylated liposomal Doxorubicin in combination with bortezomib for multiple myeloma: effects of adverse prognostic factors on outcome. Clin Lymphoma Myeloma Leuk. 2011 Feb; 11(1):44-9.Clin Lymphoma Myeloma Leuk2011-02-01T00:00:002011Efficacy and safety of pegylated liposomal Doxorubicin in combination with bortezomib for multiple myeloma: effects of adverse prognostic factors on outcome.21799510Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J, Haessler J, Feather J, Hoering A, Moreau P, LeLeu X, Hulin C, Klein SK, Sonneveld P, Siegel D, Blad? J, Goldschmidt H, Jagannath S, Miguel JS, Orlowski R, Palumbo A, Sezer O, Rajkumar SV, Durie BG, International Myeloma Working GroupLeukemiaRisk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia. 2012 Jan; 26(1):149-57.Leukemia2011-07-29T00:00:002011Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study.21860026Zhu YX, Braggio E, Shi CX, Bruins LA, Schmidt JE, Van Wier S, Chang XB, Bjorklund CC, Fonseca R, Bergsagel PL, Orlowski RZ, Stewart AKBloodCereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood. 2011 Nov 03; 118(18):4771-9.Blood2011-08-22T00:00:002011Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide.21887685Sharma M, Khan H, Thall PF, Orlowski RZ, Bassett RL, Shah N, Bashir Q, Parmar S, Wang M, Shah JJ, Hosing CM, Popat UR, Giralt SA, Champlin RE, Qazilbash MHCancerA randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid. Cancer. 2012 May 01; 118(9):2507-15.Cancer2011-09-01T00:00:002011A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid.22271445Ludwig H, Durie BG, McCarthy P, Palumbo A, San Miguel J, Barlogie B, Morgan G, Sonneveld P, Spencer A, Andersen KC, Facon T, Stewart KA, Einsele H, Mateos MV, Wijermans P, Waage A, Beksac M, Richardson PG, Hulin C, Niesvizky R, Lokhorst H, Landgren O, Bergsagel PL, Orlowski R, Hinke A, Cavo M, Attal M, International Myeloma Working GroupBloodIMWG consensus on maintenance therapy in multiple myeloma. Blood. 2012 Mar 29; 119(13):3003-15.Blood2012-01-23T00:00:002012IMWG consensus on maintenance therapy in multiple myeloma.22555973Vij R, Wang M, Kaufman JL, Lonial S, Jakubowiak AJ, Stewart AK, Kukreti V, Jagannath S, McDonagh KT, Alsina M, Bahlis NJ, Reu FJ, Gabrail NY, Belch A, Matous JV, Lee P, Rosen P, Sebag M, Vesole DH, Kunkel LA, Wear SM, Wong AF, Orlowski RZ, Siegel DSBloodAn open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. Blood. 2012 Jun 14; 119(24):5661-70.Blood2012-05-03T00:00:002012An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma.22833546Siegel DS, Martin T, Wang M, Vij R, Jakubowiak AJ, Lonial S, Trudel S, Kukreti V, Bahlis N, Alsina M, Chanan-Khan A, Buadi F, Reu FJ, Somlo G, Zonder J, Song K, Stewart AK, Stadtmauer E, Kunkel L, Wear S, Wong AF, Orlowski RZ, Jagannath SBloodA phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood. 2012 Oct 04; 120(14):2817-25.Blood2012-07-25T00:00:002012A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.22933706Jones RJ, Bjorklund CC, Baladandayuthapani V, Kuhn DJ, Orlowski RZMolecular cancer therapeuticsDrug resistance to inhibitors of the human double minute-2 E3 ligase is mediated by point mutations of p53, but can be overcome with the p53 targeting agent RITA. Mol Cancer Ther. 2012 Oct; 11(10):2243-53.Mol Cancer Ther2012-08-28T00:00:002012Drug resistance to inhibitors of the human double minute-2 E3 ligase is mediated by point mutations of p53, but can be overcome with the p53 targeting agent RITA.23040437Jagannath S, Vij R, Stewart AK, Trudel S, Jakubowiak AJ, Reiman T, Somlo G, Bahlis N, Lonial S, Kunkel LA, Wong A, Orlowski RZ, Siegel DSClinical lymphoma, myeloma & leukemiaAn open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2012 Oct; 12(5):310-8.Clin Lymphoma Myeloma Leuk2012-10-01T00:00:002012An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma.23066034He J, Liu Z, Zheng Y, Qian J, Li H, Lu Y, Xu J, Hong B, Zhang M, Lin P, Cai Z, Orlowski RZ, Kwak LW, Yi Q, Yang JCancer researchp38 MAPK in myeloma cells regulates osteoclast and osteoblast activity and induces bone destruction. Cancer Res. 2012 Dec 15; 72(24):6393-402.Cancer Res2012-10-11T00:00:002012p38 MAPK in myeloma cells regulates osteoclast and osteoblast activity and induces bone destruction.23432640Voorhees PM, Manges RF, Sonneveld P, Jagannath S, Somlo G, Krishnan A, Lentzsch S, Frank RC, Zweegman S, Wijermans PW, Orlowski RZ, Kranenburg B, Hall B, Casneuf T, Qin X, van de Velde H, Xie H, Thomas SKBritish journal of haematologyA phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma. Br J Haematol. 2013 May; 161(3):357-66.Br J Haematol2013-02-25T00:00:002013A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma.23447001Niesvizky R, Martin TG, Bensinger WI, Alsina M, Siegel DS, Kunkel LA, Wong AF, Lee S, Orlowski RZ, Wang MClinical cancer research : an official journal of the American Association for Cancer ResearchPhase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. Clin Cancer Res. 2013 Apr 15; 19(8):2248-56.Clin Cancer Res2013-02-27T00:00:002013Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.23614765Hajek R, Siegel D, Orlowski RZ, Ludwig H, Palumbo A, Dimopoulos MLeukemia & lymphomaThe role of histone deacetylase inhibitors in patients with relapsed/refractory multiple myeloma. Leuk Lymphoma. 2014 Jan; 55(1):11-8.Leuk Lymphoma2013-06-12T00:00:002013The role of histone deacetylase inhibitors in patients with relapsed/refractory multiple myeloma.23670297Jakubowiak AJ, Siegel DS, Martin T, Wang M, Vij R, Lonial S, Trudel S, Kukreti V, Bahlis N, Alsina M, Chanan-Khan A, Buadi F, Reu FJ, Somlo G, Zonder J, Song K, Stewart AK, Stadtmauer E, Harrison BL, Wong AF, Orlowski RZ, Jagannath SLeukemiaTreatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study. Leukemia. 2013 Dec; 27(12):2351-6.Leukemia2013-05-14T00:00:002013Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study.23760401Bjorklund CC, Baladandayuthapani V, Lin HY, Jones RJ, Kuiatse I, Wang H, Yang J, Shah JJ, Thomas SK, Wang M, Weber DM, Orlowski RZLeukemiaEvidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications. Leukemia. 2014 Feb; 28(2):373-83.Leukemia2013-06-13T00:00:002013Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications.23988451Cervantes-Gomez F, Chen LS, Orlowski RZ, Gandhi VClinical lymphoma, myeloma & leukemiaBiological effects of the Pim kinase inhibitor, SGI-1776, in multiple myeloma. Clin Lymphoma Myeloma Leuk. 2013 Sep; 13 Suppl 2:S317-29.Clin Lymphoma Myeloma Leuk2013-08-27T00:00:002013Biological effects of the Pim kinase inhibitor, SGI-1776, in multiple myeloma.24135408Orlowski RZSeminars in oncologyNovel agents for multiple myeloma to overcome resistance in phase III clinical trials. Semin Oncol. 2013 Oct; 40(5):634-51.Semin Oncol2013-10-01T00:00:002013Novel agents for multiple myeloma to overcome resistance in phase III clinical trials.24253022Ocio EM, Richardson PG, Rajkumar SV, Palumbo A, Mateos MV, Orlowski R, Kumar S, Usmani S, Roodman D, Niesvizky R, Einsele H, Anderson KC, Dimopoulos MA, Avet-Loiseau H, Mellqvist UH, Turesson I, Merlini G, Schots R, McCarthy P, Bergsagel L, Chim CS, Lahuerta JJ, Shah J, Reiman A, Mikhael J, Zweegman S, Lonial S, Comenzo R, Chng WJ, Moreau P, Sonneveld P, Ludwig H, Durie BG, Miguel JFLeukemiaNew drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG). Leukemia. 2014 Mar; 28(3):525-42.Leukemia2013-11-20T00:00:002013New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG).24335104Mulligan G, Lichter DI, Di Bacco A, Blakemore SJ, Berger A, Koenig E, Bernard H, Trepicchio W, Li B, Neuwirth R, Chattopadhyay N, Bolen JB, Dorner AJ, van de Velde H, Ricci D, Jagannath S, Berenson JR, Richardson PG, Stadtmauer EA, Orlowski RZ, Lonial S, Anderson KC, Sonneveld P, San Miguel JF, Esseltine DL, Schu MBloodMutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy. Blood. 2014 Jan 30; 123(5):632-9.Blood2013-12-11T00:00:002013Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy.24833354San-Miguel J, Blad? J, Shpilberg O, Grosicki S, Maloisel F, Min CK, Polo Zarzuela M, Robak T, Prasad SV, Tee Goh Y, Laubach J, Spencer A, Mateos MV, Palumbo A, Puchalski T, Reddy M, Uhlar C, Qin X, van de Velde H, Xie H, Orlowski RZBloodPhase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma. Blood. 2014 Jun 26; 123(26):4136-42.Blood2014-05-15T00:00:002014Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma.24939217Tang G, Wang SA, Lu V, Lee HC, Qazilbash MH, Wang XI, Yin CC, Orlowski R, Wang Y, Patel A, Medeiros LJ, Lu GLeukemia researchClinically silent clonal cytogenetic abnormalities arising in patients treated for lymphoid neoplasms. Leuk Res. 2014 Aug; 38(8):896-900.Leuk Res2014-06-04T00:00:002014Clinically silent clonal cytogenetic abnormalities arising in patients treated for lymphoid neoplasms.25188482Orlowski RZOncology (Williston Park, N.Y.)The future of proteasome inhibitors in relapsed/refractory multiple myeloma. Oncology (Williston Park). 2011 Nov 15; 25 Suppl 2:56-64.Oncology (Williston Park)2011-11-15T00:00:002011The future of proteasome inhibitors in relapsed/refractory multiple myeloma.Authorship 2359881Authorship 2412931Authorship 2436021Authorship 2443361Authorship 2452701Authorship 2465545Authorship 2467117Authorship 2470341Authorship 2475932Authorship 2482181Authorship 2488796Authorship 2495431Authorship 2502973Authorship 2503441Authorship 25093014Authorship 2520912Authorship 2522873Authorship 2537849Authorship 25501311Authorship 2550349Authorship 2551031Authorship 2561012Authorship 2563549Authorship 2565285Authorship 2569348Authorship 2569514Authorship 25716211Authorship 25786212Authorship 25827114Authorship 25916218Authorship 25977933Authorship 2600792Authorship 26030014Authorship 26030911Authorship 26097620Authorship 26134116Authorship 2614131Authorship 2615237Authorship 2624217Authorship 262432111846191Orlowski R, Miller GJournal of virologySingle-stranded structures are present within plasmids containing the Epstein-Barr virus latent origin of replication. J Virol. 1991 Feb; 65(2):677-86.J Virol1991-02-01T00:00:001991Single-stranded structures are present within plasmids containing the Epstein-Barr virus latent origin of replication.10381632Orlowski RZCell death and differentiationThe role of the ubiquitin-proteasome pathway in apoptosis. Cell Death Differ. 1999 Apr; 6(4):303-13.Cell Death Differ1999-04-01T00:00:001999The role of the ubiquitin-proteasome pathway in apoptosis.12023956Orlowski RZ, Small GW, Shi YYThe Journal of biological chemistryEvidence that inhibition of p44/42 mitogen-activated protein kinase signaling is a factor in proteasome inhibitor-mediated apoptosis. J Biol Chem. 2002 Aug 02; 277(31):27864-71.J Biol Chem2002-05-22T00:00:002002Evidence that inhibition of p44/42 mitogen-activated protein kinase signaling is a factor in proteasome inhibitor-mediated apoptosis.12941849Mitchell TMCancer researchCorrespondence re: Somasundaram et al., Dietary curcumin inhibits chemotherapy-induced apoptosis in models of human breast cancer. Cancer Res., 62: 3868-3875, 2002. Cancer Res. 2003 Aug 15; 63(16):5165-6; author reply 5166-7.Cancer Res2003-08-15T00:00:002003Correspondence re: Somasundaram et al., Dietary curcumin inhibits chemotherapy-induced apoptosis in models of human breast cancer. Cancer Res., 62: 3868-3875, 2002.15512809Orlowski RZ, Mills SR, Hartley EE, Ye X, Piantadosi S, Ambinder RF, Gore SD, Miller CBLeukemia & lymphomaOral valacyclovir as prophylaxis against herpes simplex virus reactivation during high dose chemotherapy for leukemia. Leuk Lymphoma. 2004 Nov; 45(11):2215-9.Leuk Lymphoma2004-11-01T00:00:002004Oral valacyclovir as prophylaxis against herpes simplex virus reactivation during high dose chemotherapy for leukemia.15690325Jagannath S, Barlogie B, Berenson JR, Singhal S, Alexanian R, Srkalovic G, Orlowski RZ, Richardson PG, Anderson J, Nix D, Esseltine DL, Anderson KC, SUMMIT/CREST InvestigatorsCancerBortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function. Cancer. 2005 Mar 15; 103(6):1195-200.Cancer2005-03-15T00:00:002005Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function.15743149Orlowski RZ, Multiple Myeloma Research FoundationOncology (Williston Park, N.Y.)Bortezomib therapy following first relapse. Oncology (Williston Park). 2005 Jan; 19(1):23-6.Oncology (Williston Park)2005-01-01T00:00:002005Bortezomib therapy following first relapse.16099887Lonial S, Waller EK, Richardson PG, Jagannath S, Orlowski RZ, Giver CR, Jaye DL, Francis D, Giusti S, Torre C, Barlogie B, Berenson JR, Singhal S, Schenkein DP, Esseltine DL, Anderson J, Xiao H, Heffner LT, Anderson KC, SUMMIT/CREST InvestigatorsBloodRisk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood. 2005 Dec 01; 106(12):3777-84.Blood2005-08-11T00:00:002005Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma.16304384Orlowski RZHematology. American Society of Hematology. Education ProgramThe ubiquitin proteasome pathway from bench to bedside. Hematology Am Soc Hematol Educ Program. 2005; 220-5.Hematology Am Soc Hematol Educ Program2005-01-01T00:00:002005The ubiquitin proteasome pathway from bench to bedside.16401713San Miguel J, Blad? J, Boccadoro M, Cavenagh J, Glasmacher A, Jagannath S, Lonial S, Orlowski RZ, Sonneveld P, Ludwig HThe oncologistA practical update on the use of bortezomib in the management of multiple myeloma. Oncologist. 2006 Jan; 11(1):51-61.Oncologist2006-01-01T00:00:002006A practical update on the use of bortezomib in the management of multiple myeloma.16807678Shi YY, Small GW, Orlowski RZBreast cancer research and treatmentProteasome inhibitors induce a p38 mitogen-activated protein kinase (MAPK)-dependent anti-apoptotic program involving MAPK phosphatase-1 and Akt in models of breast cancer. Breast Cancer Res Treat. 2006 Nov; 100(1):33-47.Breast Cancer Res Treat2006-06-29T00:00:002006Proteasome inhibitors induce a p38 mitogen-activated protein kinase (MAPK)-dependent anti-apoptotic program involving MAPK phosphatase-1 and Akt in models of breast cancer.16879768Voorhees PM, Orlowski RZClinical lymphoma & myelomaEmerging role of novel combinations for induction therapy in multiple myeloma. Clin Lymphoma Myeloma. 2006 Jul; 7(1):33-41.Clin Lymphoma Myeloma2006-07-01T00:00:002006Emerging role of novel combinations for induction therapy in multiple myeloma.17124081Orlowski RZHematology. American Society of Hematology. Education ProgramInitial therapy of multiple myeloma patients who are not candidates for stem cell transplantation. Hematology Am Soc Hematol Educ Program. 2006; 338-47.Hematology Am Soc Hematol Educ Program2006-01-01T00:00:002006Initial therapy of multiple myeloma patients who are not candidates for stem cell transplantation.17679727Orlowski RZ, Nagler A, Sonneveld P, Blad? J, Hajek R, Spencer A, San Miguel J, Robak T, Dmoszynska A, Horvath N, Spicka I, Sutherland HJ, Suvorov AN, Zhuang SH, Parekh T, Xiu L, Yuan Z, Rackoff W, Harousseau JLJournal of clinical oncology : official journal of the American Society of Clinical OncologyRandomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol. 2007 Sep 01; 25(25):3892-901.J Clin Oncol2007-08-06T00:00:002007Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.18000495Stadtmauer EA, Lonial S, Vesole DH, Abonour R, Alsina M, Badros A, Comenzo R, Durie B, Giralt S, Hussein M, Jakubowiak A, Mehta J, Niesvizky R, Orlowski R, Siegel D, Singhal S, Vescio R, Wang M, Zangari M, Munshi NCClinical advances in hematology & oncology : H&OA practical guide to achieving and maintaining the best response to lenalidomide in multiple myeloma: roundtable proceedings. Clin Adv Hematol Oncol. 2007 Oct; 5(10 Suppl 15):7-19, quiz 21-2.Clin Adv Hematol Oncol2007-10-01T00:00:002007A practical guide to achieving and maintaining the best response to lenalidomide in multiple myeloma: roundtable proceedings.19436606Shah JJ, Orlowski RZ, Thomas SKTherapeutics and clinical risk managementRole of combination bortezomib and pegylated liposomal doxorubicin in the management of relapsed and/or refractory multiple myeloma. Ther Clin Risk Manag. 2009 Feb; 5(1):151-9.Ther Clin Risk Manag2009-03-26T00:00:002009Role of combination bortezomib and pegylated liposomal doxorubicin in the management of relapsed and/or refractory multiple myeloma.19498025Shah JJ, Kuhn DJ, Orlowski RZBloodBortezomib and EGCG: no green tea for you? Blood. 2009 Jun 04; 113(23):5695-6.Blood2009-06-04T00:00:002009Bortezomib and EGCG: no green tea for you?19791424Orlowski RZJournal of the National Comprehensive Cancer Network : JNCCNBortezomib in combination with other therapies for the treatment of multiple myeloma. J Natl Compr Canc Netw. 2004 Nov; 2 Suppl 4:S16-20.J Natl Compr Canc Netw2004-11-01T00:00:002004Bortezomib in combination with other therapies for the treatment of multiple myeloma.20532504Buda G, Ricci D, Huang CC, Favis R, Cohen N, Zhuang SH, Harousseau JL, Sonneveld P, Blad? J, Orlowski RZAnnals of hematologyPolymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin. Ann Hematol. 2010 Nov; 89(11):1133-40.Ann Hematol2010-06-08T00:00:002010Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin.20805315Ma W, Wang M, Wang ZQ, Sun L, Graber D, Matthews J, Champlin R, Yi Q, Orlowski RZ, Kwak LW, Weber DM, Thomas SK, Shah J, Kornblau S, Davis RECancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive OncologyEffect of long-term storage in TRIzol on microarray-based gene expression profiling. Cancer Epidemiol Biomarkers Prev. 2010 Oct; 19(10):2445-52.Cancer Epidemiol Biomarkers Prev2010-08-30T00:00:002010Effect of long-term storage in TRIzol on microarray-based gene expression profiling.21189262Bjorklund CC, Ma W, Wang ZQ, Davis RE, Kuhn DJ, Kornblau SM, Wang M, Shah JJ, Orlowski RZThe Journal of biological chemistryEvidence of a role for activation of Wnt/beta-catenin signaling in the resistance of plasma cells to lenalidomide. J Biol Chem. 2011 Apr 01; 286(13):11009-20.J Biol Chem2010-12-28T00:00:002010Evidence of a role for activation of Wnt/beta-catenin signaling in the resistance of plasma cells to lenalidomide.21247387Kuhn DJ, Orlowski RZ, Bjorklund CCCurrent cancer drug targetsSecond generation proteasome inhibitors: carfilzomib and immunoproteasome-specific inhibitors (IPSIs). Curr Cancer Drug Targets. 2011 Mar; 11(3):285-95.Curr Cancer Drug Targets2011-03-01T00:00:002011Second generation proteasome inhibitors: carfilzomib and immunoproteasome-specific inhibitors (IPSIs).21437886Reed V, Shah J, Medeiros LJ, Ha CS, Mazloom A, Weber DM, Arzu IY, Orlowski RZ, Thomas SK, Shihadeh F, Alexanian R, Dabaja BSCancerSolitary plasmacytomas: outcome and prognostic factors after definitive radiation therapy. Cancer. 2011 Oct 01; 117(19):4468-74.Cancer2011-03-22T00:00:002011Solitary plasmacytomas: outcome and prognostic factors after definitive radiation therapy.21447828Cavo M, Rajkumar SV, Palumbo A, Moreau P, Orlowski R, Blad? J, Sezer O, Ludwig H, Dimopoulos MA, Attal M, Sonneveld P, Boccadoro M, Anderson KC, Richardson PG, Bensinger W, Johnsen HE, Kroeger N, Gahrton G, Bergsagel PL, Vesole DH, Einsele H, Jagannath S, Niesvizky R, Durie BG, San Miguel J, Lonial S, International Myeloma Working GroupBloodInternational Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood. 2011 Jun 09; 117(23):6063-73.Blood2011-03-29T00:00:002011International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation.21477075Zangari M, Aujay M, Zhan F, Hetherington KL, Berno T, Vij R, Jagannath S, Siegel D, Keith Stewart A, Wang L, Orlowski RZ, Belch A, Jakubowiak A, Somlo G, Trudel S, Bahlis N, Lonial S, Singhal S, Kukreti V, Tricot GEuropean journal of haematologyAlkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients. Eur J Haematol. 2011 Jun; 86(6):484-7.Eur J Haematol2011-06-01T00:00:002011Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients.21724551Chauhan D, Tian Z, Zhou B, Kuhn D, Orlowski R, Raje N, Richardson P, Anderson KCClinical cancer research : an official journal of the American Association for Cancer ResearchIn vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells. Clin Cancer Res. 2011 Aug 15; 17(16):5311-21.Clin Cancer Res2011-06-30T00:00:002011In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells.22015451Vadhan-Raj S, Fayad LE, Fanale MA, Pro B, Rodriguez A, Hagemeister FB, Bueso-Ramos CE, Zhou X, McLaughlin PW, Fowler N, Shah J, Orlowski RZ, Samaniego F, Wang M, Cortes JE, Younes A, Kwak LW, Sarlis NJ, Romaguera JEAnnals of oncology : official journal of the European Society for Medical OncologyA randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome. Ann Oncol. 2012 Jun; 23(6):1640-5.Ann Oncol2011-10-19T00:00:002011A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome.22531714Zhang X, Jing Y, Qin Y, Hunsucker S, Meng H, Sui J, Jiang Y, Gao L, An G, Yang N, Orlowski RZ, Yang LThe international journal of biochemistry & cell biologyThe zinc finger transcription factor ZKSCAN3 promotes prostate cancer cell migration. Int J Biochem Cell Biol. 2012 Jul; 44(7):1166-73.Int J Biochem Cell Biol2012-04-16T00:00:002012The zinc finger transcription factor ZKSCAN3 promotes prostate cancer cell migration.22693249Chen S, Dai Y, Pei XY, Myers J, Wang L, Kramer LB, Garnett M, Schwartz DM, Su F, Simmons GL, Richey JD, Larsen DG, Dent P, Orlowski RZ, Grant SCancer researchCDK inhibitors upregulate BH3-only proteins to sensitize human myeloma cells to BH3 mimetic therapies. Cancer Res. 2012 Aug 15; 72(16):4225-37.Cancer Res2012-06-12T00:00:002012CDK inhibitors upregulate BH3-only proteins to sensitize human myeloma cells to BH3 mimetic therapies.22975377Chauhan D, Tian Z, Nicholson B, Kumar KG, Zhou B, Carrasco R, McDermott JL, Leach CA, Fulcinniti M, Kodrasov MP, Weinstock J, Kingsbury WD, Hideshima T, Shah PK, Minvielle S, Altun M, Kessler BM, Orlowski R, Richardson P, Munshi N, Anderson KCCancer cellA small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance. Cancer Cell. 2012 Sep 11; 22(3):345-58.Cancer Cell2012-09-11T00:00:002012A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance.23288300Fern?ndez de Larrea C, Kyle RA, Durie BG, Ludwig H, Usmani S, Vesole DH, Hajek R, San Miguel JF, Sezer O, Sonneveld P, Kumar SK, Mahindra A, Comenzo R, Palumbo A, Mazumber A, Anderson KC, Richardson PG, Badros AZ, Caers J, Cavo M, LeLeu X, Dimopoulos MA, Chim CS, Schots R, Noeul A, Fantl D, Mellqvist UH, Landgren O, Chanan-Khan A, Moreau P, Fonseca R, Merlini G, Lahuerta JJ, Blad? J, Orlowski RZ, Shah JJ, International Myeloma Working GroupLeukemiaPlasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia. 2013 Apr; 27(4):780-91.Leukemia2012-11-21T00:00:002012Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group.23733001Sasaki K, Lu G, Saliba RM, Bashir Q, Hosing C, Popat U, Shah N, Parmar S, Dinh Y, Ahmed S, Shpall EJ, Kebriaei P, Shah JJ, Orlowski RZ, Champlin R, Qazilbash MHBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationImpact of t(11;14)(q13;q32) on the outcome of autologous hematopoietic cell transplantation in multiple myeloma. Biol Blood Marrow Transplant. 2013 Aug; 19(8):1227-32.Biol Blood Marrow Transplant2013-05-31T00:00:002013Impact of t(11;14)(q13;q32) on the outcome of autologous hematopoietic cell transplantation in multiple myeloma.23852321Sanchorawala V, Hoering A, Seldin DC, Finn KT, Fennessey SA, Sexton R, Mattar B, Safah HF, Holmberg LA, Dean RM, Orlowski RZ, Barlogie BBone marrow transplantationModified high-dose melphalan and autologous SCT for AL amyloidosis or high-risk myeloma: analysis of SWOG trial S0115. Bone Marrow Transplant. 2013 Nov; 48(12):1537-42.Bone Marrow Transplant2013-07-15T00:00:002013Modified high-dose melphalan and autologous SCT for AL amyloidosis or high-risk myeloma: analysis of SWOG trial S0115.23872222Bashir Q, Khan H, Thall PF, Liu P, Shah N, Kebriaei P, Parmar S, Oran B, Ciurea S, Nieto Y, Jones R, Hosing CM, Popat UR, Dinh YT, Rondon G, Orlowski RZ, Shah JJ, De Lima M, Shpall E, Champlin R, Giralt S, Qazilbash MHBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationA randomized phase II trial of fludarabine/melphalan 100 versus fludarabine/melphalan 140 followed by allogeneic hematopoietic stem cell transplantation for patients with multiple myeloma. Biol Blood Marrow Transplant. 2013 Oct; 19(10):1453-8.Biol Blood Marrow Transplant2013-07-17T00:00:002013A randomized phase II trial of fludarabine/melphalan 100 versus fludarabine/melphalan 140 followed by allogeneic hematopoietic stem cell transplantation for patients with multiple myeloma.24029222Orlowski RZCancer cellWhy proteasome inhibitors cannot ERADicate multiple myeloma. Cancer Cell. 2013 Sep 09; 24(3):275-7.Cancer Cell2013-09-09T00:00:002013Why proteasome inhibitors cannot ERADicate multiple myeloma.24332045Anchoori RK, Karanam B, Peng S, Wang JW, Jiang R, Tanno T, Orlowski RZ, Matsui W, Zhao M, Rudek MA, Hung CF, Chen X, Walters KJ, Roden RBCancer cellA bis-benzylidine piperidone targeting proteasome ubiquitin receptor RPN13/ADRM1 as a therapy for cancer. Cancer Cell. 2013 Dec 09; 24(6):791-805.Cancer Cell2013-12-09T00:00:002013A bis-benzylidine piperidone targeting proteasome ubiquitin receptor RPN13/ADRM1 as a therapy for cancer.24419113Palumbo A, Rajkumar SV, San Miguel JF, Larocca A, Niesvizky R, Morgan G, Landgren O, Hajek R, Einsele H, Anderson KC, Dimopoulos MA, Richardson PG, Cavo M, Spencer A, Stewart AK, Shimizu K, Lonial S, Sonneveld P, Durie BG, Moreau P, Orlowski RZJournal of clinical oncology : official journal of the American Society of Clinical OncologyInternational Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol. 2014 Feb 20; 32(6):587-600.J Clin Oncol2014-01-13T00:00:002014International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation.24425802Chen Z, Orlowski RZ, Wang M, Kwak L, McCarty NBloodOsteoblastic niche supports the growth of quiescent multiple myeloma cells. Blood. 2014 Apr 03; 123(14):2204-8.Blood2014-01-14T00:00:002014Osteoblastic niche supports the growth of quiescent multiple myeloma cells.24886772Garcia MK, Cohen L, Guo Y, Zhou Y, You B, Chiang J, Orlowski RZ, Weber D, Shah J, Alexanian R, Thomas S, Romaguera J, Zhang L, Badillo M, Chen Y, Wei Q, Lee R, Delasalle K, Green V, Wang MJournal of hematology & oncologyElectroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in multiple myeloma: a feasibility study. J Hematol Oncol. 2014 May 09; 7:41.J Hematol Oncol2014-05-09T00:00:002014Electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in multiple myeloma: a feasibility study.24921909Wu W, Merriman K, Nabaah A, Seval N, Seval D, Lin H, Wang M, Qazilbash MH, Baladandayuthapani V, Berry D, Orlowski RZ, Lee MH, Yeung SCBritish journal of cancerThe association of diabetes and anti-diabetic medications with clinical outcomes in multiple myeloma. Br J Cancer. 2014 Jul 29; 111(3):628-36.Br J Cancer2014-06-12T00:00:002014The association of diabetes and anti-diabetic medications with clinical outcomes in multiple myeloma.Authorship 2665091Authorship 2666785Authorship 2670329Authorship 2681505Authorship 2682567Authorship 26907913Authorship 2710268Authorship 27111917Authorship 2711543Authorship 2715368Authorship 2716453Authorship 2720018Authorship 2722271314557375Small GW, Somasundaram S, Moore DT, Shi YY, Orlowski RZThe Journal of pharmacology and experimental therapeuticsRepression of mitogen-activated protein kinase (MAPK) phosphatase-1 by anthracyclines contributes to their antiapoptotic activation of p44/42-MAPK. J Pharmacol Exp Ther. 2003 Dec; 307(3):861-9.J Pharmacol Exp Ther2003-10-13T00:00:002003Repression of mitogen-activated protein kinase (MAPK) phosphatase-1 by anthracyclines contributes to their antiapoptotic activation of p44/42-MAPK.15061219Orlowski RZLeukemia & lymphomaSuccessful pregnancy after cladribine therapy for hairy cell leukemia. Leuk Lymphoma. 2004 Jan; 45(1):187-8.Leuk Lymphoma2004-01-01T00:00:002004Successful pregnancy after cladribine therapy for hairy cell leukemia.17075878Ryan DP, O'Neil BH, Supko JG, Rocha Lima CM, Dees EC, Appleman LJ, Clark J, Fidias P, Orlowski RZ, Kashala O, Eder JP, Cusack JCCancerA Phase I study of bortezomib plus irinotecan in patients with advanced solid tumors. Cancer. 2006 Dec 01; 107(11):2688-97.Cancer2006-12-01T00:00:002006A Phase I study of bortezomib plus irinotecan in patients with advanced solid tumors.19344406Voorhees PM, Chen Q, Small GW, Kuhn DJ, Hunsucker SA, Nemeth JA, Orlowski RZBritish journal of haematologyTargeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death. Br J Haematol. 2009 May; 145(4):481-90.Br J Haematol2008-03-06T00:00:002008Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death.19775297Gloghini A, Buglio D, Khaskhely NM, Georgakis G, Orlowski RZ, Neelapu SS, Carbone A, Younes ABritish journal of haematologyExpression of histone deacetylases in lymphoma: implication for the development of selective inhibitors. Br J Haematol. 2009 Nov; 147(4):515-25.Br J Haematol2009-09-22T00:00:002009Expression of histone deacetylases in lymphoma: implication for the development of selective inhibitors.21241278Hunsucker SA, Magarotto V, Kuhn DJ, Kornblau SM, Wang M, Weber DM, Thomas SK, Shah JJ, Voorhees PM, Xie H, Cornfeld M, Nemeth JA, Orlowski RZBritish journal of haematologyBlockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma. Br J Haematol. 2011 Mar; 152(5):579-92.Br J Haematol2011-01-17T00:00:002011Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma.22932796Kuhn DJ, Berkova Z, Jones RJ, Woessner R, Bjorklund CC, Ma W, Davis RE, Lin P, Wang H, Madden TL, Wei C, Baladandayuthapani V, Wang M, Thomas SK, Shah JJ, Weber DM, Orlowski RZBloodTargeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma. Blood. 2012 Oct 18; 120(16):3260-70.Blood2012-08-29T00:00:002012Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma.23009979Jain P, Verstovsek S, Orlowski RZ, Yap E, Amin HMClinical lymphoma, myeloma & leukemiaAn unusual case of aggressive systemic mastocytosis with associated refractory plasma cell myeloma. Clin Lymphoma Myeloma Leuk. 2012 Dec; 12(6):459-62.Clin Lymphoma Myeloma Leuk2012-09-24T00:00:002012An unusual case of aggressive systemic mastocytosis with associated refractory plasma cell myeloma.23820125Jones RJ, Gu D, Bjorklund CC, Kuiatse I, Remaley AT, Bashir T, Vreys V, Orlowski RZThe Journal of pharmacology and experimental therapeuticsThe novel anticancer agent JNJ-26854165 induces cell death through inhibition of cholesterol transport and degradation of ABCA1. J Pharmacol Exp Ther. 2013 Sep; 346(3):381-92.J Pharmacol Exp Ther2013-07-02T00:00:002013The novel anticancer agent JNJ-26854165 induces cell death through inhibition of cholesterol transport and degradation of ABCA1.24014245Wang M, Martin T, Bensinger W, Alsina M, Siegel DS, Kavalerchik E, Huang M, Orlowski RZ, Niesvizky RBloodPhase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. Blood. 2013 Oct 31; 122(18):3122-8.Blood2013-09-06T00:00:002013Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.24166296Thakurta A, Gandhi AK, Waldman MF, Bjorklund C, Ning Y, Mendy D, Schafer P, Lopez-Girona A, Lentzsch S, Schey SA, Calle Y, Chelliah R, Orlowski RZ, Madan A, Avet-Loiseau H, Chopra RLeukemiaAbsence of mutations in cereblon (CRBN) and DNA damage-binding protein 1 (DDB1) genes and significance for IMiD therapy. Leukemia. 2014 May; 28(5):1129-31.Leukemia2013-10-29T00:00:002013Absence of mutations in cereblon (CRBN) and DNA damage-binding protein 1 (DDB1) genes and significance for IMiD therapy.24350987Ocio EM, Mitsiades CS, Orlowski RZ, Anderson KCExpert review of hematologyFuture agents and treatment directions in multiple myeloma. Expert Rev Hematol. 2014 Feb; 7(1):127-41.Expert Rev Hematol2013-12-18T00:00:002013Future agents and treatment directions in multiple myeloma.25002530Chen S, Zhou L, Zhang Y, Leng Y, Pei XY, Lin H, Jones R, Orlowski RZ, Dai Y, Grant SMolecular and cellular biologyTargeting SQSTM1/p62 induces cargo loading failure and converts autophagy to apoptosis via NBK/Bik. Mol Cell Biol. 2014 Sep 15; 34(18):3435-49.Mol Cell Biol2014-07-07T00:00:002014Targeting SQSTM1/p62 induces cargo loading failure and converts autophagy to apoptosis via NBK/Bik.Authorship 27354615Authorship 2736234Authorship 2757281Authorship 27699252161154Orlowski R, Polvino-Bodnar M, Hearing J, Miller GVirologyInhibition of specific binding of EBNA 1 to DNA by murine monoclonal and certain human polyclonal antibodies. Virology. 1990 Jun; 176(2):638-42.Virology1990-06-01T00:00:001990Inhibition of specific binding of EBNA 1 to DNA by murine monoclonal and certain human polyclonal antibodies.11085542Lewis BC, Prescott JE, Campbell SE, Shim H, Orlowski RZ, Dang CVCancer researchTumor induction by the c-Myc target genes rcl and lactate dehydrogenase A. Cancer Res. 2000 Nov 01; 60(21):6178-83.Cancer Res2000-11-01T00:00:002000Tumor induction by the c-Myc target genes rcl and lactate dehydrogenase A.18305219Chen Q, Xie W, Kuhn DJ, Voorhees PM, Lopez-Girona A, Mendy D, Corral LG, Krenitsky VP, Xu W, Moutouh-de Parseval L, Webb DR, Mercurio F, Nakayama KI, Nakayama K, Orlowski RZBloodTargeting the p27 E3 ligase SCF(Skp2) results in p27- and Skp2-mediated cell-cycle arrest and activation of autophagy. Blood. 2008 May 01; 111(9):4690-9.Blood2008-02-27T00:00:002008Targeting the p27 E3 ligase SCF(Skp2) results in p27- and Skp2-mediated cell-cycle arrest and activation of autophagy.19494840Palumbo A, Sezer O, Kyle R, Miguel JS, Orlowski RZ, Moreau P, Niesvizky R, Morgan G, Comenzo R, Sonneveld P, Kumar S, Hajek R, Giralt S, Bringhen S, Anderson KC, Richardson PG, Cavo M, Davies F, Blad? J, Einsele H, Dimopoulos MA, Spencer A, Dispenzieri A, Reiman T, Shimizu K, Lee JH, Attal M, Boccadoro M, Mateos M, Chen W, Ludwig H, Joshua D, Chim J, Hungria V, Turesson I, Durie BG, Lonial S, IMWGLeukemiaInternational Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. Leukemia. 2009 Oct; 23(10):1716-30.Leukemia2009-06-04T00:00:002009International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation.Authorship 2872853Authorship 28780911Authorship 2882199Authorship 28906211Authorship 2892237Authorship 2899518Authorship 29022012Authorship 2903039Authorship 2908687Authorship 2910539Authorship 2911664Authorship 2913852Authorship 2915779Authorship 29159911Authorship 2917889Authorship 2921896Authorship 2922081Authorship 29302113Authorship 2931165Authorship 2932784Authorship 2941343Authorship 29459611Authorship 29541514Authorship 29566410Authorship 29588814Authorship 2961615Authorship 29666914Authorship 2971742Authorship 29721513Authorship 29797812Authorship 29856021Authorship 29932710Authorship 2993309Authorship 2993789Authorship 29947510Authorship 30008313Authorship 3005944Authorship 30073744Authorship 30244121Authorship 30254417Authorship 30344013Authorship 30386815Authorship 3039382Authorship 304400323714530Lee HC, Shah JJ, Orlowski RZAmerican Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual MeetingNovel approaches to treatment of double-refractory multiple myeloma. Am Soc Clin Oncol Educ Book. 2013.Am Soc Clin Oncol Educ Book2013-01-01T00:00:002013Novel approaches to treatment of double-refractory multiple myeloma.24144643Dhodapkar MV, Sexton R, Waheed S, Usmani S, Papanikolaou X, Nair B, Petty N, Shaughnessy JD, Hoering A, Crowley J, Orlowski RZ, Barlogie BBloodClinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120). Blood. 2014 Jan 02; 123(1):78-85.Blood2013-10-21T00:00:002013Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120).24419515Patel K, Nusrat M, Shah N, Bashir Q, Parmar S, Shah J, Thomas S, Weber D, Orlowski RZ, Champlin R, Qazilbash MHBone marrow transplantationDurable responses with autologous hematopoietic SCT in patients with POEMS syndrome. Bone Marrow Transplant. 2014 Mar; 49(3):465-6.Bone Marrow Transplant2014-01-13T00:00:002014Durable responses with autologous hematopoietic SCT in patients with POEMS syndrome.24594907Pei XY, Dai Y, Felthousen J, Chen S, Takabatake Y, Zhou L, Youssefian LE, Sanderson MW, Bodie WW, Kramer LB, Orlowski RZ, Grant SPloS oneCircumvention of Mcl-1-dependent drug resistance by simultaneous Chk1 and MEK1/2 inhibition in human multiple myeloma cells. PLoS One. 2014; 9(3):e89064.PLoS One2014-03-04T00:00:002014Circumvention of Mcl-1-dependent drug resistance by simultaneous Chk1 and MEK1/2 inhibition in human multiple myeloma cells.24727327Coughlin K, Anchoori R, Iizuka Y, Meints J, MacNeill L, Vogel RI, Orlowski RZ, Lee MK, Roden RB, Bazzaro MClinical cancer research : an official journal of the American Association for Cancer ResearchSmall-molecule RA-9 inhibits proteasome-associated DUBs and ovarian cancer in vitro and in vivo via exacerbating unfolded protein responses. Clin Cancer Res. 2014 Jun 15; 20(12):3174-86.Clin Cancer Res2014-04-11T00:00:002014Small-molecule RA-9 inhibits proteasome-associated DUBs and ovarian cancer in vitro and in vivo via exacerbating unfolded protein responses.24844357Glitza IC, Lu G, Shah R, Bashir Q, Shah N, Champlin RE, Shah J, Orlowski RZ, Qazilbash MHLeukemia & lymphomaChromosome 8q24.1/c-MYC abnormality: a marker for high-risk myeloma. Leuk Lymphoma. 2015 Mar; 56(3):602-7.Leuk Lymphoma2014-08-18T00:00:002014Chromosome 8q24.1/c-MYC abnormality: a marker for high-risk myeloma.24887378Parmar S, Kongtim P, Champlin R, Dinh Y, Elgharably Y, Wang M, Bashir Q, Shah JJ, Shah N, Popat U, Giralt SA, Orlowski RZ, Qazilbash MHBone marrow transplantationAuto-SCT improves survival in systemic light chain amyloidosis: a retrospective analysis with 14-year follow-up. Bone Marrow Transplant. 2014 Aug; 49(8):1036-41.Bone Marrow Transplant2014-06-02T00:00:002014Auto-SCT improves survival in systemic light chain amyloidosis: a retrospective analysis with 14-year follow-up.24913924Srkalovic G, Hussein MA, Hoering A, Zonder JA, Popplewell LL, Trivedi H, Mazzoni S, Sexton R, Orlowski RZ, Barlogie BCancer medicineA phase II trial of BAY 43-9006 (sorafenib) (NSC-724772) in patients with relapsing and resistant multiple myeloma: SWOG S0434. Cancer Med. 2014 Oct; 3(5):1275-83.Cancer Med2014-06-10T00:00:002014A phase II trial of BAY 43-9006 (sorafenib) (NSC-724772) in patients with relapsing and resistant multiple myeloma: SWOG S0434.25042852Wen J, Tao W, Kuiatse I, Lin P, Feng Y, Jones RJ, Orlowski RZ, Zu YInternational journal of cancerDynamic balance of multiple myeloma clonogenic side population cell percentages controlled by environmental conditions. Int J Cancer. 2015 Mar 01; 136(5):991-1002.Int J Cancer2014-07-23T00:00:002014Dynamic balance of multiple myeloma clonogenic side population cell percentages controlled by environmental conditions.25107338Pemmaraju N, Shah D, Kantarjian H, Orlowski RZ, Nogueras Gonz?lez GM, Baladandayuthapani V, Jain N, Wagner V, Garcia-Manero G, Shah J, Ravandi F, Pierce S, Takahashi K, Daver N, Nazha A, Verstovsek S, Jabbour E, De Lima M, Champlin R, Cortes J, Qazilbash MHClinical lymphoma, myeloma & leukemiaCharacteristics and outcomes of patients with multiple myeloma who develop therapy-related myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2015 Feb; 15(2):110-4.Clin Lymphoma Myeloma Leuk2014-07-15T00:00:002014Characteristics and outcomes of patients with multiple myeloma who develop therapy-related myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia.25181509Gu D, Wang S, Kuiatse I, Wang H, He J, Dai Y, Jones RJ, Bjorklund CC, Yang J, Grant S, Orlowski RZPloS oneInhibition of the MDM2 E3 Ligase induces apoptosis and autophagy in wild-type and mutant p53 models of multiple myeloma, and acts synergistically with ABT-737. PLoS One. 2014; 9(9):e103015.PLoS One2014-09-02T00:00:002014Inhibition of the MDM2 E3 Ligase induces apoptosis and autophagy in wild-type and mutant p53 models of multiple myeloma, and acts synergistically with ABT-737.25168239Martin-Antonio B, Najjar A, Robinson SN, Chew C, Li S, Yvon E, Thomas MW, Mc Niece I, Orlowski R, Mu?oz-Pinedo C, Bueno C, Menendez P, Fern?ndez de Larrea C, Urbano-Ispizua A, Shpall EJ, Shah NCell death and differentiationTransmissible cytotoxicity of multiple myeloma cells by cord blood-derived NK cells is mediated by vesicle trafficking. Cell Death Differ. 2015 Jan; 22(1):96-107.Cell Death Differ2014-08-29T00:00:002014Transmissible cytotoxicity of multiple myeloma cells by cord blood-derived NK cells is mediated by vesicle trafficking.25208888Chen S, Zhang Y, Zhou L, Leng Y, Lin H, Kmieciak M, Pei XY, Jones R, Orlowski RZ, Dai Y, Grant SBloodA Bim-targeting strategy overcomes adaptive bortezomib resistance in myeloma through a novel link between autophagy and apoptosis. Blood. 2014 Oct 23; 124(17):2687-97.Blood2014-09-10T00:00:002014A Bim-targeting strategy overcomes adaptive bortezomib resistance in myeloma through a novel link between autophagy and apoptosis.25248883Wang XS, Shi Q, Williams LA, Shah ND, Mendoza TR, Cohen EN, Reuben JM, Cleeland CS, Orlowski RZLeukemia & lymphomaLongitudinal analysis of patient-reported symptoms post-autologous stem cell transplant and their relationship to inflammation in patients with multiple myeloma. Leuk Lymphoma. 2015 May; 56(5):1335-41.Leuk Lymphoma2014-11-20T00:00:002014Longitudinal analysis of patient-reported symptoms post-autologous stem cell transplant and their relationship to inflammation in patients with multiple myeloma.25261096Dimopoulos MA, Orlowski RZ, Facon T, Sonneveld P, Anderson KC, Beksac M, Benboubker L, Roddie H, Potamianou A, Couturier C, Feng H, Ataman O, van de Velde H, Richardson PGHaematologicaRetrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma. Haematologica. 2015 Jan; 100(1):100-6.Haematologica2014-09-26T00:00:002014Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma.25284489Gertz MA, Terpos E, Dispenzieri A, Kumar S, Shah RA, Orlowski R, Kastritis E, Dimopoulos MA, Shah JLeukemia & lymphomaTherapy-related myelodysplastic syndrome/acute leukemia after multiple myeloma in the era of novel agents. Leuk Lymphoma. 2015 Jun; 56(6):1723-6.Leuk Lymphoma2014-11-03T00:00:002014Therapy-related myelodysplastic syndrome/acute leukemia after multiple myeloma in the era of novel agents.25294016Orlowski RZ, Gercheva L, Williams C, Sutherland H, Robak T, Masszi T, Goranova-Marinova V, Dimopoulos MA, Cavenagh JD, ?picka I, Maiolino A, Suvorov A, Blad? J, Samoylova O, Puchalski TA, Reddy M, Bandekar R, van de Velde H, Xie H, Rossi JFAmerican journal of hematologyA phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma. Am J Hematol. 2015 Jan; 90(1):42-9.Am J Hematol2015-01-01T00:00:002015A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma.25439689Fowler NH, Davis RE, Rawal S, Nastoupil L, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale MA, Fayad LE, Westin JR, Shah J, Orlowski RZ, Wang M, Turturro F, Oki Y, Claret LC, Feng L, Baladandayuthapani V, Muzzafar T, Tsai KY, Samaniego F, Neelapu SSThe Lancet. OncologySafety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Lancet Oncol. 2014 Nov; 15(12):1311-8.Lancet Oncol2014-10-15T00:00:002014Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial.25469832Shi Q, Wang XS, Li G, Shah ND, Orlowski RZ, Williams LA, Mendoza TR, Cleeland CSCancerRacial/ethnic disparities in inflammatory gene single-nucleotide polymorphisms as predictors of a high risk for symptom burden in patients with multiple myeloma 1 year after diagnosis. Cancer. 2015 Apr 01; 121(7):1138-46.Cancer2014-12-02T00:00:002014Racial/ethnic disparities in inflammatory gene single-nucleotide polymorphisms as predictors of a high risk for symptom burden in patients with multiple myeloma 1 year after diagnosis.25520554Zhang L, Morris JS, Zhang J, Orlowski RZ, Baladandayuthapani VCancer informaticsBayesian joint selection of genes and pathways: applications in multiple myeloma genomics. Cancer Inform. 2014; 13(Suppl 2):113-23.Cancer Inform2014-12-07T00:00:002014Bayesian joint selection of genes and pathways: applications in multiple myeloma genomics.25612941Corrales-Medina FF, Manton CA, Orlowski RZ, Chandra JLeukemia researchEfficacy of panobinostat and marizomib in acute myeloid leukemia and bortezomib-resistant models. Leuk Res. 2015 Mar; 39(3):371-9.Leuk Res2015-01-03T00:00:002015Efficacy of panobinostat and marizomib in acute myeloid leukemia and bortezomib-resistant models.25721897Shah N, Thall PF, Fox PS, Bashir Q, Shah JJ, Parmar S, Lin P, Kebriaei P, Nieto Y, Popat UR, Hosing CM, Cornelison A, Shpall EJ, Orlowski RZ, Champlin RE, Qazilbash MHLeukemiaPhase I/II trial of lenalidomide and high-dose melphalan with autologous stem cell transplantation for relapsed myeloma. Leukemia. 2015 Sep; 29(9):1945-8.Leukemia2015-02-27T00:00:002015Phase I/II trial of lenalidomide and high-dose melphalan with autologous stem cell transplantation for relapsed myeloma.25730192Kongtim P, Qazilbash MH, Shah JJ, Hamdi A, Shah N, Bashir Q, Wang M, Champlin R, Manasanch EE, Weber D, Orlowski RZ, Parmar SBone marrow transplantationHigh-dose therapy with auto-SCT is feasible in high-risk cardiac amyloidosis. Bone Marrow Transplant. 2015 May; 50(5):668-72.Bone Marrow Transplant2015-03-02T00:00:002015High-dose therapy with auto-SCT is feasible in high-risk cardiac amyloidosis.25748087Kuiatse I, Baladandayuthapani V, Lin HY, Thomas SK, Bjorklund CC, Weber DM, Wang M, Shah JJ, Zhang XD, Jones RJ, Ansell SM, Yang G, Treon SP, Orlowski RZClinical cancer research : an official journal of the American Association for Cancer ResearchTargeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy against Waldenstr?m Macroglobulinemia. Clin Cancer Res. 2015 Jun 01; 21(11):2538-45.Clin Cancer Res2015-03-06T00:00:002015Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy against Waldenstr?m Macroglobulinemia.25810013Zaman S, Shentu S, Yang J, He J, Orlowski RZ, Stellrecht CM, Gandhi VNeoplasia (New York, N.Y.)Targeting the pro-survival protein MET with tivantinib (ARQ 197) inhibits growth of multiple myeloma cells. Neoplasia. 2015 Mar; 17(3):289-300.Neoplasia2015-03-01T00:00:002015Targeting the pro-survival protein MET with tivantinib (ARQ 197) inhibits growth of multiple myeloma cells.25842049Afrough A, Saliba RM, Hamdi A, El Fakih R, Varma A, Dinh YT, Rondon G, Cornelison AM, Shah ND, Bashir Q, Shah JJ, Hosing C, Popat U, Orlowski RZ, Champlin RE, Parmar S, Qazilbash MHBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationOutcome of Patients with Immunoglobulin Light-Chain Amyloidosis with Lung, Liver, Gastrointestinal, Neurologic, and Soft Tissue Involvement after Autologous Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2015 Aug; 21(8):1413-7.Biol Blood Marrow Transplant2015-04-02T00:00:002015Outcome of Patients with Immunoglobulin Light-Chain Amyloidosis with Lung, Liver, Gastrointestinal, Neurologic, and Soft Tissue Involvement after Autologous Hematopoietic Stem Cell Transplantation.25895124Zhang M, He J, Liu Z, Lu Y, Zheng Y, Li H, Xu J, Liu H, Qian J, Orlowski RZ, Kwak LW, Yi Q, Yang JOncotargetAnti-?2-microglobulin monoclonal antibodies overcome bortezomib resistance in multiple myeloma by inhibiting autophagy. Oncotarget. 2015 Apr 20; 6(11):8567-78.Oncotarget2015-04-20T00:00:002015Anti-?2-microglobulin monoclonal antibodies overcome bortezomib resistance in multiple myeloma by inhibiting autophagy.25963284El Fakih R, Fox P, Popat U, Nieto Y, Shah N, Parmar S, Oran B, Ciurea S, Kebriaei P, Hosing C, Ahmed S, Shah J, Orlowski R, Champlin R, Qazilbash M, Bashir QClinical lymphoma, myeloma & leukemiaAutologous Hematopoietic Stem Cell Transplantation in Dialysis-Dependent Myeloma Patients. Clin Lymphoma Myeloma Leuk. 2015 Aug; 15(8):472-6.Clin Lymphoma Myeloma Leuk2015-03-27T00:00:002015Autologous Hematopoietic Stem Cell Transplantation in Dialysis-Dependent Myeloma Patients.26035255Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I, Walter-Croneck A, Moreau P, Mateos MV, Magen H, Belch A, Reece D, Beksac M, Spencer A, Oakervee H, Orlowski RZ, Taniwaki M, R?llig C, Einsele H, Wu KL, Singhal A, San-Miguel J, Matsumoto M, Katz J, Bleickardt E, Poulart V, Anderson KC, Richardson P, ELOQUENT-2 InvestigatorsThe New England journal of medicineElotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2015 Aug 13; 373(7):621-31.N Engl J Med2015-06-02T00:00:002015Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.26044891Cheah CY, Orlowski RZ, Manasanch EE, Oo THAnnals of hematologyThrombotic thrombocytopenic purpura in a patient with lenalidomide-responsive multiple myeloma. Ann Hematol. 2015 Sep; 94(9):1605-7.Ann Hematol2015-06-05T00:00:002015Thrombotic thrombocytopenic purpura in a patient with lenalidomide-responsive multiple myeloma.26104577Cao X, Ye Q, Orlowski RZ, Wang X, Loghavi S, Tu M, Thomas SK, Shan J, Li S, Qazilbash M, Yin CC, Weber D, Miranda RN, Xu-Monette ZY, Medeiros LJ, Young KHJournal of hematology & oncologyWaldenstr?m macroglobulinemia with extramedullary involvement at initial diagnosis portends a poorer prognosis. J Hematol Oncol. 2015 Jun 24; 8:74.J Hematol Oncol2015-06-24T00:00:002015Waldenstr?m macroglobulinemia with extramedullary involvement at initial diagnosis portends a poorer prognosis.26202857Voorhees PM, Orlowski RZ, Mulkey F, Watson P, Geyer S, Sanford BL, Bennett E, Chanan-Khan AA, Bloomfield CD, Larson RABritish journal of haematologyLong-term outcomes for newly-diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: final results of CALGB (Alliance) 10301, a multicentre phase II study. Br J Haematol. 2015 Nov; 171(3):373-7.Br J Haematol2015-07-22T00:00:002015Long-term outcomes for newly-diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: final results of CALGB (Alliance) 10301, a multicentre phase II study.26240224Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, Richardson P, Caltagirone S, Lahuerta JJ, Facon T, Bringhen S, Gay F, Attal M, Passera R, Spencer A, Offidani M, Kumar S, Musto P, Lonial S, Petrucci MT, Orlowski RZ, Zamagni E, Morgan G, Dimopoulos MA, Durie BG, Anderson KC, Sonneveld P, San Miguel J, Cavo M, Rajkumar SV, Moreau PJournal of clinical oncology : official journal of the American Society of Clinical OncologyRevised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. J Clin Oncol. 2015 Sep 10; 33(26):2863-9.J Clin Oncol2015-08-03T00:00:002015Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group.26252787Usmani SZ, Sexton R, Ailawadhi S, Shah JJ, Valent J, Rosenzweig M, Lipe B, Zonder JA, Fredette S, Durie B, Hoering A, Bartlett B, Orlowski RZBlood cancer journalPhase I safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211. Blood Cancer J. 2015 Aug 07; 5:e334.Blood Cancer J2015-08-07T00:00:002015Phase I safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211.26361647Kazmi SM, Nusrat M, Gunaydin H, Cornelison AM, Shah N, Kebriaei P, Nieto Y, Parmar S, Popat UR, Oran B, Shah JJ, Orlowski RZ, Champlin RE, Qazilbash MH, Bashir QClinical lymphoma, myeloma & leukemiaOutcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation. Clin Lymphoma Myeloma Leuk. 2015 Nov; 15(11):687-93.Clin Lymphoma Myeloma Leuk2015-08-05T00:00:002015Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation.26384354Shah JJ, Stadtmauer EA, Abonour R, Cohen AD, Bensinger WI, Gasparetto C, Kaufman JL, Lentzsch S, Vogl DT, Gomes CL, Pascucci N, Smith DD, Orlowski RZ, Durie BGBloodCarfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma. Blood. 2015 Nov 12; 126(20):2284-90.Blood2015-09-17T00:00:002015Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma.26428082Giralt S, Garderet L, Durie B, Cook G, Gahrton G, Bruno B, Hari P, Lokhorst H, McCarthy P, Krishnan A, Sonneveld P, Goldschmidt H, Jagannath S, Barlogie B, Mateos M, Gimsing P, Sezer O, Mikhael J, Lu J, Dimopoulos M, Mazumder A, Palumbo A, Abonour R, Anderson K, Attal M, Blade J, Bird J, Cavo M, Comenzo R, de la Rubia J, Einsele H, Garcia-Sanz R, Hillengass J, Holstein S, Johnsen HE, Joshua D, Koehne G, Kumar S, Kyle R, Leleu X, Lonial S, Ludwig H, Nahi H, Nooka A, Orlowski R, Rajkumar V, Reiman A, Richardson P, Riva E, San Miguel J, Turreson I, Usmani S, Vesole D, Bensinger W, Qazilbash M, Efebera Y, Mohty M, Gasparreto C, Gajewski J, LeMaistre CF, Bredeson C, Moreau P, Pasquini M, Kroeger N, Stadtmauer EBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationAmerican Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. Biol Blood Marrow Transplant. 2015 Dec; 21(12):2039-2051.Biol Blood Marrow Transplant2015-09-30T00:00:002015American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma.26455377Liu Z, Xu J, He J, Liu H, Lin P, Wan X, Navone NM, Tong Q, Kwak LW, Orlowski RZ, Yang JOncotargetMature adipocytes in bone marrow protect myeloma cells against chemotherapy through autophagy activation. Oncotarget. 2015 Oct 27; 6(33):34329-41.Oncotarget2015-10-27T00:00:002015Mature adipocytes in bone marrow protect myeloma cells against chemotherapy through autophagy activation.26455434Vallabhapurapu SD, Noothi SK, Pullum DA, Lawrie CH, Pallapati R, Potluri V, Kuntzen C, Khan S, Plas DR, Orlowski RZ, Chesi M, Kuehl WM, Bergsagel PL, Karin M, Vallabhapurapu SNature communicationsTranscriptional repression by the HDAC4-RelB-p52 complex regulates multiple myeloma survival and growth. Nat Commun. 2015 Oct 12; 6:8428.Nat Commun2015-10-12T00:00:002015Transcriptional repression by the HDAC4-RelB-p52 complex regulates multiple myeloma survival and growth.26468228Dhodapkar MV, Sexton R, Das R, Dhodapkar KM, Zhang L, Sundaram R, Soni S, Crowley JJ, Orlowski RZ, Barlogie BBloodProspective analysis of antigen-specific immunity, stem-cell antigens, and immune checkpoints in monoclonal gammopathy. Blood. 2015 Nov 26; 126(22):2475-8.Blood2015-10-14T00:00:002015Prospective analysis of antigen-specific immunity, stem-cell antigens, and immune checkpoints in monoclonal gammopathy.26483548Li B, Fu J, Chen P, Ge X, Li Y, Kuiatse I, Wang H, Wang H, Zhang X, Orlowski RZThe Journal of biological chemistryThe Nuclear Factor (Erythroid-derived 2)-like 2 and Proteasome Maturation Protein Axis Mediate Bortezomib Resistance in Multiple Myeloma. J Biol Chem. 2015 Dec 11; 290(50):29854-68.J Biol Chem2015-10-19T00:00:002015The Nuclear Factor (Erythroid-derived 2)-like 2 and Proteasome Maturation Protein Axis Mediate Bortezomib Resistance in Multiple Myeloma.26561559Shah JJ, Jakubowiak AJ, O'Connor OA, Orlowski RZ, Harvey RD, Smith MR, Lebovic D, Diefenbach C, Kelly K, Hua Z, Berger AJ, Mulligan G, Faessel HM, Tirrell S, Dezube BJ, Lonial SClinical cancer research : an official journal of the American Association for Cancer ResearchPhase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma. Clin Cancer Res. 2016 Jan 01; 22(1):34-43.Clin Cancer Res2015-11-11T00:00:002015Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma.26671818Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, H?jek R, Facon T, Ludwig H, Oriol A, Goldschmidt H, Rosi?ol L, Straub J, Suvorov A, Araujo C, Rimashevskaya E, Pika T, Gaidano G, Weisel K, Goranova-Marinova V, Schwarer A, Minuk L, Masszi T, Karamanesht I, Offidani M, Hungria V, Spencer A, Orlowski RZ, Gillenwater HH, Mohamed N, Feng S, Chng WJ, ENDEAVOR InvestigatorsThe Lancet. OncologyCarfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016 Jan; 17(1):27-38.Lancet Oncol2015-12-05T00:00:002015Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.26702475Jacobs RW, Saliba RM, Sasaki K, Farhan S, Armas A, Shah ND, Bashir Q, Qureshi S, Rondon G, Hosing C, Popat U, Parmar S, Shah JJ, Wang M, Weber DM, Thomas SK, Orlowski RZ, Champlin RE, Qazilbash MHClinical lymphoma, myeloma & leukemiaOutcome of Patients With Nonsecretory Multiple Myeloma After Autologous Hematopoietic Stem Cell Transplantation. Clin Lymphoma Myeloma Leuk. 2016 Jan; 16(1):36-42.Clin Lymphoma Myeloma Leuk2015-12-01T00:00:002015Outcome of Patients With Nonsecretory Multiple Myeloma After Autologous Hematopoietic Stem Cell Transplantation.74Professor10Assistant Professor14Associate Professor27132469Zhang XD, Baladandayuthapani V, Lin H, Mulligan G, Li B, Esseltine DW, Qi L, Xu J, Hunziker W, Barlogie B, Usmani SZ, Zhang Q, Crowley J, Hoering A, Shah JJ, Weber DM, Manasanch EE, Thomas SK, Li BZ, Wang HH, Zhang J, Kuiatse I, Tang JL, Wang H, He J, Yang J, Milan E, Cenci S, Ma WC, Wang ZQ, Davis RE, Yang L, Orlowski RZCancer cellTight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling. Cancer Cell. 2016 05 09; 29(5):639-652.Cancer Cell2016-04-28T00:00:002016Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling.18094721Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San Miguel J, Barlogie B, Harousseau J, Zonder JA, Cavo M, Zangari M, Attal M, Belch A, Knop S, Joshua D, Sezer O, Ludwig H, Vesole D, Blad? J, Kyle R, Westin J, Weber D, Bringhen S, Niesvizky R, Waage A, von Lilienfeld-Toal M, Lonial S, Morgan GJ, Orlowski RZ, Shimizu K, Anderson KC, Boccadoro M, Durie BG, Sonneveld P, Hussein MA, International Myeloma Working GroupLeukemiaPrevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia. 2008 Feb; 22(2):414-23.Leukemia2007-12-20T00:00:002007Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.19050304Kuhn DJ, Hunsucker SA, Chen Q, Voorhees PM, Orlowski M, Orlowski RZBloodTargeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors. Blood. 2009 May 07; 113(19):4667-76.Blood2008-12-02T00:00:002008Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors.27420405Gaballa S, Saliba RM, Srour S, Lu G, Brammer JE, Shah N, Bashir Q, Patel K, Bock F, Parmar S, Hosing C, Popat U, Delgado R, Rondon G, Shah JJ, Manasanch EE, Orlowski RZ, Champlin R, Qazilbash MHAmerican journal of hematologyOutcomes in patients with multiple myeloma with TP53 deletion after autologous hematopoietic stem cell transplant. Am J Hematol. 2016 10; 91(10):E442-7.Am J Hematol2016-09-03T00:00:002016Outcomes in patients with multiple myeloma with TP53 deletion after autologous hematopoietic stem cell transplant.27638366Bock F, Lu G, Srour SA, Gaballa S, Lin HY, Baladandayuthapani V, Honhar M, Stich M, Shah ND, Bashir Q, Patel K, Popat U, Hosing C, Korbling M, Delgado R, Rondon G, Shah JJ, Thomas SK, Manasanch EE, Isermann B, Orlowski RZ, Champlin RE, Qazilbash MHBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationOutcome of Patients with Multiple Myeloma and CKS1B Gene Amplification after Autologous Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2016 12; 22(12):2159-2164.Biol Blood Marrow Transplant2016-09-13T00:00:002016Outcome of Patients with Multiple Myeloma and CKS1B Gene Amplification after Autologous Hematopoietic Stem Cell Transplantation.27862330Badar T, Srour S, Bashir Q, Shah N, Al-Atrash G, Hosing C, Popat U, Nieto Y, Orlowski RZ, Champlin R, Qazilbash MHEuropean journal of haematologyPredictors of inferior clinical outcome in patients with standard-risk multiple myeloma. Eur J Haematol. 2017 Mar; 98(3):263-268.Eur J Haematol2016-12-01T00:00:002016Predictors of inferior clinical outcome in patients with standard-risk multiple myeloma.22425892Yang J, He J, Wang J, Cao Y, Ling J, Qian J, Lu Y, Li H, Zheng Y, Lan Y, Hong S, Matthews J, Starbuck MW, Navone NM, Orlowski RZ, Lin P, Kwak LW, Yi QLeukemiaConstitutive activation of p38 MAPK in tumor cells contributes to osteolytic bone lesions in multiple myeloma. Leukemia. 2012 Sep; 26(9):2114-23.Leukemia2012-03-19T00:00:002012Constitutive activation of p38 MAPK in tumor cells contributes to osteolytic bone lesions in multiple myeloma.Authorship 841441Authorship 841514Authorship 842305Authorship 844321Authorship 844350Authorship 844877Authorship 845393Authorship 845735Authorship 846349Authorship 846603Authorship 846853Authorship 846953Authorship 847158Authorship 847548Authorship 848079Authorship 849761Authorship 850324Authorship 850507Authorship 851901Authorship 852488Authorship 852689Authorship 852693Authorship 853337Authorship 853797Authorship 853846Authorship 855020Authorship 855689Authorship 856282Authorship 857065Authorship 859119Authorship 859129Authorship 859205Authorship 859268Authorship 859708Authorship 860147Authorship 861677Authorship 862488Authorship 863326Authorship 864672Authorship 864872Authorship 865306Authorship 865944Authorship 866038Authorship 866145Authorship 867043Authorship 867252Authorship 868102BloodProspective analysis of antigen-specific immunity, stem-cell antigens, and immune checkpoints in monoclonal gammopathy. Blood. 126:2475-2478.Prospective analysis of antigen-specific immunity, stem-cell antigens, and immune checkpoints in monoclonal gammopathyBloodTreatment of multiple myeloma with high-risk cytogenetics. Blood. 127:2955-2962.Treatment of multiple myeloma with high-risk cytogeneticsClinical Cancer ResearchTargeting the spleen tyrosine kinase with fostamatinib as a strategy against Waldenström Macroglobulinemia. Clinical Cancer Research. 21:2538-2545.Targeting the spleen tyrosine kinase with fostamatinib as a strategy against Waldenström MacroglobulinemiaCancer CellTight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling. Cancer Cell. Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 SignalingLeukemia and LymphomaChromosome 8q24.1/c-MYC abnormality. Leukemia and Lymphoma. 56:602-607.Chromosome 8q24.1/c-MYC abnormalityBiology of Blood and Marrow TransplantationAmerican Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. Biology of Blood and Marrow Transplantation. 21:2039-2051.American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple MyelomaLeukemiaErratum. Leukemia. 26:1153.ErratumJournal of Clinical OncologyInternational Myeloma working group recommendations for the diagnosis and management of Myeloma-Related Renal Impairment. Journal of Clinical Oncology. 34:1544-1557.International Myeloma working group recommendations for the diagnosis and management of Myeloma-Related Renal ImpairmentHistopathologyCrystal-storing histiocytosis. Histopathology. 68:482-491.Crystal-storing histiocytosisBloodErrata. Blood. 127:2777.ErrataOncotargetAnti-β<inf>2</inf>-microglobulin monoclonal antibodies overcome bortezomib resistance in multiple myeloma by inhibiting autophagy. Oncotarget. 6:8567-8578.Anti-β<inf>2</inf>-microglobulin monoclonal antibodies overcome bortezomib resistance in multiple myeloma by inhibiting autophagyClinical Lymphoma, Myeloma and LeukemiaOutcome of Patients With Nonsecretory Multiple Myeloma After Autologous Hematopoietic Stem Cell Transplantation. Clinical Lymphoma, Myeloma and Leukemia. Outcome of Patients With Nonsecretory Multiple Myeloma After Autologous Hematopoietic Stem Cell TransplantationLeukemia and LymphomaLongitudinal analysis of patient-reported symptoms post-autologous stem cell transplant and their relationship to inflammation in patients with multiple myeloma. Leukemia and Lymphoma. 56:1335-1341.Longitudinal analysis of patient-reported symptoms post-autologous stem cell transplant and their relationship to inflammation in patients with multiple myelomaClinical Lymphoma, Myeloma and LeukemiaOutcomes among high-risk and standard-risk multiple myeloma patients treated with high-dose chemotherapy and autologous hematopoietic stem-cell transplantation. Clinical Lymphoma, Myeloma and Leukemia. 15:687-693.Outcomes among high-risk and standard-risk multiple myeloma patients treated with high-dose chemotherapy and autologous hematopoietic stem-cell transplantationOncotargetMature adipocytes in bone marrow protect myeloma cells against chemotherapy through autophagy activation. Oncotarget. 6:34329-34341.Mature adipocytes in bone marrow protect myeloma cells against chemotherapy through autophagy activationBloodCarfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma. Blood. 126:2284-2290.Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myelomaLeukemiaManagement of relapsed multiple myeloma. Leukemia. Management of relapsed multiple myelomaBiology of Blood and Marrow TransplantationOutcome of Patients with Immunoglobulin Light-Chain Amyloidosis with Lung, Liver, Gastrointestinal, Neurologic, andSoft Tissue Involvement after Autologous Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation. 21:1413-1417.Outcome of Patients with Immunoglobulin Light-Chain Amyloidosis with Lung, Liver, Gastrointestinal, Neurologic, andSoft Tissue Involvement after Autologous Hematopoietic Stem Cell TransplantationBlood Cancer JournalPhase i safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma. Blood Cancer Journal. 5.Phase i safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myelomaMilestones in Drug TherapyBortezomib in relapsed and relapsed/refractory multiple myeloma. Milestones in Drug Therapy. 79-94.Bortezomib in relapsed and relapsed/refractory multiple myelomaClinical Lymphoma, Myeloma and LeukemiaAutologous Hematopoietic Stem Cell Transplantation in Dialysis-Dependent Myeloma Patients. Clinical Lymphoma, Myeloma and Leukemia. 15:472-476.Autologous Hematopoietic Stem Cell Transplantation in Dialysis-Dependent Myeloma PatientsCancerFinal overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma. Cancer. Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myelomaBiology of Blood and Marrow TransplantationOutcome of Patients with Multiple Myeloma and CKS1B Gene Amplification after Autologous Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation. 22:2159-2164.Outcome of Patients with Multiple Myeloma and CKS1B Gene Amplification after Autologous Hematopoietic Stem Cell TransplantationNew England Journal of MedicineElotuzumab therapy for relapsed or refractory multiple myeloma. New England Journal of Medicine. 373:621-631.Elotuzumab therapy for relapsed or refractory multiple myelomaJournal of Biological ChemistryThe nuclear factor (erythroid-derived 2)-like 2 and proteasome maturation protein axis mediate bortezomib resistance in multiple myeloma. Journal of Biological Chemistry. 290:29854-29868.The nuclear factor (erythroid-derived 2)-like 2 and proteasome maturation protein axis mediate bortezomib resistance in multiple myelomaBloodClinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (swog s0120). Blood. 123:78-85.Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (swog s0120)Journal of Hematology and OncologyWaldenström macroglobulinemia with extramedullary involvement at initial diagnosis portends a poorer prognosis. Journal of Hematology and Oncology. 8.Waldenström macroglobulinemia with extramedullary involvement at initial diagnosis portends a poorer prognosisBritish Journal of HaematologyLong-term outcomes for newly-diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib. British Journal of Haematology. 171:373-377.Long-term outcomes for newly-diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomibClinical Cancer ResearchLenalidomide, thalidomide, and pomalidomide reactivate the Epstein-Barr virus lytic cycle through phosphoinositide 3-kinase signaling and ikaros expression. Clinical Cancer Research. 22:4901-4912.Lenalidomide, thalidomide, and pomalidomide reactivate the Epstein-Barr virus lytic cycle through phosphoinositide 3-kinase signaling and ikaros expressionNew England Journal of MedicineDaratumumab, lenalidomide, and dexamethasone for multiple myeloma. New England Journal of Medicine. 375:1319-1331.Daratumumab, lenalidomide, and dexamethasone for multiple myelomaNovel proteasome inhibitors. 157-180.Novel proteasome inhibitorsMilestones in Drug TherapyBortezomib in relapsed and relapsed/ refractory multiple myeloma. Milestones in Drug Therapy. 37:79-94.Bortezomib in relapsed and relapsed/ refractory multiple myelomaBritish Journal of HaematologyDose adjusted-EPOCH-R and mediastinal disease may improve outcomes for patients with gray-zone lymphoma. British Journal of Haematology. Dose adjusted-EPOCH-R and mediastinal disease may improve outcomes for patients with gray-zone lymphomaThe Lancet OncologyInternational Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. The Lancet Oncology. 17:e328-e346.International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myelomaClinical Cancer ResearchPhase I study of the novel investigational NEDD8-activating enzyme inhibitor pevonedistat (MLN4924) in patients with relapsed/refractory multiple myeloma or lymphoma. Clinical Cancer Research. 22:34-43.Phase I study of the novel investigational NEDD8-activating enzyme inhibitor pevonedistat (MLN4924) in patients with relapsed/refractory multiple myeloma or lymphomaBlood Cancer JournalPhase I safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma. Blood Cancer Journal. 5.Phase I safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myelomaCancerProlonged survival with a longer duration of maintenance lenalidomide after autologous hematopoietic stem cell transplantation for multiple myeloma. Cancer. Prolonged survival with a longer duration of maintenance lenalidomide after autologous hematopoietic stem cell transplantation for multiple myelomaLeukemia and LymphomaAsia-Pacific Hematology Consortium Report on approach to multiple myeloma. Survey results from the 6th International Hematologic Malignancies Conference. Leukemia and Lymphoma. 1-5.Asia-Pacific Hematology Consortium Report on approach to multiple myeloma. Survey results from the 6th International Hematologic Malignancies ConferenceJournal for ImmunoTherapy of CancerThe society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of hematologic malignancies. Journal for ImmunoTherapy of Cancer. 4.The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of hematologic malignanciesClinical Cancer ResearchIntegration of novel agents into the care of patients with multiple myeloma. Clinical Cancer Research. 22:5443-5452.Integration of novel agents into the care of patients with multiple myelomaJournal of Oncology PracticeASCO 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. Journal of Oncology Practice. 3:236.ASCO 2007 clinical practice guideline update on the role of bisphosphonates in multiple myelomaTargeting the proteasome in cancer therapy. 243-274.Targeting the proteasome in cancer therapyLeukemia and LymphomaClinicopathologic features and outcomes of lymphoplasmacytic lymphoma patients with monoclonal IgG or IgA paraprotein expression. Leukemia and Lymphoma. 1-10.Clinicopathologic features and outcomes of lymphoplasmacytic lymphoma patients with monoclonal IgG or IgA paraprotein expressionCancer Epidemiology Biomarkers and PreventionA meta-analysis of multiple myeloma risk regions in African and European ancestry populations identifies putatively functional loci. Cancer Epidemiology Biomarkers and Prevention. 25:1609-1618.A meta-analysis of multiple myeloma risk regions in African and European ancestry populations identifies putatively functional lociScience SignalingATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies. Science Signaling. 9.ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignanciesUpdate on Cancer TherapeuticsProteasome inhibitors and modulators of heat shock protein function. Update on Cancer Therapeutics. 1:91-116.Proteasome inhibitors and modulators of heat shock protein functionNature CommunicationsTranscriptional repression by the HDAC4-RelB-p52 complex regulates multiple myeloma survival and growth. Nature Communications. 6.Transcriptional repression by the HDAC4-RelB-p52 complex regulates multiple myeloma survival and growth28295190Shah N, Li L, McCarty J, Kaur I, Yvon E, Shaim H, Muftuoglu M, Liu E, Orlowski RZ, Cooper L, Lee D, Parmar S, Cao K, Sobieiski C, Saliba R, Hosing C, Ahmed S, Nieto Y, Bashir Q, Patel K, Bollard C, Qazilbash M, Champlin R, Rezvani K, Shpall EJBritish journal of haematologyPhase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma. Br J Haematol. 2017 05; 177(3):457-466.Br J Haematol2017-03-14T00:00:002017Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma.28522110Nieto Y, Valdez BC, Pingali SR, Bassett R, Delgado R, Nguyen J, Shah N, Popat U, Jones RB, Andersson BS, Gulbis A, Ahmed S, Bashir Q, Parmar S, Patel K, Myers A, Rondon G, Orlowski RZ, Champlin R, Qazilbash MThe Lancet. HaematologyHigh-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan. Lancet Haematol. 2017 Jun; 4(6):e283-e292.Lancet Haematol2017-05-15T00:00:002017High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan.D009101Disorders36221390.432212Multiple MyelomaAuthorship 88777731Authorship 8878769Authorship 88803618Authorship 88806417Authorship 88865821Authorship 8891909D011719Chemicals & Drugs2324980.780223PyrazinesAuthorship 90523912Authorship 90645326Authorship 90662212Authorship 90679813Authorship 9073381Authorship 90822311Authorship 90880411Authorship 90941513Authorship 91027811Authorship 91031015Authorship 91031832Authorship 9105399Authorship 91062812Authorship 91083615Authorship 9109069Authorship 91121913Authorship 9116339Authorship 91269494Authorship 9130881Authorship 91603322Authorship 9161972Authorship 91697217Authorship 91719510Authorship 91743633Authorship 91803016Authorship 9183249Authorship 91863926Authorship 91866015Authorship 9187795Authorship 9190406Authorship 9191387Authorship 91976514Authorship 9202738Authorship 92127117Authorship 92143010Authorship 9214582Authorship 92184128Authorship 9219985Authorship 92240214Authorship 9225612Authorship 9231945Authorship 92332420Authorship 92350412Authorship 9241929Authorship 9255897Authorship 92600136Authorship 9270956Authorship 92733512Authorship 92750711Authorship 92765411Authorship 9276989Authorship 9279401Authorship 9286678Authorship 9286893Authorship 92936711Authorship 93101716Authorship 93331916Authorship 93486610Authorship 93518315Authorship 93558116Authorship 93571315Authorship 93601218Authorship 93770010Authorship 939929226118455Kanagal-Shamanna R, Xu-Monette ZY, Miranda RN, Dogan A, Zou D, Luthra R, Weber DM, O'Malley DP, Jorgensen JL, Khoury JD, Bueso-Ramos CE, Orlowski RZ, Medeiros LJ, Young KHHistopathologyCrystal-storing histiocytosis: a clinicopathological study of 13 cases. Histopathology. 2016 Mar; 68(4):482-91.Histopathology2015-08-27T00:00:002015Crystal-storing histiocytosis: a clinicopathological study of 13 cases.26421453Cao X, Medeiros LJ, Xia Y, Wang X, Thomas SK, Loghavi S, Li X, Shah JJ, Gustafson SA, Weber DM, Miranda RN, Xu-Monette ZY, Orlowski RZ, Young KHLeukemia & lymphomaClinicopathologic features and outcomes of lymphoplasmacytic lymphoma patients with monoclonal IgG or IgA paraprotein expression. Leuk Lymphoma. 2016 May; 57(5):1104-13.Leuk Lymphoma2015-12-23T00:00:002015Clinicopathologic features and outcomes of lymphoplasmacytic lymphoma patients with monoclonal IgG or IgA paraprotein expression.26773409Badar T, Cornelison AM, Shah ND, Bashir Q, Parmar S, Patel K, Hosing C, Popat U, Weber DM, Thomas SK, Shah JJ, Orlowski RZ, Champlin RE, Qazilbash MHEuropean journal of haematologyOutcome of patients with systemic light chain amyloidosis with concurrent renal and cardiac involvement. Eur J Haematol. 2016 Oct; 97(4):342-7.Eur J Haematol2016-02-15T00:00:002016Outcome of patients with systemic light chain amyloidosis with concurrent renal and cardiac involvement.26884599Ishizawa J, Kojima K, Chachad D, Ruvolo P, Ruvolo V, Jacamo RO, Borthakur G, Mu H, Zeng Z, Tabe Y, Allen JE, Wang Z, Ma W, Lee HC, Orlowski R, Sarbassov dos D, Lorenzi PL, Huang X, Neelapu SS, McDonnell T, Miranda RN, Wang M, Kantarjian H, Konopleva M, Davis RE, Andreeff MScience signalingATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies. Sci Signal. 2016 Feb 16; 9(415):ra17.Sci Signal2016-02-16T00:00:002016ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies.26887657Lu J, Hou J, Liu KY, Parmar S, De La Fuente A, Andersson B, Yan C, Zhou D, Tan D, Ritchie D, Wu D, Shpall E, Laport GG, Li J, Hu J, Zhang LS, Wang M, Malhotra P, Jiang Q, Qin Y, Wong R, Champlin R, Issaragrisil S, Iyer S, Mathews V, Wang Y, Hu Y, Xiao Z, Shao Z, Rosengarten R, Steuernagle J, Xiao JH, Orlowski R, Chim CSLeukemia & lymphomaAsia-Pacific Hematology Consortium Report on approach to multiple myeloma. Survey results from the 6th International Hematologic Malignancies Conference: Bridging the Gap 2015, Beijing, China. Leuk Lymphoma. 2016 07; 57(7):1534-8.Leuk Lymphoma2016-02-17T00:00:002016Asia-Pacific Hematology Consortium Report on approach to multiple myeloma. Survey results from the 6th International Hematologic Malignancies Conference: Bridging the Gap 2015, Beijing, China.26871714Shah JJ, Feng L, Thomas SK, Berkova Z, Weber DM, Wang M, Qazilbash MH, Champlin RE, Mendoza TR, Cleeland C, Orlowski RZBlood cancer journalSiltuximab (CNTO 328) with lenalidomide, bortezomib and dexamethasone in newly-diagnosed, previously untreated multiple myeloma: an open-label phase I trial. Blood Cancer J. 2016 Feb 12; 6:e396.Blood Cancer J2016-02-12T00:00:002016Siltuximab (CNTO 328) with lenalidomide, bortezomib and dexamethasone in newly-diagnosed, previously untreated multiple myeloma: an open-label phase I trial.27002115Sonneveld P, Avet-Loiseau H, Lonial S, Usmani S, Siegel D, Anderson KC, Chng WJ, Moreau P, Attal M, Kyle RA, Caers J, Hillengass J, San Miguel J, van de Donk NW, Einsele H, Blad? J, Durie BG, Goldschmidt H, Mateos MV, Palumbo A, Orlowski RBloodTreatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood. 2016 06 16; 127(24):2955-62.Blood2016-03-21T00:00:002016Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group.26710887Laubach J, Garderet L, Mahindra A, Gahrton G, Caers J, Sezer O, Voorhees P, Leleu X, Johnsen HE, Streetly M, Jurczyszyn A, Ludwig H, Mellqvist UH, Chng WJ, Pilarski L, Einsele H, Hou J, Turesson I, Zamagni E, Chim CS, Mazumder A, Westin J, Lu J, Reiman T, Kristinsson S, Joshua D, Roussel M, O'Gorman P, Terpos E, McCarthy P, Dimopoulos M, Moreau P, Orlowski RZ, Miguel JS, Anderson KC, Palumbo A, Kumar S, Rajkumar V, Durie B, Richardson PGLeukemiaManagement of relapsed multiple myeloma: recommendations of the International Myeloma Working Group. Leukemia. 2016 05; 30(5):1005-17.Leukemia2015-12-29T00:00:002015Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group.26778538Lonial S, Weiss BM, Usmani SZ, Singhal S, Chari A, Bahlis NJ, Belch A, Krishnan A, Vescio RA, Mateos MV, Mazumder A, Orlowski RZ, Sutherland HJ, Blad? J, Scott EC, Oriol A, Berdeja J, Gharibo M, Stevens DA, LeBlanc R, Sebag M, Callander N, Jakubowiak A, White D, de la Rubia J, Richardson PG, Lisby S, Feng H, Uhlar CM, Khan I, Ahmadi T, Voorhees PMLancet (London, England)Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet. 2016 Apr 09; 387(10027):1551-1560.Lancet2016-01-07T00:00:002016Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial.26914976Rychak E, Mendy D, Shi T, Ning Y, Leisten J, Lu L, Miller K, Narla RK, Orlowski RZ, Raymon HK, Bjorklund CC, Thakurta A, Gandhi AK, Cathers BE, Chopra R, Daniel TO, Lopez-Girona ABritish journal of haematologyPomalidomide in combination with dexamethasone results in synergistic anti-tumour responses in pre-clinical models of lenalidomide-resistant multiple myeloma. Br J Haematol. 2016 Mar; 172(6):889-901.Br J Haematol2016-02-23T00:00:002016Pomalidomide in combination with dexamethasone results in synergistic anti-tumour responses in pre-clinical models of lenalidomide-resistant multiple myeloma.26976420Dimopoulos MA, Sonneveld P, Leung N, Merlini G, Ludwig H, Kastritis E, Goldschmidt H, Joshua D, Orlowski RZ, Powles R, Vesole DH, Garderet L, Einsele H, Palumbo A, Cavo M, Richardson PG, Moreau P, San Miguel J, Rajkumar SV, Durie BG, Terpos EJournal of clinical oncology : official journal of the American Society of Clinical OncologyInternational Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment. J Clin Oncol. 2016 05 01; 34(13):1544-57.J Clin Oncol2016-03-14T00:00:002016International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment.27378601Chihara D, Westin JR, Miranda RN, Cheah CY, Oki Y, Turturro F, Romaguera JE, Neelapu SS, Nastoupil LJ, Fayad LE, Rodriguez MA, Fowler NH, Orlowski RZ, Wang M, Hagemeister FB, Medeiros LJ, Fanale MABritish journal of haematologyDose adjusted-EPOCH-R and mediastinal disease may improve outcomes for patients with gray-zone lymphoma. Br J Haematol. 2017 11; 179(3):503-506.Br J Haematol2016-07-05T00:00:002016Dose adjusted-EPOCH-R and mediastinal disease may improve outcomes for patients with gray-zone lymphoma.27297582Jones RJ, Iempridee T, Wang X, Lee HC, Mertz JE, Kenney SC, Lin HC, Baladandayuthapani V, Dawson CW, Shah JJ, Weber DM, Orlowski RZClinical cancer research : an official journal of the American Association for Cancer ResearchLenalidomide, Thalidomide, and Pomalidomide Reactivate the Epstein-Barr Virus Lytic Cycle through Phosphoinositide 3-Kinase Signaling and Ikaros Expression. Clin Cancer Res. 2016 Oct 01; 22(19):4901-4912.Clin Cancer Res2016-06-13T00:00:002016Lenalidomide, Thalidomide, and Pomalidomide Reactivate the Epstein-Barr Virus Lytic Cycle through Phosphoinositide 3-Kinase Signaling and Ikaros Expression.27511158Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, Munshi N, Lonial S, Blad? J, Mateos MV, Dimopoulos M, Kastritis E, Boccadoro M, Orlowski R, Goldschmidt H, Spencer A, Hou J, Chng WJ, Usmani SZ, Zamagni E, Shimizu K, Jagannath S, Johnsen HE, Terpos E, Reiman A, Kyle RA, Sonneveld P, Richardson PG, McCarthy P, Ludwig H, Chen W, Cavo M, Harousseau JL, Lentzsch S, Hillengass J, Palumbo A, Orfao A, Rajkumar SV, Miguel JS, Avet-Loiseau HThe Lancet. OncologyInternational Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016 08; 17(8):e328-e346.Lancet Oncol2016-08-01T00:00:002016International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.27191689Orlowski RZ, Nagler A, Sonneveld P, Blad? J, Hajek R, Spencer A, Robak T, Dmoszynska A, Horvath N, Spicka I, Sutherland HJ, Suvorov AN, Xiu L, Cakana A, Parekh T, San-Miguel JFCancerFinal overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma. Cancer. 2016 Jul 01; 122(13):2050-6.Cancer2016-05-18T00:00:002016Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma.27587788Rand KA, Song C, Dean E, Serie DJ, Curtin K, Sheng X, Hu D, Huff CA, Bernal-Mizrachi L, Tomasson MH, Ailawadhi S, Singhal S, Pawlish K, Peters ES, Bock CH, Stram A, Van Den Berg DJ, Edlund CK, Conti DV, Zimmerman T, Hwang AE, Huntsman S, Graff J, Nooka A, Kong Y, Pregja SL, Berndt SI, Blot WJ, Carpten J, Casey G, Chu L, Diver WR, Stevens VL, Lieber MR, Goodman PJ, Hennis AJ, Hsing AW, Mehta J, Kittles RA, Kolb S, Klein EA, Leske C, Murphy AB, Nemesure B, Neslund-Dudas C, Strom SS, Vij R, Rybicki BA, Stanford JL, Signorello LB, Witte JS, Ambrosone CB, Bhatti P, John EM, Bernstein L, Zheng W, Olshan AF, Hu JJ, Ziegler RG, Nyante SJ, Bandera EV, Birmann BM, Ingles SA, Press MF, Atanackovic D, Glenn MJ, Cannon-Albright LA, Jones B, Tricot G, Martin TG, Kumar SK, Wolf JL, Deming Halverson SL, Rothman N, Brooks-Wilson AR, Rajkumar SV, Kolonel LN, Chanock SJ, Slager SL, Severson RK, Janakiraman N, Terebelo HR, Brown EE, De Roos AJ, Mohrbacher AF, Colditz GA, Giles GG, Spinelli JJ, Chiu BC, Munshi NC, Anderson KC, Levy J, Zonder JA, Orlowski RZ, Lonial S, Camp NJ, Vachon CM, Ziv E, Stram DO, Hazelett DJ, Haiman CA, Cozen WCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive OncologyA Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci. Cancer Epidemiol Biomarkers Prev. 2016 12; 25(12):1609-1618.Cancer Epidemiol Biomarkers Prev2016-09-01T00:00:002016A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci.28053023Vogl DT, Raje N, Jagannath S, Richardson P, Hari P, Orlowski R, Supko JG, Tamang D, Yang M, Jones SS, Wheeler C, Markelewicz RJ, Lonial SClinical cancer research : an official journal of the American Association for Cancer ResearchRicolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma. Clin Cancer Res. 2017 07 01; 23(13):3307-3315.Clin Cancer Res2017-01-04T00:00:002017Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma.27705267Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, Rabin N, Orlowski RZ, Komarnicki M, Suzuki K, Plesner T, Yoon SS, Ben Yehuda D, Richardson PG, Goldschmidt H, Reece D, Lisby S, Khokhar NZ, O'Rourke L, Chiu C, Qin X, Guckert M, Ahmadi T, Moreau P, POLLUX InvestigatorsThe New England journal of medicineDaratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2016 10 06; 375(14):1319-1331.N Engl J Med2016-10-06T00:00:002016Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.28018601Boyiadzis M, Bishop MR, Abonour R, Anderson KC, Ansell SM, Avigan D, Barbarotta L, Barrett AJ, Van Besien K, Bergsagel PL, Borrello I, Brody J, Brufsky J, Cairo M, Chari A, Cohen A, Cortes J, Forman SJ, Friedberg JW, Fuchs EJ, Gore SD, Jagannath S, Kahl BS, Kline J, Kochenderfer JN, Kwak LW, Levy R, de Lima M, Litzow MR, Mahindra A, Miller J, Munshi NC, Orlowski RZ, Pagel JM, Porter DL, Russell SJ, Schwartz K, Shipp MA, Siegel D, Stone RM, Tallman MS, Timmerman JM, Van Rhee F, Waller EK, Welsh A, Werner M, Wiernik PH, Dhodapkar MVJournal for immunotherapy of cancerThe Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia. J Immunother Cancer. 2016; 4:90.J Immunother Cancer2016-12-20T00:00:002016The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia.28117417Manasanch EE, Orlowski RZNature reviews. Clinical oncologyProteasome inhibitors in cancer therapy. Nat Rev Clin Oncol. 2017 Jul; 14(7):417-433.Nat Rev Clin Oncol2017-01-24T00:00:002017Proteasome inhibitors in cancer therapy.27680710Mian I, Milton DR, Shah N, Nieto Y, Popat UR, Kebriaei P, Parmar S, Oran B, Shah JJ, Manasanch EE, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH, Bashir QCancerProlonged survival with a longer duration of maintenance lenalidomide after autologous hematopoietic stem cell transplantation for multiple myeloma. Cancer. 2016 Dec 15; 122(24):3831-3837.Cancer2016-09-28T00:00:002016Prolonged survival with a longer duration of maintenance lenalidomide after autologous hematopoietic stem cell transplantation for multiple myeloma.27903673Van Roosbroeck K, Fanini F, Setoyama T, Ivan C, Rodriguez-Aguayo C, Fuentes-Mattei E, Xiao L, Vannini I, Redis RS, D'Abundo L, Zhang X, Nicoloso MS, Rossi S, Gonzalez-Villasana V, Rupaimoole R, Ferracin M, Morabito F, Neri A, Ruvolo PP, Ruvolo VR, Pecot CV, Amadori D, Abruzzo L, Calin S, Wang X, You MJ, Ferrajoli A, Orlowski R, Plunkett W, Lichtenberg TM, Davuluri RV, Berindan-Neagoe I, Negrini M, Wistuba II, Kantarjian HM, Sood AK, Lopez-Berestein G, Keating MJ, Fabbri M, Calin GAClinical cancer research : an official journal of the American Association for Cancer ResearchCombining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers. Clin Cancer Res. 2017 06 01; 23(11):2891-2904.Clin Cancer Res2016-11-30T00:00:002016Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers.28017406Durie BGM, Hoering A, Abidi MH, Rajkumar SV, Epstein J, Kahanic SP, Thakuri M, Reu F, Reynolds CM, Sexton R, Orlowski RZ, Barlogie B, Dispenzieri ALancet (London, England)Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet. 2017 02 04; 389(10068):519-527.Lancet2016-12-23T00:00:002016Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.28100459Yu L, Tu M, Cortes J, Xu-Monette ZY, Miranda RN, Zhang J, Orlowski RZ, Neelapu S, Boddu PC, Akosile MA, Uldrick TS, Yarchoan R, Medeiros LJ, Li Y, Fajgenbaum DC, Young KHBloodClinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease. Blood. 2017 03 23; 129(12):1658-1668.Blood2017-01-18T00:00:002017Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease.28151712Orlowski RZ, Lonial SClinical cancer research : an official journal of the American Association for Cancer ResearchIntegration of Novel Agents into the Care of Patients with Multiple Myeloma. Clin Cancer Res. 2016 Nov 15; 22(22):5443-5452.Clin Cancer Res2016-11-14T00:00:002016Integration of Novel Agents into the Care of Patients with Multiple Myeloma.28306169Robinson D, Orlowski RZ, Stokes M, He J, Huse S, Chitnis A, Kranenburg B, Lam AEuropean journal of haematologyEconomic burden of relapsed or refractory multiple myeloma: Results from an international trial. Eur J Haematol. 2017 Aug; 99(2):119-132.Eur J Haematol2017-05-11T00:00:002017Economic burden of relapsed or refractory multiple myeloma: Results from an international trial.28369725Lee HC, Wang H, Baladandayuthapani V, Lin H, He J, Jones RJ, Kuiatse I, Gu D, Wang Z, Ma W, Lim J, O'Brien S, Keats J, Yang J, Davis RE, Orlowski RZBritish journal of haematologyRNA Polymerase I Inhibition with CX-5461 as a Novel Therapeutic Strategy to Target MYC in Multiple Myeloma. Br J Haematol. 2017 04; 177(1):80-94.Br J Haematol2017-04-01T00:00:002017RNA Polymerase I Inhibition with CX-5461 as a Novel Therapeutic Strategy to Target MYC in Multiple Myeloma.28368259Cavo M, Terpos E, Nanni C, Moreau P, Lentzsch S, Zweegman S, Hillengass J, Engelhardt M, Usmani SZ, Vesole DH, San-Miguel J, Kumar SK, Richardson PG, Mikhael JR, da Costa FL, Dimopoulos MA, Zingaretti C, Abildgaard N, Goldschmidt H, Orlowski RZ, Chng WJ, Einsele H, Lonial S, Barlogie B, Anderson KC, Rajkumar SV, Durie BGM, Zamagni EThe Lancet. OncologyRole of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncol. 2017 04; 18(4):e206-e217.Lancet Oncol2017-04-01T00:00:002017Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group.28655599Voorhees PM, Gasparetto C, Moore DT, Winans D, Orlowski RZ, Hurd DDClinical lymphoma, myeloma & leukemiaFinal Results of a Phase 1 Study of Vorinostat, Pegylated Liposomal Doxorubicin, and Bortezomib in Relapsed or Refractory Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2017 07; 17(7):424-432.Clin Lymphoma Myeloma Leuk2017-05-10T00:00:002017Final Results of a Phase 1 Study of Vorinostat, Pegylated Liposomal Doxorubicin, and Bortezomib in Relapsed or Refractory Multiple Myeloma.28664940Hao S, Lin P, Medeiros LJ, Fang L, Carballo-Zarate AA, Konoplev SN, Sargent RL, Weber DM, Thomas SK, Manasanch EE, Orlowski RZ, Lu XModern pathology : an official journal of the United States and Canadian Academy of Pathology, IncClinical implications of cytogenetic heterogeneity in multiple myeloma patients with TP53 deletion. Mod Pathol. 2017 10; 30(10):1378-1386.Mod Pathol2017-06-30T00:00:002017Clinical implications of cytogenetic heterogeneity in multiple myeloma patients with TP53 deletion.28669490Marchesini M, Ogoti Y, Fiorini E, Aktas Samur A, Nezi L, D'Anca M, Storti P, Samur MK, Ganan-Gomez I, Fulciniti MT, Mistry N, Jiang S, Bao N, Marchica V, Neri A, Bueso-Ramos C, Wu CJ, Zhang L, Liang H, Peng X, Giuliani N, Draetta G, Clise-Dwyer K, Kantarjian H, Munshi N, Orlowski R, Garcia-Manero G, DePinho RA, Colla SCancer cellILF2 Is a Regulator of RNA Splicing and DNA Damage Response in 1q21-Amplified Multiple Myeloma. Cancer Cell. 2017 07 10; 32(1):88-100.e6.Cancer Cell2017-06-29T00:00:002017ILF2 Is a Regulator of RNA Splicing and DNA Damage Response in 1q21-Amplified Multiple Myeloma.28281554Carballo-Zarate AA, Medeiros LJ, Fang L, Shah JJ, Weber DM, Thomas SK, Manasanch EE, Hao S, Shen Q, Orlowski RZ, Lin P, Lu XModern pathology : an official journal of the United States and Canadian Academy of Pathology, IncAdditional-structural-chromosomal aberrations are associated with inferior clinical outcome in patients with hyperdiploid multiple myeloma: a single-institution experience. Mod Pathol. 2017 06; 30(6):843-853.Mod Pathol2017-03-10T00:00:002017Additional-structural-chromosomal aberrations are associated with inferior clinical outcome in patients with hyperdiploid multiple myeloma: a single-institution experience.28337527Baljevic M, Zaman S, Baladandayuthapani V, Lin YH, de Partovi CM, Berkova Z, Amini B, Thomas SK, Shah JJ, Weber DM, Fu M, Cleeland CS, Wang XS, Stellrecht CM, Davis RE, Gandhi V, Orlowski RZAnnals of hematologyPhase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma. Ann Hematol. 2017 Jun; 96(6):977-985.Ann Hematol2017-03-23T00:00:002017Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma.28404929Huang XJ, Liu K, Ritchie D, Andersson B, Lu J, Hou J, Burguera AF, Wang J, Yeoh A, Yan C, Zhou D, Tan D, Kim DW, Wu D, Shpall E, Kornblau S, Neelapu S, Hongeng S, Li J, Hu J, Zhang LS, Wang M, Malhotra P, Jiang Q, Qin Y, Wong R, Champlin R, Hagemeister F, Westin J, Iyer S, Mathews V, Wang Y, Hu Y, Xiao Z, Shao Z, Orlowski RZ, Chim CS, Mulligan S, Sanz M, Ozawa K, Parmar S, Issaragrisil SOncotargetHematology oncology practice in the Asia-Pacific APHCON survey results from the 6th international hematologic malignancies conference: bridging the gap 2015, Beijing, China. Oncotarget. 2017 Jun 20; 8(25):41620-41630.Oncotarget2017-06-20T00:00:002017Hematology oncology practice in the Asia-Pacific APHCON survey results from the 6th international hematologic malignancies conference: bridging the gap 2015, Beijing, China.28466536Laubach JP, Moslehi JJ, Francis SA, San Miguel JF, Sonneveld P, Orlowski RZ, Moreau P, Rosi?ol L, Faber EA, Voorhees P, Mateos MV, Marquez L, Feng H, Desai A, van de Velde H, Elliott J, Shi H, Dow E, Jobanputra N, Esseltine DL, Niculescu L, Anderson KC, Lonial S, Richardson PGBritish journal of haematologyA retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma. Br J Haematol. 2017 08; 178(4):547-560.Br J Haematol2017-05-03T00:00:002017A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma.28513828Veltri LW, Milton DR, Delgado R, Shah N, Patel K, Nieto Y, Kebriaei P, Popat UR, Parmar S, Oran B, Ciurea S, Hosing C, Lee HC, Manasanch E, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH, Bashir QCancerOutcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma. Cancer. 2017 Sep 15; 123(18):3568-3575.Cancer2017-05-17T00:00:002017Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma.28673185Mohyuddin GR, Faisal MS, Badar T, Shah N, Bashir Q, Patel KK, Hosing C, Popat UR, Rondon G, Delgado R, Shah JJ, Weber DM, Thomas SK, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MHLeukemia & lymphomaA case control study of syngeneic transplantation versus autologous transplantation for multiple myeloma: two decades of experiences from a single center. Leuk Lymphoma. 2018 02; 59(2):515-518.Leuk Lymphoma2017-07-03T00:00:002017A case control study of syngeneic transplantation versus autologous transplantation for multiple myeloma: two decades of experiences from a single center.28745330Yao Z, Deng L, Xu-Monette ZY, Manyam GC, Jain P, Tzankov A, Visco C, Bhagat G, Wang J, Dybkaer K, Tam W, Hsi ED, van Krieken JH, Ponzoni M, Ferreri AJM, M?ller MB, Winter JN, Piris MA, Fayad L, Liu Y, Song Y, Orlowski RZ, Kantarjian H, Medeiros LJ, Li Y, Cortes J, Young KHLeukemiaConcordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy. Leukemia. 2018 02; 32(2):353-363.Leukemia2017-07-12T00:00:002017Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy.28863346Tu YS, He J, Liu H, Lee HC, Wang H, Ishizawa J, Allen JE, Andreeff M, Orlowski RZ, Davis RE, Yang JNeoplasia (New York, N.Y.)The Imipridone ONC201 Induces Apoptosis and Overcomes Chemotherapy Resistance by Up-Regulation of Bim in Multiple Myeloma. Neoplasia. 2017 Oct; 19(10):772-780.Neoplasia2017-08-30T00:00:002017The Imipridone ONC201 Induces Apoptosis and Overcomes Chemotherapy Resistance by Up-Regulation of Bim in Multiple Myeloma.28937327Goldschmidt H, Moreau P, Ludwig H, Niesvizky R, Chng WJ, Joshua D, Weisel K, Spencer A, Orlowski RZ, Feng S, Iskander KS, Dimopoulos MALeukemia & lymphomaCarfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study. Leuk Lymphoma. 2018 06; 59(6):1364-1374.Leuk Lymphoma2017-09-22T00:00:002017Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study.28938651Zhang Y, Zhou L, Leng Y, Dai Y, Orlowski RZ, Grant SOncotargetPositive transcription elongation factor b (P-TEFb) is a therapeutic target in human multiple myeloma. Oncotarget. 2017 Aug 29; 8(35):59476-59491.Oncotarget2017-08-01T00:00:002017Positive transcription elongation factor b (P-TEFb) is a therapeutic target in human multiple myeloma.28983805Yan X, Clemens PL, Puchalski T, Lonial S, Lokhorst H, Voorhees PM, Usmani S, Richardson PG, Plesner T, Liu K, Orlowski RZ, Losic N, Jansson R, Ahmadi T, Lantz K, Ruixo JJP, Zhou H, Xu XSClinical pharmacokineticsInfluence of Disease and Patient Characteristics on Daratumumab Exposure and Clinical Outcomes in Relapsed or Refractory Multiple Myeloma. Clin Pharmacokinet. 2018 04; 57(4):529-538.Clin Pharmacokinet2018-04-01T00:00:002018Influence of Disease and Patient Characteristics on Daratumumab Exposure and Clinical Outcomes in Relapsed or Refractory Multiple Myeloma.28843768Dimopoulos MA, Goldschmidt H, Niesvizky R, Joshua D, Chng WJ, Oriol A, Orlowski RZ, Ludwig H, Facon T, Hajek R, Weisel K, Hungria V, Minuk L, Feng S, Zahlten-Kumeli A, Kimball AS, Moreau PThe Lancet. OncologyCarfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncol. 2017 10; 18(10):1327-1337.Lancet Oncol2017-08-23T00:00:002017Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.29233917Yang J, Liu Z, Liu H, He J, Yang J, Lin P, Wang Q, Du J, Ma W, Yin Z, Davis E, Orlowski RZ, Hou J, Yi QScience signalingC-reactive protein promotes bone destruction in human myeloma through the CD32-p38 MAPK-Twist axis. Sci Signal. 2017 Dec 12; 10(509).Sci Signal2017-12-12T00:00:002017C-reactive protein promotes bone destruction in human myeloma through the CD32-p38 MAPK-Twist axis.29241222Zhou L, Zhang Y, Sampath D, Leverson J, Dai Y, Kmieciak M, Nguyen M, Orlowski RZ, Grant SBritish journal of cancerFlavopiridol enhances ABT-199 sensitivity in unfavourable-risk multiple myeloma cells in vitro and in vivo. Br J Cancer. 2018 02 06; 118(3):388-397.Br J Cancer2017-12-14T00:00:002017Flavopiridol enhances ABT-199 sensitivity in unfavourable-risk multiple myeloma cells in vitro and in vivo.28817190Shah JJ, Kaufman JL, Zonder JA, Cohen AD, Bensinger WI, Hilder BW, Rush SA, Walker DH, Tunquist BJ, Litwiler KS, Ptaszynski M, Orlowski RZ, Lonial SCancerA Phase 1 and 2 study of Filanesib alone and in combination with low-dose dexamethasone in relapsed/refractory multiple myeloma. Cancer. 2017 Dec 01; 123(23):4617-4630.Cancer2017-08-17T00:00:002017A Phase 1 and 2 study of Filanesib alone and in combination with low-dose dexamethasone in relapsed/refractory multiple myeloma.29088739Purushothaman A, Bandari SK, Chandrashekar DS, Jones RJ, Lee HC, Weber DM, Orlowski RZOncotargetChondroitin sulfate proteoglycan serglycin influences protein cargo loading and functions of tumor-derived exosomes. Oncotarget. 2017 Sep 26; 8(43):73723-73732.Oncotarget2017-08-27T00:00:002017Chondroitin sulfate proteoglycan serglycin influences protein cargo loading and functions of tumor-derived exosomes.29257139Chim CS, Kumar SK, Orlowski RZ, Cook G, Richardson PG, Gertz MA, Giralt S, Mateos MV, Leleu X, Anderson KCLeukemiaManagement of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond. Leukemia. 2018 02; 32(2):252-262.Leukemia2017-11-16T00:00:002017Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond.29402766Steiner RE, Orlowski RZ, Lee HCActa haematologicaAcute Pancreatitis Associated with Ixazomib in a Multiple Myeloma Patient. Acta Haematol. 2018; 139(1):67-70.Acta Haematol2018-02-02T00:00:002018Acute Pancreatitis Associated with Ixazomib in a Multiple Myeloma Patient.29694283Orlowski RZJournal of managed care & specialty pharmacyLetter--Incorporating Real-World Evidence and Patient Value Criteria into Value-Based Frameworks for Relapsed/Refractory Multiple Myeloma. J Manag Care Spec Pharm. 2018 May; 24(5):487.J Manag Care Spec Pharm2018-05-01T00:00:002018Letter--Incorporating Real-World Evidence and Patient Value Criteria into Value-Based Frameworks for Relapsed/Refractory Multiple Myeloma.29669929Nair S, Sng J, Boddupalli CS, Seckinger A, Chesi M, Fulciniti M, Zhang L, Rauniyar N, Lopez M, Neparidze N, Parker T, Munshi NC, Sexton R, Barlogie B, Orlowski R, Bergsagel L, Hose D, Flavell RA, Mistry PK, Meffre E, Dhodapkar MVJCI insightAntigen-mediated regulation in monoclonal gammopathies and myeloma. JCI Insight. 2018 04 19; 3(8).JCI Insight2018-04-19T00:00:002018Antigen-mediated regulation in monoclonal gammopathies and myeloma.29371952Wang H, Baladandayuthapani V, Wang Z, Lin H, Berkova Z, Davis RE, Yang L, Orlowski RZOncotargetTruncated protein tyrosine phosphatase receptor type O suppresses AKT signaling through IQ motif containing GTPase activating protein 1 and confers sensitivity to bortezomib in multiple myeloma. Oncotarget. 2017 Dec 26; 8(69):113858-113873.Oncotarget2017-12-07T00:00:002017Truncated protein tyrosine phosphatase receptor type O suppresses AKT signaling through IQ motif containing GTPase activating protein 1 and confers sensitivity to bortezomib in multiple myeloma.29581547Zhang X, Lee HC, Shirazi F, Baladandayuthapani V, Lin H, Kuiatse I, Wang H, Jones RJ, Berkova Z, Singh RK, Lu J, Qian Y, Raina K, Coleman KG, Crews CM, Li B, Wang H, Hailemichael Y, Thomas SK, Wang Z, Davis RE, Orlowski RZLeukemiaProtein targeting chimeric molecules specific for bromodomain and extra-terminal motif family proteins are active against pre-clinical models of multiple myeloma. Leukemia. 2018 10; 32(10):2224-2239.Leukemia2018-03-27T00:00:002018Protein targeting chimeric molecules specific for bromodomain and extra-terminal motif family proteins are active against pre-clinical models of multiple myeloma.29723393Romaguera JE, Wang M, Feng L, Fayad LE, Hagemeister F, McLaughlin P, Rodriguez MA, Fanale M, Orlowski R, Kwak LW, Neelapu S, Oki Y, Pro B, Younes A, Samaniego F, Fowler N, Hartig K, Valentinetti M, Smith J, Ford P, Naig A, Medeiros LJ, Kantarjian HM, Goy ACancerPhase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma. Cancer. 2018 06 15; 124(12):2561-2569.Cancer2018-05-03T00:00:002018Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma.30126942Ni H, Shirazi F, Baladandayuthapani V, Lin H, Kuiatse I, Wang H, Jones RJ, Berkova Z, Hitoshi Y, Ansell SM, Treon SP, Thomas SK, Lee HC, Wang Z, Davis RE, Orlowski RZClinical cancer research : an official journal of the American Association for Cancer ResearchTargeting Myddosome Signaling in Waldenstr?m's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191. Clin Cancer Res. 2018 12 15; 24(24):6408-6420.Clin Cancer Res2018-08-20T00:00:002018Targeting Myddosome Signaling in Waldenstr?m's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191.29980678Ailawadhi S, Jacobus S, Sexton R, Stewart AK, Dispenzieri A, Hussein MA, Zonder JA, Crowley J, Hoering A, Barlogie B, Orlowski RZ, Rajkumar SVBlood cancer journalDisease and outcome disparities in multiple myeloma: exploring the role of race/ethnicity in the Cooperative Group clinical trials. Blood Cancer J. 2018 07 06; 8(7):67.Blood Cancer J2018-07-06T00:00:002018Disease and outcome disparities in multiple myeloma: exploring the role of race/ethnicity in the Cooperative Group clinical trials.30016656Afrough A, Saliba RM, Hamdi A, Honhar M, Varma A, Cornelison AM, Rondon G, Parmar S, Shah ND, Bashir Q, Hosing C, Popat U, Weber DM, Thomas S, Orlowski RZ, Champlin RE, Qazilbash MHBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationImpact of Induction Therapy on the Outcome of Immunoglobulin Light Chain Amyloidosis after Autologous Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2018 11; 24(11):2197-2203.Biol Blood Marrow Transplant2018-08-09T00:00:002018Impact of Induction Therapy on the Outcome of Immunoglobulin Light Chain Amyloidosis after Autologous Hematopoietic Stem Cell Transplantation.30032678Hu B, Thall P, Milton DR, Sasaki K, Bashir Q, Shah N, Patel K, Popat U, Hosing C, Nieto Y, Lin P, Delgado R, Jorgensen J, Manasanch E, Weber D, Thomas S, Orlowski RZ, Champlin R, Qazilbash MHLeukemia & lymphomaHigh-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomes. Leuk Lymphoma. 2019 02; 60(2):442-452.Leuk Lymphoma2018-07-22T00:00:002018High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomes.30227761Chaudhry M, Steiner R, Claussen C, Patel K, Lee H, Weber D, Thomas S, Feng C, Amini B, Orlowski R, Feng L, Manasanch EELeukemia & lymphomaCarfilzomib-based combination regimens are highly effective frontline therapies for multiple myeloma and Waldenstr?m's macroglobulinemia. Leuk Lymphoma. 2019 04; 60(4):964-970.Leuk Lymphoma2018-09-19T00:00:002018Carfilzomib-based combination regimens are highly effective frontline therapies for multiple myeloma and Waldenstr?m's macroglobulinemia.30501870Manasanch EE, Shah JJ, Lee HC, Weber DM, Thomas SK, Amini B, Feng L, Berkova Z, Hildebrandt M, Orlowski RZThe Lancet. HaematologyBortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial. Lancet Haematol. 2018 Dec; 5(12):e628-e640.Lancet Haematol2018-12-01T00:00:002018Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial.30691369Kunacheewa C, Orlowski RZAnnual review of medicineNew Drugs in Multiple Myeloma. Annu Rev Med. 2019 01 27; 70:521-547.Annu Rev Med2019-01-27T00:00:002019New Drugs in Multiple Myeloma.30300461Saini NY, Patel R, Varma A, Bashir Q, Delgado R, Rondon G, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Weber DM, Thomas SK, Lee HC, Manasanch EE, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MHAmerican journal of hematologyMelphalan-based autologous transplant in octogenarian multiple myeloma patients. Am J Hematol. 2019 01; 94(1):E2-E5.Am J Hematol2018-10-31T00:00:002018Melphalan-based autologous transplant in octogenarian multiple myeloma patients.30446740Gowda L, Shah M, Badar I, Bashir Q, Shah N, Patel K, Kanagal-Shamanna R, Mehta R, Weber DM, Lee HC, Manasanch EE, Shah A, Thomas SK, Parmar S, Nieto Y, Orlowski RZ, Champlin R, Qazilbash MHBone marrow transplantationPrimary plasma cell leukemia: autologous stem cell transplant in an era of novel induction drugs. Bone Marrow Transplant. 2019 07; 54(7):1089-1093.Bone Marrow Transplant2018-11-16T00:00:002018Primary plasma cell leukemia: autologous stem cell transplant in an era of novel induction drugs.30548467Saini NY, Patel RD, Varma A, Bashir Q, Delgado R, Rondon G, Popat U, Hosing C, Nieto Y, Kebriaei P, Weber DM, Thomas SK, Lee HC, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MH, Patel KKAmerican journal of hematologyLong-term durable efficacy of autologous stem cell transplantation in POEMS syndrome. Am J Hematol. 2019 03; 94(3):E72-E74.Am J Hematol2018-12-21T00:00:002018Long-term durable efficacy of autologous stem cell transplantation in POEMS syndrome.D001897Chemicals & Drugs1583630.839276Boronic AcidsAuthorship 941461330842604Chim CS, Kumar SK, Orlowski RZ, Cook G, Richardson PG, Gertz MA, Giralt S, Mateos MV, Leleu X, Anderson KCLeukemiaCorrection: Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond. Leukemia. 2019 Apr; 33(4):1058-1059.Leukemia2019-04-01T00:00:002019Correction: Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond.Authorship 94322823Authorship 9434781030910541Bashir Q, Thall PF, Milton DR, Fox PS, Kawedia JD, Kebriaei P, Shah N, Patel K, Andersson BS, Nieto YL, Valdez BC, Parmar S, Rondon G, Delgado R, Hosing C, Popat UR, Oran B, Ciurea SO, Lin P, Weber DM, Thomas SK, Lee HC, Manasanch EE, Orlowski RZ, Williams LA, Champlin RE, Qazilbash MHThe Lancet. HaematologyConditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial. Lancet Haematol. 2019 May; 6(5):e266-e275.Lancet Haematol2019-03-22T00:00:002019Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial.30910787Godfrey J, Tumuluru S, Bao R, Leukam M, Venkataraman G, Phillip J, Fitzpatrick C, McElherne J, MacNabb BW, Orlowski R, Smith SM, Kline JBloodPD-L1 gene alterations identify a subset of diffuse large B-cell lymphoma harboring a T-cell-inflamed phenotype. Blood. 2019 05 23; 133(21):2279-2290.Blood2019-03-25T00:00:002019PD-L1 gene alterations identify a subset of diffuse large B-cell lymphoma harboring a T-cell-inflamed phenotype.Authorship 9437291930737236Zhuang J, Shirazi F, Singh RK, Kuiatse I, Wang H, Lee HC, Berkova Z, Berger A, Hyer M, Chattopadhyay N, Syed S, Shi JQ, Yu J, Shinde V, Tirrell S, Jones RJ, Wang Z, Davis RE, Orlowski RZBloodUbiquitin-activating enzyme inhibition induces an unfolded protein response and overcomes drug resistance in myeloma. Blood. 2019 04 04; 133(14):1572-1584.Blood2019-02-08T00:00:002019Ubiquitin-activating enzyme inhibition induces an unfolded protein response and overcomes drug resistance in myeloma.D0000692861945440.841095BortezomibD061988Chemicals & Drugs1302310.874797Proteasome Inhibitors21780997Bashir Q, Shah N, Parmar S, Wei W, Rondon G, Weber DM, Wang M, Orlowski RZ, Thomas SK, Shah J, Qureshi SR, Dinh YT, Popat U, Anderlini P, Hosing C, Giralt S, Champlin RE, Qazilbash MHLeukemia & lymphomaFeasibility of autologous hematopoietic stem cell transplant in patients aged =70 years with multiple myeloma. Leuk Lymphoma. 2012 Jan; 53(1):118-22.Leuk Lymphoma2011-08-24T00:00:002011Feasibility of autologous hematopoietic stem cell transplant in patients aged =70 years with multiple myeloma.22231283Bashir Q, Khan H, Orlowski RZ, Amjad AI, Shah N, Parmar S, Wei W, Rondon G, Weber DM, Wang M, Thomas SK, Shah JJ, Qureshi SR, Dinh YT, Popat U, Anderlini P, Hosing C, Giralt S, Champlin RE, Qazilbash MHAmerican journal of hematologyPredictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma. Am J Hematol. 2012 Mar; 87(3):272-6.Am J Hematol2012-01-09T00:00:002012Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma.23627452Lu G, Muddasani R, Orlowski RZ, Abruzzo LV, Qazilbash MH, You MJ, Wang Y, Zhao M, Chen S, Glitza IC, Medeiros LJArchives of pathology & laboratory medicinePlasma cell enrichment enhances detection of high-risk cytogenomic abnormalities by fluorescence in situ hybridization and improves risk stratification of patients with plasma cell neoplasms. Arch Pathol Lab Med. 2013 May; 137(5):625-31.Arch Pathol Lab Med2013-05-01T00:00:002013Plasma cell enrichment enhances detection of high-risk cytogenomic abnormalities by fluorescence in situ hybridization and improves risk stratification of patients with plasma cell neoplasms.Authorship 9473551Authorship 9474222Authorship 94797422Authorship 94799813Authorship 9480355Authorship 948360131090915Mateos MV, Orlowski RZ, Ocio EM, Rodr?guez-Otero P, Reece D, Moreau P, Munshi N, Avigan DE, Siegel DS, Ghori R, Farooqui MZH, Marinello P, San-Miguel JBritish journal of haematologyPembrolizumab combined with lenalidomide and low-dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE-023 study. Br J Haematol. 2019 09; 186(5):e117-e121.Br J Haematol2019-05-15T00:00:002019Pembrolizumab combined with lenalidomide and low-dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE-023 study.31104525Baljevic M, Orlowski RZExpert opinion on drug metabolism & toxicologyPharmacodynamics and pharmacokinetics of proteasome inhibitors for the treatment of multiple myeloma. Expert Opin Drug Metab Toxicol. 2019 Jun; 15(6):459-473.Expert Opin Drug Metab Toxicol2019-06-01T00:00:002019Pharmacodynamics and pharmacokinetics of proteasome inhibitors for the treatment of multiple myeloma.31141632Facon T, Kumar S, Plesner T, Orlowski RZ, Moreau P, Bahlis N, Basu S, Nahi H, Hulin C, Quach H, Goldschmidt H, O'Dwyer M, Perrot A, Venner CP, Weisel K, Mace JR, Raje N, Attal M, Tiab M, Macro M, Frenzel L, Leleu X, Ahmadi T, Chiu C, Wang J, Van Rampelbergh R, Uhlar CM, Kobos R, Qi M, Usmani SZ, MAIA Trial InvestigatorsThe New England journal of medicineDaratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma. N Engl J Med. 2019 05 30; 380(22):2104-2115.N Engl J Med2019-05-30T00:00:002019Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.31142679Liu H, He J, Koh SP, Zhong Y, Liu Z, Wang Z, Zhang Y, Li Z, Tam BT, Lin P, Xiao M, Young KH, Amini B, Starbuck MW, Lee HC, Navone NM, Davis RE, Tong Q, Bergsagel PL, Hou J, Yi Q, Orlowski RZ, Gagel RF, Yang JScience translational medicineReprogrammed marrow adipocytes contribute to myeloma-induced bone disease. Sci Transl Med. 2019 05 29; 11(494).Sci Transl Med2019-05-29T00:00:002019Reprogrammed marrow adipocytes contribute to myeloma-induced bone disease.31133526Elhammali A, Milgrom SA, Amini B, Gunther JR, Yoder A, Ludmir EB, Moon B, Weber DM, Thomas SK, Garg N, Manasanch EE, Patel KK, Orlowski RZ, Lee HC, Bird JE, Satcher R, Lin P, Pinnix CC, Dabaja BSClinical lymphoma, myeloma & leukemiaPostoperative Radiotherapy for Multiple Myeloma of Long Bones: Should the Entire Rod Be Treated? Clin Lymphoma Myeloma Leuk. 2019 08; 19(8):e465-e469.Clin Lymphoma Myeloma Leuk2019-05-02T00:00:002019Postoperative Radiotherapy for Multiple Myeloma of Long Bones: Should the Entire Rod Be Treated?31160237Orlowski RZ, Moreau P, Niesvizky R, Ludwig H, Oriol A, Chng WJ, Goldschmidt H, Yang Z, Kimball AS, Dimopoulos MClinical lymphoma, myeloma & leukemiaCarfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and Subgroups. Clin Lymphoma Myeloma Leuk. 2019 08; 19(8):522-530.e1.Clin Lymphoma Myeloma Leuk2019-05-02T00:00:002019Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and Subgroups.Authorship 9491481331201134Tabchi S, Nair R, Kunacheewa C, Patel KK, Lee HC, Thomas SK, Amini B, Ahmed S, Mehta RS, Bashir Q, Qazilbash MH, Weber DM, Orlowski RZ, Alexanian R, Feng L, Manasanch EEClinical lymphoma, myeloma & leukemiaRetrospective Review of the Use of High-Dose Cyclophosphamide, Bortezomib, Doxorubicin, and Dexamethasone for the Treatment of Multiple Myeloma and Plasma Cell Leukemia. Clin Lymphoma Myeloma Leuk. 2019 09; 19(9):560-569.Clin Lymphoma Myeloma Leuk2019-05-17T00:00:002019Retrospective Review of the Use of High-Dose Cyclophosphamide, Bortezomib, Doxorubicin, and Dexamethasone for the Treatment of Multiple Myeloma and Plasma Cell Leukemia.Authorship 9506761631243571Saini NY, Patel RD, Varma A, Bashir Q, Delgado R, Rondon G, Mukherjee A, Popat U, Hosing C, Nieto Y, Kebriaei P, Weber DM, Thomas SK, Lee HC, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MH, Patel KKAnnals of hematologyOutcomes of autologous stem cell transplantation in Waldenstr?m's macroglobulinemia. Ann Hematol. 2019 Sep; 98(9):2233-2235.Ann Hematol2019-06-26T00:00:002019Outcomes of autologous stem cell transplantation in Waldenstr?m's macroglobulinemia.31282244Bashir Q, Chamoun K, Milton DR, Khan M, Ahmed S, Mehta R, Popat UR, Kebriaei P, Nieto Y, Oran B, Ciurea SO, Hosing C, Khouri I, Patel K, Manasanch EE, Lee HC, Orlowski RZ, Champlin RE, Qazilbash MHLeukemia & lymphomaOutcomes of autologous hematopoietic cell transplantation in myeloma patients aged =75 years. Leuk Lymphoma. 2019 12; 60(14):3536-3543.Leuk Lymphoma2019-07-08T00:00:002019Outcomes of autologous hematopoietic cell transplantation in myeloma patients aged =75 years.Authorship 95195716Authorship 95373421Authorship 9538511231405950Manasanch EE, Han G, Mathur R, Qing Y, Zhang Z, Lee H, Weber DM, Amini B, Berkova Z, Eterovic K, Zhang S, Zhang J, Song X, Mao X, Morgan M, Feng L, Baladandayuthapani V, Futreal A, Wang L, Neelapu SS, Orlowski RZBlood advancesA pilot study of pembrolizumab in smoldering myeloma: report of the clinical, immune, and genomic analysis. Blood Adv. 2019 08 13; 3(15):2400-2408.Blood Adv2019-08-13T00:00:002019A pilot study of pembrolizumab in smoldering myeloma: report of the clinical, immune, and genomic analysis.31413094Manasanch EE, Shah JJ, Lee HC, Weber DM, Thomas SK, Amini B, Olsem J, Crumpton B, Morphey A, Berkova Z, Feng L, Orlowski RZHaematologicaPhase I/Ib study of carfilzomib and panobinostat with or without dexamethasone in patients with relapsed/refractory multiple myeloma. Haematologica. 2020 05; 105(5):e242-e245.Haematologica2019-08-14T00:00:002019Phase I/Ib study of carfilzomib and panobinostat with or without dexamethasone in patients with relapsed/refractory multiple myeloma.Authorship 95488925Authorship 9550171031481508Saini N, Ma J, Milton DR, Patel R, Varma A, Bashir Q, Delgado R, Mukherjee A, Rondon G, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Tang G, Mehta R, Srour S, Khouri IF, Iyer S, Weber DM, Thomas SK, Lee HC, Manasanch EE, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MHClinical cancer research : an official journal of the American Association for Cancer ResearchImpact of Autologous Transplantation in Patients with Multiple Myeloma with t(11;14): A Propensity-Score Matched Analysis. Clin Cancer Res. 2019 11 15; 25(22):6781-6787.Clin Cancer Res2019-09-03T00:00:002019Impact of Autologous Transplantation in Patients with Multiple Myeloma with t(11;14): A Propensity-Score Matched Analysis.31489991Lee HC, Shah JJ, Feng L, Morphey A, Johnson RJ, Wesson ET, Wang ML, Alexanian R, Thomas SK, Orlowski RZ, Weber DMAmerican journal of hematologyA phase I/II trial of the combination of lenalidomide, thalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. Am J Hematol. 2019 12; 94(12):E319-E322.Am J Hematol2019-10-04T00:00:002019A phase I/II trial of the combination of lenalidomide, thalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.Authorship 9563041331575851Lee HC, Shah JJ, Feng L, Manasanch EE, Lu R, Morphey A, Crumpton B, Patel KK, Wang ML, Alexanian R, Thomas SK, Weber DM, Orlowski RZBlood cancer journalA phase 1 study of filanesib, carfilzomib, and dexamethasone in patients with relapsed and/or refractory multiple myeloma. Blood Cancer J. 2019 10 01; 9(10):80.Blood Cancer J2019-10-01T00:00:002019A phase 1 study of filanesib, carfilzomib, and dexamethasone in patients with relapsed and/or refractory multiple myeloma.Authorship 9571912331609651Armand P, Rodig S, Melnichenko V, Thieblemont C, Bouabdallah K, Tumyan G, ?zcan M, Portino S, Fogliatto L, Caballero MD, Walewski J, Gulbas Z, Ribrag V, Christian B, Perini GF, Salles G, Svoboda J, Zain J, Patel S, Chen PH, Ligon AH, Ouyang J, Neuberg D, Redd R, Chatterjee A, Balakumaran A, Orlowski R, Shipp M, Zinzani PLJournal of clinical oncology : official journal of the American Society of Clinical OncologyPembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma. J Clin Oncol. 2019 12 01; 37(34):3291-3299.J Clin Oncol2019-10-14T00:00:002019Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma.Authorship 957863631652094Lonial S, Jacobus S, Fonseca R, Weiss M, Kumar S, Orlowski RZ, Kaufman JL, Yacoub AM, Buadi FK, O'Brien T, Matous JV, Anderson DM, Emmons RV, Mahindra A, Wagner LI, Dhodapkar MV, Rajkumar SVJournal of clinical oncology : official journal of the American Society of Clinical OncologyRandomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma. J Clin Oncol. 2020 04 10; 38(11):1126-1137.J Clin Oncol2019-10-25T00:00:002019Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma.31786242Cordas Dos Santos DM, Saliba RM, Patel R, Bashir Q, Saini N, Hosing C, Kebriaei P, Khouri IF, Nieto Y, Popat U, Ahmed H, Lee HC, Manasanch EE, Patel KK, Thomas SK, Weber DM, Orlowski RZ, Champlin RE, Qazilbash MHBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationAge Is a Prognostic Factor for the Overall Survival of Patients with Multiple Myeloma Undergoing Upfront Autologous Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2020 06; 26(6):1077-1083.Biol Blood Marrow Transplant2019-11-29T00:00:002019Age Is a Prognostic Factor for the Overall Survival of Patients with Multiple Myeloma Undergoing Upfront Autologous Hematopoietic Stem Cell Transplantation.Authorship 96261917Authorship 9747652831881283Varma A, Sui D, Milton DR, Tang G, Saini N, Hasan O, Mukherjee A, Joseph JJ, Bashir Q, Rondon G, Srour S, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Mehta R, Khouri IF, Ahmed H, Iyer S, Weber DM, Thomas SK, Manasanch E, Lee HC, Patel K, Ciurea SO, Shpall EJ, Orlowski RZ, Champlin RE, Qazilbash MHBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationOutcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after Autologous Hematopoietic Stem Cell Transplantation: Propensity Score Matched Analysis. Biol Blood Marrow Transplant. 2020 04; 26(4):665-671.Biol Blood Marrow Transplant2019-12-24T00:00:002019Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after Autologous Hematopoietic Stem Cell Transplantation: Propensity Score Matched Analysis.Authorship 9754241031919088Elhammali A, Amini B, Ludmir EB, Gunther JR, Milgrom SA, Pinnix CC, Andraos T, Yoder A, Weber D, Orlowski R, Manasanch E, Patel K, Strati P, Nair R, Lee HC, Thomas S, Iyer S, Kaufmann G, Garg N, Dabaja BSHaematologicaNew paradigm for radiation in multiple myeloma: lower yet effective dose to avoid radiation toxicity. Haematologica. 2020 07; 105(7):e355-e357.Haematologica2020-01-09T00:00:002020New paradigm for radiation in multiple myeloma: lower yet effective dose to avoid radiation toxicity.Authorship 9757516731935283Du Z, Weinhold N, Song GC, Rand KA, Van Den Berg DJ, Hwang AE, Sheng X, Hom V, Ailawadhi S, Nooka AK, Singhal S, Pawlish K, Peters ES, Bock C, Mohrbacher A, Stram A, Berndt SI, Blot WJ, Casey G, Stevens VL, Kittles R, Goodman PJ, Diver WR, Hennis A, Nemesure B, Klein EA, Rybicki BA, Stanford JL, Witte JS, Signorello L, John EM, Bernstein L, Stroup AM, Stephens OW, Zangari M, Van Rhee F, Olshan A, Zheng W, Hu JJ, Ziegler R, Nyante SJ, Ingles SA, Press MF, Carpten JD, Chanock SJ, Mehta J, Colditz GA, Wolf J, Martin TG, Tomasson M, Fiala MA, Terebelo H, Janakiraman N, Kolonel L, Anderson KC, Le Marchand L, Auclair D, Chiu BC, Ziv E, Stram D, Vij R, Bernal-Mizrachi L, Morgan GJ, Zonder JA, Huff CA, Lonial S, Orlowski RZ, Conti DV, Haiman CA, Cozen WBlood advancesA meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry. Blood Adv. 2020 01 14; 4(1):181-190.Blood Adv2020-01-14T00:00:002020A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry.Authorship 97773212Authorship 977911432054831Dimopoulos MA, Jakubowiak AJ, McCarthy PL, Orlowski RZ, Attal M, Blad? J, Goldschmidt H, Weisel KC, Ramasamy K, Zweegman S, Spencer A, Huang JSY, Lu J, Sunami K, Iida S, Chng WJ, Holstein SA, Rocci A, Skacel T, Labotka R, Palumbo A, Anderson KCBlood cancer journalDevelopments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma. Blood Cancer J. 2020 02 13; 10(2):17.Blood Cancer J2020-02-13T00:00:002020Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma.32037287Kunacheewa C, Lee HC, Patel K, Thomas S, Amini B, Srour S, Bashir Q, Nieto Y, Qazilbash MH, Weber DM, Feng L, Orlowski RZ, Lin P, Manasanch EEClinical lymphoma, myeloma & leukemiaMinimal Residual Disease Negativity Does Not Overcome Poor Prognosis in High-Risk Multiple Myeloma: A Single-Center Retrospective Study. Clin Lymphoma Myeloma Leuk. 2020 05; 20(5):e221-e238.Clin Lymphoma Myeloma Leuk2020-01-15T00:00:002020Minimal Residual Disease Negativity Does Not Overcome Poor Prognosis in High-Risk Multiple Myeloma: A Single-Center Retrospective Study.Authorship 978618832108443Moreau P, Stewart KA, Dimopoulos M, Siegel D, Facon T, Berenson J, Raje N, Berdeja JG, Orlowski RZ, Yang H, Ma H, Klippel Z, Zahlten-Kumeli A, Mezzi K, Iskander K, Mateos MVCancer medicineOnce-weekly (70 mg/m2 ) vs twice-weekly (56 mg/m2 ) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: A post hoc analysis of the ENDEAVOR, A.R.R.O.W., and CHAMPION-1 trials. Cancer Med. 2020 05; 9(9):2989-2996.Cancer Med2020-02-28T00:00:002020Once-weekly (70 mg/m2 ) vs twice-weekly (56 mg/m2 ) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: A post hoc analysis of the ENDEAVOR, A.R.R.O.W., and CHAMPION-1 trials.Authorship 9791471532167863Makker V, Taylor MH, Aghajanian C, Oaknin A, Mier J, Cohn AL, Romeo M, Bratos R, Brose MS, DiSimone C, Messing M, Stepan DE, Dutcus CE, Wu J, Schmidt EV, Orlowski R, Sachdev P, Shumaker R, Casado Herraez AJournal of clinical oncology : official journal of the American Society of Clinical OncologyLenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer. J Clin Oncol. 2020 09 10; 38(26):2981-2992.J Clin Oncol2020-03-13T00:00:002020Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer.Authorship 98751814Authorship 9879121832299820Ailawadhi S, Sexton R, Lentzsch S, Abidi MH, Voorhees PM, Cohen AD, Rohren EM, Heitner S, Kelly K, Mackler NJ, Baer DM, Hoering A, Durie B, Orlowski RZClinical cancer research : an official journal of the American Association for Cancer ResearchLow-dose versus High-dose Carfilzomib with Dexamethasone (S1304) in Patients with Relapsed-Refractory Multiple Myeloma. Clin Cancer Res. 2020 08 01; 26(15):3969-3978.Clin Cancer Res2020-04-16T00:00:002020Low-dose versus High-dose Carfilzomib with Dexamethasone (S1304) in Patients with Relapsed-Refractory Multiple Myeloma.32325490Voorhees PM, Kaufman JL, Laubach J, Sborov DW, Reeves B, Rodriguez C, Chari A, Silbermann R, Costa LJ, Anderson LD, Nathwani N, Shah N, Efebera YA, Holstein SA, Costello C, Jakubowiak A, Wildes TM, Orlowski RZ, Shain KH, Cowan AJ, Murphy S, Lutska Y, Pei H, Ukropec J, Vermeulen J, de Boer C, Hoehn D, Lin TS, Richardson PGBloodDaratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood. 2020 08 20; 136(8):936-945.Blood2020-08-20T00:00:002020Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial.Authorship 98922610Authorship 9892278Authorship 98927812Authorship 989365232401342Einsele H, Borghaei H, Orlowski RZ, Subklewe M, Roboz GJ, Zugmaier G, Kufer P, Iskander K, Kantarjian HMCancerThe BiTE (bispecific T-cell engager) platform: Development and future potential of a targeted immuno-oncology therapy across tumor types. Cancer. 2020 07 15; 126(14):3192-3201.Cancer2020-05-13T00:00:002020The BiTE (bispecific T-cell engager) platform: Development and future potential of a targeted immuno-oncology therapy across tumor types.32390093Kamal M, Wang XS, Shi Q, Zyczynski TM, Davis C, Williams LA, Lin HK, Garcia-Gonzalez A, Cleeland CS, Orlowski RSupportive care in cancer : official journal of the Multinational Association of Supportive Care in CancerSymptom burden and its functional impact in patients with "symptomatic" relapsed or refractory multiple myeloma. Support Care Cancer. 2021 Jan; 29(1):467-475.Support Care Cancer2020-05-11T00:00:002020Symptom burden and its functional impact in patients with "symptomatic" relapsed or refractory multiple myeloma.32390148Manasanch EE, Jain P, Chen W, Oriabure O, Badillo M, Feng L, Berkova Z, Orlowski RZ, Wang MAmerican journal of hematologyPhase I/II study of high dose pomalidomide with G-CSF support and dexamethasone in patients with relapsed/refractory multiple myeloma. Am J Hematol. 2020 09; 95(9):E232-E235.Am J Hematol2020-06-10T00:00:002020Phase I/II study of high dose pomalidomide with G-CSF support and dexamethasone in patients with relapsed/refractory multiple myeloma.32393732Durie BGM, Hoering A, Sexton R, Abidi MH, Epstein J, Rajkumar SV, Dispenzieri A, Kahanic SP, Thakuri MC, Reu FJ, Reynolds CM, Orlowski RZ, Barlogie BBlood cancer journalLonger term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT). Blood Cancer J. 2020 05 11; 10(5):53.Blood Cancer J2020-05-11T00:00:002020Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT).Authorship 9904762732469686Yu Y, Brown Wade N, Hwang AE, Nooka AK, Fiala MA, Mohrbacher A, Peters ES, Pawlish K, Bock C, Van Den Berg DJ, Rand KA, Stram D, Conti DV, Auclair D, Colditz GA, Mehta J, Haiman CA, Terebelo H, Janakiraman N, Singhal S, Chiu B, Vij R, Bernal-Mizrachi L, Zonder JA, Huff CA, Lonial S, Orlowski RZ, Cozen W, Ailawadhi SJCO oncology practiceVariability in Cytogenetic Testing for Multiple Myeloma: A Comprehensive Analysis From Across the United States. JCO Oncol Pract. 2020 10; 16(10):e1169-e1180.JCO Oncol Pract2020-05-29T00:00:002020Variability in Cytogenetic Testing for Multiple Myeloma: A Comprehensive Analysis From Across the United States.Authorship 9919941332544980Armand P, Murawski N, Molin D, Zain J, Eichhorst B, Gulbas Z, Hawkes EA, Pagel JM, Phillips T, Ribrag V, Svoboda J, Stathis A, Chatterjee A, Orlowski R, Marinello P, Christian BBritish journal of haematologyPembrolizumab in relapsed or refractory Richter syndrome. Br J Haematol. 2020 07; 190(2):e117-e120.Br J Haematol2020-06-16T00:00:002020Pembrolizumab in relapsed or refractory Richter syndrome.Authorship 9937382032632752Zou J, Jones RJ, Wang H, Kuiatse I, Shirazi F, Manasanch EE, Lee HC, Sullivan R, Fung L, Richard N, Erdman P, Torres E, Hecht D, Lam I, McElwee B, Chourasia AH, Chan KWH, Mercurio F, Stirling DI, Orlowski RZJournal of molecular medicine (Berlin, Germany)The novel protein homeostatic modulator BTX306 is active in myeloma and overcomes bortezomib and lenalidomide resistance. J Mol Med (Berl). 2020 08; 98(8):1161-1173.J Mol Med (Berl)2020-07-06T00:00:002020The novel protein homeostatic modulator BTX306 is active in myeloma and overcomes bortezomib and lenalidomide resistance.Authorship 9960541232747568Shirazi F, Jones RJ, Singh RK, Zou J, Kuiatse I, Berkova Z, Wang H, Lee HC, Hong S, Dick L, Chattopadhyay N, Orlowski RZProceedings of the National Academy of Sciences of the United States of AmericaActivating KRAS, NRAS, and BRAF mutants enhance proteasome capacity and reduce endoplasmic reticulum stress in multiple myeloma. Proc Natl Acad Sci U S A. 2020 08 18; 117(33):20004-20014.Proc Natl Acad Sci U S A2020-08-03T00:00:002020Activating KRAS, NRAS, and BRAF mutants enhance proteasome capacity and reduce endoplasmic reticulum stress in multiple myeloma.Authorship 9974476Authorship 9974891332816893Dhodapkar MV, Sexton R, Hoering A, Van Rhee F, Barlogie B, Orlowski RClinical cancer research : an official journal of the American Association for Cancer ResearchRace-Dependent Differences in Risk, Genomics, and Epstein-Barr Virus Exposure in Monoclonal Gammopathies: Results of SWOG S0120. Clin Cancer Res. 2020 11 15; 26(22):5814-5819.Clin Cancer Res2020-08-18T00:00:002020Race-Dependent Differences in Risk, Genomics, and Epstein-Barr Virus Exposure in Monoclonal Gammopathies: Results of SWOG S0120.32819881Kaufman JL, Mina R, Shah JJ, Laubach JP, Nooka AK, Lewis C, Gleason C, Sharp C, Harvey RD, Heffner LT, Richardson P, Lonial S, Orlowski RZClinical lymphoma, myeloma & leukemiaPhase 1 Trial Evaluating Vorinostat Plus Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2020 12; 20(12):797-803.Clin Lymphoma Myeloma Leuk2020-07-25T00:00:002020Phase 1 Trial Evaluating Vorinostat Plus Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma.Authorship 99833115Authorship 9984741932866432Kumar SK, Jacobus SJ, Cohen AD, Weiss M, Callander N, Singh AK, Parker TL, Menter A, Yang X, Parsons B, Kumar P, Kapoor P, Rosenberg A, Zonder JA, Faber E, Lonial S, Anderson KC, Richardson PG, Orlowski RZ, Wagner LI, Rajkumar SVThe Lancet. OncologyCarfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 2020 10; 21(10):1317-1330.Lancet Oncol2020-08-28T00:00:002020Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial.32887873Dimopoulos MA, Lonial S, White D, Moreau P, Weisel K, San-Miguel J, Shpilberg O, Grosicki S, ?picka I, Walter-Croneck A, Magen H, Mateos MV, Belch A, Reece D, Beksac M, Spencer A, Oakervee H, Orlowski RZ, Taniwaki M, R?llig C, Einsele H, Matsumoto M, Wu KL, Anderson KC, Jou YM, Ganetsky A, Singhal AK, Richardson PGBlood cancer journalElotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study. Blood Cancer J. 2020 09 04; 10(9):91.Blood Cancer J2020-09-04T00:00:002020Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study.Authorship 99921611Authorship 9992601432903557Jones RJ, Singh RK, Shirazi F, Wan J, Wang H, Wang X, Ha MJ, Baljevic M, Kuiatse I, Davis RE, Orlowski RZFrontiers in immunologyIntravenous Immunoglobulin G Suppresses Heat Shock Protein (HSP)-70 Expression and Enhances the Activity of HSP90 and Proteasome Inhibitors. Front Immunol. 2020; 11:1816.Front Immunol2020-08-13T00:00:002020Intravenous Immunoglobulin G Suppresses Heat Shock Protein (HSP)-70 Expression and Enhances the Activity of HSP90 and Proteasome Inhibitors.32908255Hao S, Lu X, Gong Z, Bassett RL, Hu S, Konoplev SN, Tang G, Li S, Xu J, Khanlari M, Lee HC, Manasanch EE, Weber DM, Orlowski RZ, Medeiros LJ, Lin PModern pathology : an official journal of the United States and Canadian Academy of Pathology, IncThe survival impact of CKS1B gains or amplification is dependent on the background karyotype and TP53 deletion status in patients with myeloma. Mod Pathol. 2021 02; 34(2):327-335.Mod Pathol2020-09-09T00:00:002020The survival impact of CKS1B gains or amplification is dependent on the background karyotype and TP53 deletion status in patients with myeloma.Authorship 10022511833027527Saini N, Bashir Q, Milton DR, Tang G, Delgado R, Rondon G, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Mehta R, Srour S, Khouri IF, Weber DM, Thomas SK, Lee HC, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MHBlood advancesBusulfan and melphalan conditioning is superior to melphalan alone in autologous stem cell transplantation for high-risk MM. Blood Adv. 2020 10 13; 4(19):4834-4837.Blood Adv2020-10-13T00:00:002020Busulfan and melphalan conditioning is superior to melphalan alone in autologous stem cell transplantation for high-risk MM.Authorship 100444520Authorship 10047371433167721Manasanch EE, Mulanovich V, Manzano JG, Gaeta MS, Becnel M, Kaufman GP, Lee HC, Amini B, Thomas SK, Iyer SP, Weber DM, Berkova Z, Flowers CR, Orlowski RZ, Patel KKLeukemia & lymphomaSARS-CoV-2 in multiple myeloma: initial observation and management. Leuk Lymphoma. 2020 11; 61(11):2763-2766.Leuk Lymphoma2020-06-17T00:00:002020SARS-CoV-2 in multiple myeloma: initial observation and management.33147277Danziger SA, McConnell M, Gockley J, Young MH, Rosenthal A, Schmitz F, Reiss DJ, Farmer P, Alapat DV, Singh A, Ashby C, Bauer M, Ren Y, Smith K, Couto SS, van Rhee F, Davies F, Zangari M, Petty N, Orlowski RZ, Dhodapkar MV, Copeland WB, Fox B, Hoering A, Fitch A, Newhall K, Barlogie B, Trotter MWB, Hershberg RM, Walker BA, Dervan AP, Ratushny AV, Morgan GJPLoS medicineBone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: A cohort study of patients in the Total Therapy clinical trials. PLoS Med. 2020 11; 17(11):e1003323.PLoS Med2020-11-04T00:00:002020Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: A cohort study of patients in the Total Therapy clinical trials.Authorship 1006990733326255Perrot A, Facon T, Plesner T, Usmani SZ, Kumar S, Bahlis NJ, Hulin C, Orlowski RZ, Nahi H, Mollee P, Ramasamy K, Roussel M, Jaccard A, Delforge M, Karlin L, Arnulf B, Chari A, He J, Ho KF, Van Rampelbergh R, Uhlar CM, Wang J, Kobos R, Gries KS, Fastenau J, Weisel KJournal of clinical oncology : official journal of the American Society of Clinical OncologyHealth-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial. J Clin Oncol. 2021 01 20; 39(3):227-237.J Clin Oncol2020-12-16T00:00:002020Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial.Authorship 10077171733357482Usmani SZ, Hoering A, Ailawadhi S, Sexton R, Lipe B, Hita SF, Valent J, Rosenzweig M, Zonder JA, Dhodapkar M, Callander N, Zimmerman T, Voorhees PM, Durie B, Rajkumar SV, Richardson PG, Orlowski RZ, SWOG1211 Trial InvestigatorsThe Lancet. HaematologyBortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial. Lancet Haematol. 2021 Jan; 8(1):e45-e54.Lancet Haematol2020-12-22T00:00:002020Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial.Authorship 10083271533406405Li Z, Liu H, He J, Wang Z, Yin Z, You G, Wang Z, Davis RE, Lin P, Bergsagel PL, Manasanch EE, Wong STC, Esnaola NF, Chang JC, Orlowski RZ, Yi Q, Yang JCell metabolismAcetyl-CoA Synthetase 2: A Critical Linkage in Obesity-Induced Tumorigenesis in Myeloma. Cell Metab. 2021 01 05; 33(1):78-93.e7.Cell Metab2021-01-05T00:00:002021Acetyl-CoA Synthetase 2: A Critical Linkage in Obesity-Induced Tumorigenesis in Myeloma.Authorship 1009396633454143Clemency BM, Innes JC, Waldrop M, White LJ, Dievendorf E, Orlowski R, Wang K, Lindstrom HA, Canty JM, Hostler DThe Journal of emergency medicineChanges in Field Termination of Resuscitation and Survival Rates After an Educational Intervention to Promote on Scene Resuscitation for Out-of-Hospital Cardiac Arrest. J Emerg Med. 2021 Mar; 60(3):349-354.J Emerg Med2021-01-13T00:00:002021Changes in Field Termination of Resuscitation and Survival Rates After an Educational Intervention to Promote on Scene Resuscitation for Out-of-Hospital Cardiac Arrest.Authorship 10098251933486754Manasanch EE, Berrios D, Fountain E, Claussen CM, Chuang T, Kaufman G, Amini B, Bashir Q, Nieto Y, Qazilbash M, Patel K, Thomas SK, Weber DM, Berkova Z, Toruner G, Lin P, Feng L, Lee HC, Orlowski RZ, Kunacheewa CBritish journal of haematologyGene expression profiling predicts relapse-free and overall survival in newly diagnosed myeloma patients treated with novel therapies. Br J Haematol. 2021 02; 192(4):e115-e120.Br J Haematol2021-01-24T00:00:002021Gene expression profiling predicts relapse-free and overall survival in newly diagnosed myeloma patients treated with novel therapies.Authorship 10110451133563896Manasanch EE, Kunacheewa C, Claussen CM, Lee HC, Thomas SK, Gunther J, Pinnix CC, Dabaja BS, Amini B, Alexanian R, Orlowski RZ, Dong W, Feng L, Weber DMBlood cancer journalSerum paraprotein persistence and size determine outcome in a cohort of patients with a modern definition of plasmacytoma with up to 19 years of follow up. Blood Cancer J. 2021 02 08; 11(2):17.Blood Cancer J2021-02-08T00:00:002021Serum paraprotein persistence and size determine outcome in a cohort of patients with a modern definition of plasmacytoma with up to 19 years of follow up.Authorship 10140281333735664Wang Y, Gali VL, Xu-Monette ZY, Sano D, Thomas SK, Weber DM, Zhu F, Fang X, Deng M, Zhang M, Hagemeister FB, Li Y, Orlowski RZ, Lee HC, Young KHNeoplasia (New York, N.Y.)Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenstr?m macroglobulinemia. Neoplasia. 2021 04; 23(4):361-374.Neoplasia2021-03-15T00:00:002021Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenstr?m macroglobulinemia.Authorship 10143301333748943Kunacheewa C, Feng L, Manasanch EE, Bashir Q, Patel KK, Mehta R, Kaufman GP, Srour S, Saini N, Iyer SP, Thomas SK, Weber DM, Orlowski RZ, Qazilbash MH, Lee HCBritish journal of haematologyOutcomes of lenalidomide retreatment with novel triplet regimens in patients with multiple myeloma progressing on lenalidomide-based maintenance therapy. Br J Haematol. 2021 05; 193(3):e23-e26.Br J Haematol2021-03-21T00:00:002021Outcomes of lenalidomide retreatment with novel triplet regimens in patients with multiple myeloma progressing on lenalidomide-based maintenance therapy.Authorship 101544615Authorship 10156509Authorship 10158691133781521Srour SA, Saliba RM, Bashir Q, Popat UR, Ahmed S, Mehta RS, Delgado R, Rondon G, Parmar S, Kebriaei P, Hosing C, Manasanch EE, Lee HC, Patel KK, Orlowski RZ, Shpall E, Champlin RE, Qazilbash MH, Nieto YTransplantation and cellular therapyInfluence of Overlapping Genetic Abnormalities on Treatment Outcomes of Multiple Myeloma. Transplant Cell Ther. 2021 03; 27(3):243.e1-243.e6.Transplant Cell Ther2020-12-20T00:00:002020Influence of Overlapping Genetic Abnormalities on Treatment Outcomes of Multiple Myeloma.33792800Wang XS, Shi Q, Mendoza TR, Garcia-Gonzalez A, Chen TY, Kamal M, Chen TH, Heijnen C, Orlowski RZ, Cleeland CSSupportive care in cancer : official journal of the Multinational Association of Supportive Care in CancerMinocycline for symptom reduction in patients with multiple myeloma during maintenance therapy: a phase II placebo-controlled randomized trial. Support Care Cancer. 2021 Oct; 29(10):6099-6107.Support Care Cancer2021-04-01T00:00:002021Minocycline for symptom reduction in patients with multiple myeloma during maintenance therapy: a phase II placebo-controlled randomized trial.33811767Lee HC, Feng L, Oriabure O, Graham V, Chen W, Badillo M, Lu R, Lee HJ, Jain P, Manasanch EE, Orlowski RZ, Wang MLAmerican journal of hematologyA phase one trial of carfilzomib, bendamustine, and dexamethasone in relapsed and/or refractory multiple myeloma. Am J Hematol. 2021 07 01; 96(7):E243-E246.Am J Hematol2021-05-06T00:00:002021A phase one trial of carfilzomib, bendamustine, and dexamethasone in relapsed and/or refractory multiple myeloma.Authorship 10241875Authorship 1024413534190370Makker V, Taylor MH, Oaknin A, Casado Herraez A, Orlowski R, Dutta L, Ren M, Zale M, O'Malley DMThe oncologistCharacterization and Management of Adverse Reactions in Patients with Advanced Endometrial Carcinoma Treated with Lenvatinib Plus Pembrolizumab. Oncologist. 2021 09; 26(9):e1599-e1608.Oncologist2021-07-30T00:00:002021Characterization and Management of Adverse Reactions in Patients with Advanced Endometrial Carcinoma Treated with Lenvatinib Plus Pembrolizumab.34216957Belachew AA, Wu X, Callender R, Waller R, Orlowski RZ, Vachon CM, Camp NJ, Ziv E, Hildebrandt MATCancer epidemiologyGenetic determinants of multiple myeloma risk within the Wnt/beta-catenin signaling pathway. Cancer Epidemiol. 2021 08; 73:101972.Cancer Epidemiol2021-06-30T00:00:002021Genetic determinants of multiple myeloma risk within the Wnt/beta-catenin signaling pathway.Authorship 10248671334249462Cornell RF, Bishop MR, Kumar S, Giralt SA, Nooka AK, Larson SM, Locke FL, Raje NS, Lei L, Dong J, Le Gall JB, Rossi JM, Orlowski RZAmerican journal of cancer researchA phase 1, multicenter study evaluating the safety and efficacy of KITE-585, an autologous anti-BCMA CAR T-cell therapy, in patients with relapsed/refractory multiple myeloma. Am J Cancer Res. 2021; 11(6):3285-3293.Am J Cancer Res2021-06-15T00:00:002021A phase 1, multicenter study evaluating the safety and efficacy of KITE-585, an autologous anti-BCMA CAR T-cell therapy, in patients with relapsed/refractory multiple myeloma.Authorship 10279771734407606Srour SA, Milton DR, Bashir Q, Nieto Y, Saini N, Daher M, Ramdial J, Im J, Hosing C, Delgado R, Manasanch E, Lee HC, Thomas S, Kaufman G, Patel K, Popat U, Weber D, Orlowski R, Shpall E, Champlin RE, Qazilbash MHHaematologicaMelphalan dose intensity for autologous stem cell transplantation in multiple myeloma. Haematologica. 2021 12 01; 106(12):3211-3214.Haematologica2021-12-01T00:00:002021Melphalan dose intensity for autologous stem cell transplantation in multiple myeloma.Authorship 10297321834521108Qazilbash MH, Saini NY, Cha SC, Wang Z, Stadtmauer EA, Baladandayuthapani V, Lin H, Tross B, Honhar M, Rao SS, Kim K, Popescu M, Szymura S, Zhang T, Anderson A, Bashir Q, Shpall EJ, Orlowski RZ, Levine BL, Kerr N, Garfall A, Cohen A, Vogl DT, Dengel K, June CH, Champlin R, Kwak LWBloodA randomized phase 2 trial of idiotype vaccination and adoptive autologous T-cell transfer in patients with multiple myeloma. Blood. 2022 03 03; 139(9):1289-1301.Blood2022-03-03T00:00:002022A randomized phase 2 trial of idiotype vaccination and adoptive autologous T-cell transfer in patients with multiple myeloma.Authorship 10303101834559916Patel R, Ma J, Bashir Q, Delgado R, Rondon G, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Daher M, Mehta R, Srour S, Weber DM, Thomas SK, Lee HC, Patel KK, Orlowski RZ, Shpall ES, Champlin RE, Saini N, Qazilbash MHAmerican journal of hematologyBlack multiple myeloma patients undergoing upfront autologous stem cell transplant have similar survival outcomes compared to Whites: A propensity-score matched analysis. Am J Hematol. 2021 12 01; 96(12):E455-E457.Am J Hematol2021-10-04T00:00:002021Black multiple myeloma patients undergoing upfront autologous stem cell transplant have similar survival outcomes compared to Whites: A propensity-score matched analysis.Authorship 1031550634651428Wang X, Shirazi F, Yan W, Liu X, Wang H, Orlowski RZ, Wang HJournal of cellular and molecular medicineMucin 20 modulates proteasome capacity through c-Met signalling to increase carfilzomib sensitivity in mantle cell lymphoma. J Cell Mol Med. 2021 11; 25(21):10164-10174.J Cell Mol Med2021-10-14T00:00:002021Mucin 20 modulates proteasome capacity through c-Met signalling to increase carfilzomib sensitivity in mantle cell lymphoma.Authorship 103196321Authorship 1031984434686083Gaballa MR, Ma J, Tanner MR, Al-Juhaishi T, Bashir Q, Srour SA, Saini NY, Ramdial JL, Nieto Y, Murphy R, Rezvani K, Tang G, Lee HC, Patel KK, Kaufman GP, Manasanch EE, Ullah MR, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MHLeukemia & lymphomaReal-world long-term outcomes in multiple myeloma with VRD induction, Mel200-conditioned auto-HCT, and lenalidomide maintenance. Leuk Lymphoma. 2022 03; 63(3):710-721.Leuk Lymphoma2021-10-22T00:00:002021Real-world long-term outcomes in multiple myeloma with VRD induction, Mel200-conditioned auto-HCT, and lenalidomide maintenance.34655533Facon T, Kumar SK, Plesner T, Orlowski RZ, Moreau P, Bahlis N, Basu S, Nahi H, Hulin C, Quach H, Goldschmidt H, O'Dwyer M, Perrot A, Venner CP, Weisel K, Mace JR, Raje N, Tiab M, Macro M, Frenzel L, Leleu X, Ahmadi T, Wang J, Van Rampelbergh R, Uhlar CM, Tromp B, Delioukina M, Vermeulen J, Usmani SZThe Lancet. OncologyDaratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2021 11; 22(11):1582-1596.Lancet Oncol2021-10-13T00:00:002021Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial.Authorship 1033380934826777Bennett MK, Li M, Tea MN, Pitman MR, Toubia J, Wang PP, Anderson D, Creek DJ, Orlowski RZ, Gliddon BL, Powell JA, Wallington-Beddoe CT, Pitson SMNeoplasia (New York, N.Y.)Resensitising proteasome inhibitor-resistant myeloma with sphingosine kinase 2 inhibition. Neoplasia. 2022 01; 24(1):1-11.Neoplasia2021-11-23T00:00:002021Resensitising proteasome inhibitor-resistant myeloma with sphingosine kinase 2 inhibition.Authorship 1035183734888496Cheng T, Kiser K, Grasse L, Iles L, Bartholomeusz G, Samaniego F, Orlowski RZ, Chandra JCancer drug resistance (Alhambra, Calif.)Expression of histone deacetylase (HDAC) family members in bortezomib-refractory multiple myeloma and modulation by panobinostat. Cancer Drug Resist. 2021; 4(4):888-902.Cancer Drug Resist2021-09-23T00:00:002021Expression of histone deacetylase (HDAC) family members in bortezomib-refractory multiple myeloma and modulation by panobinostat.Authorship 10367201334992070Patel KK, Shah JJ, Feng L, Lee HC, Manasanch EM, Olsem J, Morphey A, Huo XJ, Thomas SK, Bashir Q, Qazilbash MH, Weber DM, Orlowski RZClinical cancer research : an official journal of the American Association for Cancer ResearchSafety and Efficacy of Combination Maintenance Therapy with Ixazomib and Lenalidomide in Patients with Posttransplant Myeloma. Clin Cancer Res. 2022 04 01; 28(7):1277-1284.Clin Cancer Res2022-04-01T00:00:002022Safety and Efficacy of Combination Maintenance Therapy with Ixazomib and Lenalidomide in Patients with Posttransplant Myeloma.Authorship 103884019Authorship 1041436535242510Cadieux B, Coleman R, Jafarinasabian P, Lipton A, Orlowski RZ, Saad F, Scagliotti GV, Shimizu K, Stopeck AJournal of bone oncologyExperience with denosumab (XGEVA?) for prevention of skeletal-related events in the 10 years after approval. J Bone Oncol. 2022 Apr; 33:100416.J Bone Oncol2022-02-07T00:00:002022Experience with denosumab (XGEVA?) for prevention of skeletal-related events in the 10 years after approval.35331973Afrough A, Pasvolsky O, Ma J, Srour S, Bashir Q, Saini N, Hosing C, Popat UR, Kebriaei P, Delgado R, Ullah MR, Murphy R, Manasanch EE, Lee HC, Kaufman GP, Patel KK, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MHTransplantation and cellular therapyImpact of Induction With VCD Versus VRD on the Outcome of Patients With Multiple Myeloma After an Autologous Hematopoietic Stem Cell Transplantation. Transplant Cell Ther. 2022 06; 28(6):307.e1-307.e8.Transplant Cell Ther2022-03-22T00:00:002022Impact of Induction With VCD Versus VRD on the Outcome of Patients With Multiple Myeloma After an Autologous Hematopoietic Stem Cell Transplantation.Authorship 10445213135472167Mohan M, Becnel MR, Shah UA, Dong H, Gundarlapalli S, Peterson T, Orozco JS, Horowitz S, Chhabra S, Dhakal B, Thanendrarajan S, Radhakrishnan SV, Al Hadidi S, Tan C, Mailankody S, Hultcrantz M, Korde N, Hassoun H, Lesokhin AM, Thomas SK, Patel KK, Manasanch EE, Weber DM, Szabo A, Kaufman GP, Lee HC, Zangari M, van Rhee F, Usmani SZ, D'Souza A, Orlowski RZ, Schinke CAmerican journal of hematologyClinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multi-institutional experience. Am J Hematol. 2022 07; 97(7):E276-E280.Am J Hematol2022-05-02T00:00:002022Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multi-institutional experience.Authorship 10452742635523847Gaballa MR, Ma J, Rauf M, Bassett R, Pasvolsky O, Tanner MR, Bashir Q, Srour SA, Saini N, Ramdial J, Nieto Y, Murphy R, Rezvani K, Tang G, Lin P, Lee HC, Patel KK, Ullah MR, Kaufman GP, Manasanch EE, Kebriaei P, Thomas SK, Weber DM, Shpall EJ, Champlin RE, Orlowski RZ, Qazilbash MHBone marrow transplantationKRD vs. VRD as induction before autologous hematopoietic progenitor cell transplantation for high-risk multiple myeloma. Bone Marrow Transplant. 2022 07; 57(7):1142-1149.Bone Marrow Transplant2022-05-06T00:00:002022KRD vs. VRD as induction before autologous hematopoietic progenitor cell transplantation for high-risk multiple myeloma.Authorship 104646918Authorship 10466851735621632Ndacayisaba LJ, Rappard KE, Shishido SN, Ruiz Velasco C, Matsumoto N, Navarez R, Tang G, Lin P, Setayesh SM, Naghdloo A, Hsu CJ, Maney C, Symer D, Bethel K, Kelly K, Merchant A, Orlowski R, Hicks J, Mason J, Manasanch EE, Kuhn PCurrent oncology (Toronto, Ont.)Enrichment-Free Single-Cell Detection and Morphogenomic Profiling of Myeloma Patient Samples to Delineate Circulating Rare Plasma Cell Clones. Curr Oncol. 2022 04 21; 29(5):2954-2972.Curr Oncol2022-04-21T00:00:002022Enrichment-Free Single-Cell Detection and Morphogenomic Profiling of Myeloma Patient Samples to Delineate Circulating Rare Plasma Cell Clones.35605883Afrough A, Alsfeld LC, Milton DR, Delgado R, Popat UR, Nieto Y, Kebriaei P, Oran B, Saini N, Srour S, Hosing C, Cheema FH, Ahmed S, Manasanch EE, Lee HC, Kaufman GP, Patel KK, Weber DM, Orlowski RZ, Pinnix CC, Dabaja BS, Thomas SK, Champlin RE, Shpall EJ, Qazilbash MH, Bashir QTransplantation and cellular therapyLong-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma. Transplant Cell Ther. 2023 04; 29(4):264.e1-264.e9.Transplant Cell Ther2022-05-20T00:00:002022Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma.Authorship 10470671835653112Davies FE, Pawlyn C, Usmani SZ, San-Miguel JF, Einsele H, Boyle EM, Corre J, Auclair D, Cho HJ, Lonial S, Sonneveld P, Stewart AK, Bergsagel PL, Kaiser MF, Weisel K, Keats JJ, Mikhael JR, Morgan KE, Ghobrial IM, Orlowski RZ, Landgren CO, Gay F, Caers J, Chng WJ, Chari A, Walker BA, Kumar SK, Costa LJ, Anderson KC, Morgan GJBlood cancer discoveryPerspectives on the Risk-Stratified Treatment of Multiple Myeloma. Blood Cancer Discov. 2022 07 06; 3(4):273-284.Blood Cancer Discov2022-07-06T00:00:002022Perspectives on the Risk-Stratified Treatment of Multiple Myeloma.Authorship 10475171135660812Richardson PG, Jacobus SJ, Weller EA, Hassoun H, Lonial S, Raje NS, Medvedova E, McCarthy PL, Libby EN, Voorhees PM, Orlowski RZ, Anderson LD, Zonder JA, Milner CP, Gasparetto C, Agha ME, Khan AM, Hurd DD, Gowin K, Kamble RT, Jagannath S, Nathwani N, Alsina M, Cornell RF, Hashmi H, Campagnaro EL, Andreescu AC, Gentile T, Liedtke M, Godby KN, Cohen AD, Openshaw TH, Pasquini MC, Giralt SA, Kaufman JL, Yee AJ, Scott E, Torka P, Foley A, Fulciniti M, Hebert K, Samur MK, Masone K, Maglio ME, Zeytoonjian AA, Nadeem O, Schlossman RL, Laubach JP, Paba-Prada C, Ghobrial IM, Perrot A, Moreau P, Avet-Loiseau H, Attal M, Anderson KC, Munshi NC, DETERMINATION InvestigatorsThe New England journal of medicineTriplet Therapy, Transplantation, and Maintenance until Progression in Myeloma. N Engl J Med. 2022 07 14; 387(2):132-147.N Engl J Med2022-06-05T00:00:002022Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma.Authorship 1048090635700034Macauda A, Clay-Gilmour A, Hielscher T, Hildebrandt MAT, Kruszewski M, Orlowski RZ, Kumar SK, Ziv E, Orciuolo E, Brown EE, F?rsti A, Waller RG, Machiela MJ, Chanock SJ, Camp NJ, Rymko M, Razny M, Cozen W, V?rkonyi J, Piredda C, Pelosini M, Belachew AA, Subocz E, Hemminki K, Rybicka-Ramos M, Giles GG, Milne RL, Hofmann JN, Zaucha JM, Vangsted AJ, Goldschmidt H, Rajkumar SV, Tomczak W, Sainz J, Butrym A, Watek M, Iskierka-Jazdzewska E, Buda G, Robinson DP, Jurczyszyn A, Dudzinski M, Martinez-Lopez J, Sinnwell JP, Slager SL, Jamroziak K, Reis RMV, Weinhold N, Bhatti P, Carvajal-Carmona LG, Zawirska D, Norman AD, Mazur G, Berndt SI, Campa D, Vachon CM, Canzian FCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive OncologyDoes a Multiple Myeloma Polygenic Risk Score Predict Overall Survival of Patients with Myeloma? Cancer Epidemiol Biomarkers Prev. 2022 09 02; 31(9):1863-1866.Cancer Epidemiol Biomarkers Prev2022-09-02T00:00:002022Does a Multiple Myeloma Polygenic Risk Score Predict Overall Survival of Patients with Myeloma?Authorship 10625808Authorship 105719025Authorship 105555516Authorship 10575047Authorship 105462021Authorship 10611067Authorship 105876718Authorship 106183815Authorship 105651117Authorship 10571521235940528Pasvolsky O, Milton DR, Rauf M, Tanner MR, Bashir Q, Srour S, Tang G, Saini N, Ramdial J, Masood A, Nieto Y, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MHTransplantation and cellular therapyLenalidomide-Based Maintenance after Autologous Hematopoietic Stem Cell Transplantation for Patients with High-Risk Multiple Myeloma. Transplant Cell Ther. 2022 11; 28(11):752.e1-752.e6.Transplant Cell Ther2022-08-05T00:00:002022Lenalidomide-Based Maintenance after Autologous Hematopoietic Stem Cell Transplantation for Patients with High-Risk Multiple Myeloma.36608305Makker V, Aghajanian C, Cohn AL, Romeo M, Bratos R, Brose MS, Messing M, Dutta L, Dutcus CE, Huang J, Schmidt EV, Orlowski R, Taylor MHJournal of clinical oncology : official journal of the American Society of Clinical OncologyA Phase Ib/II Study of Lenvatinib and Pembrolizumab in Advanced Endometrial Carcinoma (Study 111/KEYNOTE-146): Long-Term Efficacy and Safety Update. J Clin Oncol. 2023 02 10; 41(5):974-979.J Clin Oncol2023-01-06T00:00:002023A Phase Ib/II Study of Lenvatinib and Pembrolizumab in Advanced Endometrial Carcinoma (Study 111/KEYNOTE-146): Long-Term Efficacy and Safety Update.36082445Dicanio M, Giaccherini M, Clay-Gilmour A, Macauda A, Sainz J, Machiela MJ, Rybicka-Ramos M, Norman AD, Tyczynska A, Chanock SJ, Barington T, Kumar SK, Bhatti P, Cozen W, Brown EE, Suska A, Haastrup EK, Orlowski RZ, Dudzinski M, Garcia-Sanz R, Kruszewski M, Martinez-Lopez J, Beider K, Iskierka-Jazdzewska E, Pelosini M, Berndt SI, Razny M, Jamroziak K, Rajkumar SV, Jurczyszyn A, Vangsted AJ, Collado PG, Vogel U, Hofmann JN, Petrini M, Butrym A, Slager SL, Ziv E, Subocz E, Giles GG, Andersen NF, Mazur G, Watek M, Lesueur F, Hildebrandt MAT, Zawirska D, Ebbesen LH, Marques H, Gemignani F, Dumontet C, V?rkonyi J, Buda G, Nagler A, Druzd-Sitek A, Wu X, Kadar K, Camp NJ, Grzasko N, Waller RG, Vachon C, Canzian F, Campa DInternational journal of cancerA pleiotropic variant in DNAJB4 is associated with multiple myeloma risk. Int J Cancer. 2023 01 15; 152(2):239-248.Int J Cancer2022-10-01T00:00:002022A pleiotropic variant in DNAJB4 is associated with multiple myeloma risk.36344294Kelkar SS, Prabhu VS, Corman S, Odak S, Rusibamayila N, Macahilig C, Orlowski R, Duska LGynecologic oncologyTreatment patterns and real-world clinical outcomes in patients with advanced endometrial cancer who are microsatellite instability (MSI)-high or are mismatch repair deficient (dMMR) in the United States. Gynecol Oncol. 2023 02; 169:154-163.Gynecol Oncol2022-11-04T00:00:002022Treatment patterns and real-world clinical outcomes in patients with advanced endometrial cancer who are microsatellite instability (MSI)-high or are mismatch repair deficient (dMMR) in the United States.36362214Ndacayisaba LJ, Rappard KE, Shishido SN, Setayesh SM, Tang G, Lin P, Matsumoto N, Hsu CJ, Nevarez R, Velasco CR, Naghdloo A, Yang E, Kelly K, Hicks J, Mason J, Orlowski RZ, Manasanch EE, Kuhn PInternational journal of molecular sciencesCharacterization of BCMA Expression in Circulating Rare Single Cells of Patients with Plasma Cell Neoplasms. Int J Mol Sci. 2022 Nov 03; 23(21).Int J Mol Sci2022-11-03T00:00:002022Characterization of BCMA Expression in Circulating Rare Single Cells of Patients with Plasma Cell Neoplasms.36123927Torres HA, Angelidakis G, Jiang Y, Economides M, Mustafayev K, Yibirin M, Orlowski R, Champlin R, Verstovsek S, Raad IMedicineSerologic versus molecular testing for screening for hepatitis C virus infection in patients with hematologic malignancies. Medicine (Baltimore). 2022 Sep 16; 101(37):e30608.Medicine (Baltimore)2022-09-16T00:00:002022Serologic versus molecular testing for screening for hepatitis C virus infection in patients with hematologic malignancies.35612971Yonemori K, Yunokawa M, Ushijima K, Sakata J, Shikama A, Minobe S, Usami T, Enomoto T, Takehara K, Hasegawa K, Yamagami W, Yamamoto K, Han S, Dutta L, Orlowski R, Miura T, Makker V, Fujiwara KCancer scienceLenvatinib plus pembrolizumab in Japanese patients with endometrial cancer: Results from Study 309/KEYNOTE-775. Cancer Sci. 2022 Oct; 113(10):3489-3497.Cancer Sci2022-07-26T00:00:002022Lenvatinib plus pembrolizumab in Japanese patients with endometrial cancer: Results from Study 309/KEYNOTE-775.36599114Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, Rabin N, Orlowski RZ, Suzuki K, Plesner T, Yoon SS, Ben Yehuda D, Richardson PG, Goldschmidt H, Reece D, Ahmadi T, Qin X, Garvin Mayo W, Gai X, Carey J, Carson R, Moreau PJournal of clinical oncology : official journal of the American Society of Clinical OncologyOverall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial. J Clin Oncol. 2023 03 10; 41(8):1590-1599.J Clin Oncol2023-01-04T00:00:002023Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial.36646323Pasvolsky O, Gaballa MR, Milton DR, Masood A, Sami SS, Tanner MR, Bashir Q, Srour S, Saini N, Ramdial J, Nieto Y, Tang G, Lin P, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MHTransplantation and cellular therapyAutologous Stem Cell Transplantation for Patients with Multiple Myeloma with Translocation (4;14): The MD Anderson Cancer Center Experience. Transplant Cell Ther. 2023 04; 29(4):260.e1-260.e6.Transplant Cell Ther2023-01-14T00:00:002023Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Translocation (4;14): The MD Anderson Cancer Center Experience.36494017Chhabra S, Callander N, Watts NL, Costa LJ, Thapa B, Kaufman JL, Laubach J, Sborov DW, Reeves B, Rodriguez C, Chari A, Silbermann R, Anderson LD, Bal S, Dhakal B, Nathwani N, Shah N, Medvedova E, Bumma N, Holstein SA, Costello C, Jakubowiak A, Wildes TM, Schmidt T, Orlowski RZ, Shain KH, Cowan AJ, Dholaria B, Cornell RF, Jerkins JH, Pei H, Cortoos A, Patel S, Lin TS, Usmani SZ, Richardson PG, Voorhees PMTransplantation and cellular therapyStem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials. Transplant Cell Ther. 2023 03; 29(3):174.e1-174.e10.Transplant Cell Ther2022-12-06T00:00:002022Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials.Authorship 10639861236797154Shank BR, Primeaux B, Yeung EK, Horowitz SB, Lee IY, Roccograndi L, Feng L, Kaufman GP, Lee HC, Manasanch EE, Patel KK, Orlowski RZ, Weber DM, Becnel MR, Thomas SKClinical lymphoma, myeloma & leukemiaHyperfractionated Cyclophosphamide and Dexamethasone Alone or in Combination with Daratumumab and/or Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma: A Single-Center Retrospective Analysis. Clin Lymphoma Myeloma Leuk. 2023 04; 23(4):279-290.Clin Lymphoma Myeloma Leuk2022-12-10T00:00:002022Hyperfractionated Cyclophosphamide and Dexamethasone Alone or in Combination with Daratumumab and/or Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma: A Single-Center Retrospective Analysis.Authorship 10657551636916461Pasvolsky O, Saliba RM, Masood A, Mohamedi AH, Tanner MR, Bashir Q, Srour S, Saini N, Ramdial J, Nieto Y, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MHBritish journal of haematologyImpact of gender on outcomes of patients with multiple myeloma undergoing autologous Haematopoietic stem cell transplant. Br J Haematol. 2023 05; 201(4):e37-e41.Br J Haematol2023-03-14T00:00:002023Impact of gender on outcomes of patients with multiple myeloma undergoing autologous Haematopoietic stem cell transplant.Authorship 10673671536990279Jelloul FZ, Quesada AE, Yang RK, Li S, Wang W, Xu J, Tang G, Yin CC, Fang H, El Hussein S, Khoury J, Bassett RL, Garcia-Manero G, Manasanch EE, Orlowski RZ, Qazilbash MH, Patel KP, Medeiros LJ, Lin PModern pathology : an official journal of the United States and Canadian Academy of Pathology, IncClinicopathologic Features of Therapy-Related Myeloid Neoplasms in Patients with Myeloma in the Era of Novel Therapies. Mod Pathol. 2023 06; 36(6):100166.Mod Pathol2023-03-27T00:00:002023Clinicopathologic Features of Therapy-Related Myeloid Neoplasms in Patients with Myeloma in the Era of Novel Therapies.Authorship 10678522Authorship 10689131637111346Ray U, Orlowski RZPharmaceuticals (Basel, Switzerland)Antibody-Drug Conjugates for Multiple Myeloma: Just the Beginning, or the Beginning of the End? Pharmaceuticals (Basel). 2023 Apr 14; 16(4).Pharmaceuticals (Basel)2023-04-14T00:00:002023Antibody-Drug Conjugates for Multiple Myeloma: Just the Beginning, or the Beginning of the End?37058687Makker V, Colombo N, Casado Herr?ez A, Monk BJ, Mackay H, Santin AD, Miller DS, Moore RG, Baron-Hay S, Ray-Coquard I, Ushijima K, Yonemori K, Kim YM, Guerra Alia EM, Sanli UA, Bird S, Orlowski R, McKenzie J, Okpara C, Barresi G, Lorusso DJournal of clinical oncology : official journal of the American Society of Clinical OncologyLenvatinib Plus Pembrolizumab in Previously Treated Advanced Endometrial Cancer: Updated Efficacy and Safety From the Randomized Phase III Study 309/KEYNOTE-775. J Clin Oncol. 2023 06 01; 41(16):2904-2910.J Clin Oncol2023-04-14T00:00:002023Lenvatinib Plus Pembrolizumab in Previously Treated Advanced Endometrial Cancer: Updated Efficacy and Safety From the Randomized Phase III Study 309/KEYNOTE-775.Authorship 107088720Authorship 10695644Authorship 1069563637212518Li N, Lin P, Zuo Z, You MJ, Shuai W, Orlowski R, Manasanch EE, Li S, Xu J, Garces S, Jelloul FZ, Tang Z, Wang W, Medeiros LJ, Yin CCCancer medicinePlasma cell myeloma with RAS/BRAF mutations is frequently associated with a complex karyotype, advanced stage disease, and poorer prognosis. Cancer Med. 2023 07; 12(13):14293-14304.Cancer Med2023-05-22T00:00:002023Plasma cell myeloma with RAS/BRAF mutations is frequently associated with a complex karyotype, advanced stage disease, and poorer prognosis.37212642Facon T, Kumar SK, Plesner T, Orlowski RZ, Moreau P, Bahlis N, Basu S, Nahi H, Hulin C, Quach H, Goldschmidt H, Perrot A, Weisel K, Raje N, Macro M, Frenzel L, Leleu X, Wang J, Rampelbergh RV, Uhlar CM, Vermeulen J, Duran J, Borgsten F, Usmani SZFuture oncology (London, England)Plain language summary of the MAIA study of daratumumab plus lenalidomide and dexamethasone for the treatment of people with newly diagnosed multiple myeloma. Future Oncol. 2023 Apr; 19(13):887-895.Future Oncol2023-05-22T00:00:002023Plain language summary of the MAIA study of daratumumab plus lenalidomide and dexamethasone for the treatment of people with newly diagnosed multiple myeloma.37137874Pasvolsky O, Milton DR, Rauf M, Ghanem S, Masood A, Mohamedi AH, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Tang G, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Rezvani K, Champlin R, Shpall EJ, Lin P, Qazilbash MHBlood cancer journalImpact of clonal plasma cells in autografts on outcomes in high-risk multiple myeloma patients. Blood Cancer J. 2023 05 03; 13(1):68.Blood Cancer J2023-05-03T00:00:002023Impact of clonal plasma cells in autografts on outcomes in high-risk multiple myeloma patients.Authorship 107307918Authorship 107262528Authorship 1072397437311413Dang M, Wang R, Lee HC, Patel KK, Becnel MR, Han G, Thomas SK, Hao D, Chu Y, Weber DM, Lin P, Lutter-Berka Z, Berrios Nolasco DA, Huang M, Bansal H, Song X, Zhang J, Futreal A, Moreno Rueda LY, Symer DE, Green MR, Rojas Hernandez CM, Kroll M, Afshar-Khargan V, Ndacayisaba LJ, Kuhn P, Neelapu SS, Orlowski RZ, Wang L, Manasanch EECancer cellSingle cell clonotypic and transcriptional evolution of multiple myeloma precursor disease. Cancer Cell. 2023 06 12; 41(6):1032-1047.e4.Cancer Cell2023-06-12T00:00:002023Single cell clonotypic and transcriptional evolution of multiple myeloma precursor disease.37376789Pasvolsky O, Marcoux C, Milton DR, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Lee HC, Patel KK, Kebriaei P, Tewari P, Crawford-Suber L, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MHBritish journal of haematologyOutcomes of young adults (aged?=?40?years) with newly diagnosed multiple myeloma after up-front autologous stem cell transplant. Br J Haematol. 2023 08; 202(4):866-873.Br J Haematol2023-06-27T00:00:002023Outcomes of young adults (aged?=?40?years) with newly diagnosed multiple myeloma after up-front autologous stem cell transplant.37377890Shah PD, Huang AC, Xu X, Orlowski R, Amaravadi RK, Schuchter LM, Zhang P, Tchou J, Matlawski T, Cervini A, Shea J, Gilmore J, Lledo L, Dengel K, Marshall A, Wherry EJ, Linette GP, Brennan A, Gonzalez V, Kulikovskaya I, Lacey SF, Plesa G, June CH, Vonderheide RH, Mitchell TCCancer research communicationsPhase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma. Cancer Res Commun. 2023 05; 3(5):821-829.Cancer Res Commun2023-05-09T00:00:002023Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma.Authorship 10750361837461327Pasvolsky O, Milton DR, Masood A, Sami SS, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Saeed A, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MHAmerican journal of hematologySingle-agent lenalidomide maintenance after upfront autologous stem cell transplant for newly diagnosed multiple myeloma: The MD Anderson experience. Am J Hematol. 2023 10; 98(10):1571-1578.Am J Hematol2023-07-17T00:00:002023Single-agent lenalidomide maintenance after upfront autologous stem cell transplant for newly diagnosed multiple myeloma: The MD Anderson experience.Authorship 107841619Authorship 10777978Authorship 107884117Authorship 1078286937723227Setayesh SM, Ndacayisaba LJ, Rappard KE, Hennes V, Rueda LYM, Tang G, Lin P, Orlowski RZ, Symer DE, Manasanch EE, Shishido SN, Kuhn PNPJ precision oncologyTargeted single-cell proteomic analysis identifies new liquid biopsy biomarkers associated with multiple myeloma. NPJ Precis Oncol. 2023 Sep 18; 7(1):95.NPJ Precis Oncol2023-09-18T00:00:002023Targeted single-cell proteomic analysis identifies new liquid biopsy biomarkers associated with multiple myeloma.37646702Richardson PG, Trudel S, Popat R, Mateos MV, Vangsted AJ, Ramasamy K, Martinez-Lopez J, Quach H, Orlowski RZ, Arnao M, Lonial S, Karanes C, Pawlyn C, Kim K, Oriol A, Berdeja JG, Rodr?guez Otero P, Casas-Avil?s I, Spirli A, Poon J, Li S, Gong J, Wong L, Lamba M, Pierce DW, Amatangelo M, Peluso T, Maciag P, Katz J, Pourdehnad M, Bahlis NJ, CC-92480-MM-001 Study InvestigatorsThe New England journal of medicineMezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2023 Sep 14; 389(11):1009-1022.N Engl J Med2023-08-30T00:00:002023Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma.37673125Pasvolsky O, Ghanem S, Milton DR, Masood A, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MHTransplantation and cellular therapyOutcomes of Autologous Stem Cell Transplantation in Patients with Ultra-High-Risk Multiple Myeloma. Transplant Cell Ther. 2023 Dec; 29(12):757-762.Transplant Cell Ther2023-09-04T00:00:002023Outcomes of Autologous Stem Cell Transplantation in Patients with Ultra-High-Risk Multiple Myeloma.37708911Voorhees PM, Sborov DW, Laubach J, Kaufman JL, Reeves B, Rodriguez C, Chari A, Silbermann R, Costa LJ, Anderson LD, Nathwani N, Shah N, Bumma N, Efebera YA, Holstein SA, Costello C, Jakubowiak A, Wildes TM, Orlowski RZ, Shain KH, Cowan AJ, Dinner S, Pei H, Cortoos A, Patel S, Lin TS, Usmani SZ, Richardson PGThe Lancet. HaematologyAddition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial. Lancet Haematol. 2023 Oct; 10(10):e825-e837.Lancet Haematol2023-09-11T00:00:002023Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial.Authorship 10800521637753818Damron EP, Qazilbash MH, Fang PQ, Wu SY, Dabaja BS, Rondon G, Hosing C, Champlin RE, Bashir Q, Shpall EJ, Knafl MK, Lee HC, Manasanch EE, Patel K, Thomas SK, Orlowski RZ, Weber DM, Pinnix CC, Gunther JRTransplantation and cellular therapyRadiation Therapy Can Be Safely Incorporated into Pretransplantation Treatment Regimens for Patients with Multiple Myeloma. Transplant Cell Ther. 2023 01; 29(1):37.e1-37.e7.Transplant Cell Ther2022-10-29T00:00:002022Radiation Therapy Can Be Safely Incorporated into Pretransplantation Treatment Regimens for Patients with Multiple Myeloma.Authorship 10845308Authorship 1084408338030317Espinoza-Gutarra MR, Aiello J, Orlowski RZ, Ailawadhi SThe Lancet. HaematologyClinical trial design change implementation for inclusive studies. Lancet Haematol. 2023 Dec; 10(12):e953-e954.Lancet Haematol2023-12-01T00:00:002023Clinical trial design change implementation for inclusive studies.38048391Spencer A, Moreau P, Mateos MV, Goldschmidt H, Suzuki K, Levin MD, Sonneveld P, Orlowski RZ, Yoon SS, Usmani SZ, Weisel K, Reece D, Ahmadi T, Pei H, Mayo WG, Gai X, Carey J, Bartlett JB, Carson R, Dimopoulos MABlood advancesDaratumumab for patients with myeloma with early or late relapse after initial therapy: subgroup analysis of CASTOR and POLLUX. Blood Adv. 2024 01 23; 8(2):388-398.Blood Adv2024-01-23T00:00:002024Daratumumab for patients with myeloma with early or late relapse after initial therapy: subgroup analysis of CASTOR and POLLUX.Authorship 108554110Authorship 108564017Authorship 1085158838067393Tang G, Wu Y, Lin P, Toruner GA, Hu S, Li S, Qazilbash MH, Orlowski RZ, Ye C, Xu J, Nahmod KA, Medeiros LJ, Tang ZCancersCytogenetic Profile in Monoclonal Gammopathy of Undetermined Significance, Smoldering and Symptomatic Multiple Myeloma: A Study of 1087 Patients with Highly Purified Plasma Cells. Cancers (Basel). 2023 Dec 02; 15(23).Cancers (Basel)2023-12-02T00:00:002023Cytogenetic Profile in Monoclonal Gammopathy of Undetermined Significance, Smoldering and Symptomatic Multiple Myeloma: A Study of 1087 Patients with Highly Purified Plasma Cells.38070713Fang P, Pinnix CC, Wu SY, Lee HC, Patel KK, Saini N, Becnel MR, Kaufman G, Thomas SK, Orlowski RZ, Amini B, Lin P, Dabaja BS, Gunther JRInternational journal of radiation oncology, biology, physicsManagement and Outcomes of Patients with Refractory Solitary Plasmacytoma after Treatment with Definitive Radiation Therapy. Int J Radiat Oncol Biol Phys. 2023 Dec 08.Int J Radiat Oncol Biol Phys2023-12-08T00:00:002023Management and Outcomes of Patients with Refractory Solitary Plasmacytoma after Treatment with Definitive Radiation Therapy.38127583Pasvolsky O, Pasyar S, Bassett RL, Khan HN, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MHCancerImpact of pretransplant minimal residual disease in patients with multiple myeloma and a very good partial response or better receiving autologous hematopoietic stem cell transplantation. Cancer. 2023 Dec 21.Cancer2023-12-21T00:00:002023Impact of pretransplant minimal residual disease in patients with multiple myeloma and a very good partial response or better receiving autologous hematopoietic stem cell transplantation.Authorship 10865092038199987Pasvolsky O, Ghanem S, Milton DR, Rauf M, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Tang G, Aljawai Y, Khan HN, Kebriaei P, Lee HC, Patel KK, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MHBlood cancer journalOutcomes of patients with multiple myeloma and 1q gain/amplification receiving autologous hematopoietic stem cell transplant: the MD Anderson cancer center experience. Blood Cancer J. 2024 01 10; 14(1):4.Blood Cancer J2024-01-10T00:00:002024Outcomes of patients with multiple myeloma and 1q gain/amplification receiving autologous hematopoietic stem cell transplant: the MD Anderson cancer center experience.Authorship 108711616Authorship 10871141238242888Sun F, Cheng Y, Wanchai V, Guo W, Mery D, Xu H, Gai D, Siegel E, Bailey C, Ashby C, Al Hadidi S, Schinke C, Thanendrarajan S, Ma Y, Yi Q, Orlowski RZ, Zangari M, van Rhee F, Janz S, Bishop G, Tricot G, Shaughnessy JD, Zhan FNature communicationsBispecific BCMA/CD24 CAR-T cells control multiple myeloma growth. Nat Commun. 2024 Jan 19; 15(1):615.Nat Commun2024-01-19T00:00:002024Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth.38242717Makker V, Taylor MH, Aghajanian C, Cohn AL, Brose MS, Simone CD, Cao ZA, Suttner L, Loboda A, Cristescu R, Jelinic P, Orlowski R, Dutta L, Matsui J, Dutcus CE, Minoshima Y, Messing MJJournal for immunotherapy of cancerEvaluation of potential biomarkers for lenvatinib plus pembrolizumab among patients with advanced endometrial cancer: results from Study 111/KEYNOTE-146. J Immunother Cancer. 2024 01 19; 12(1).J Immunother Cancer2024-01-19T00:00:002024Evaluation of potential biomarkers for lenvatinib plus pembrolizumab among patients with advanced endometrial cancer: results from Study 111/KEYNOTE-146.Authorship 10876732838260385Singh RK, Jones RJ, Shirazi F, Qin L, Zou J, Hong S, Wang H, Lee HC, Patel KK, Wan J, Choudhary RK, Kuiatse I, Pahl A, Orlowski RZResearch squareNovel Anti-B-cell Maturation Antigen Alpha-Amanitin Antibody-drug Conjugate HDP-101 Shows Superior Activity to Belantamab Mafodotin and Enhanced Efficacy in Deletion 17p Myeloma Models. Res Sq. 2024 Jan 11.Res Sq2024-01-11T00:00:002024Novel Anti-B-cell Maturation Antigen Alpha-Amanitin Antibody-drug Conjugate HDP-101 Shows Superior Activity to Belantamab Mafodotin and Enhanced Efficacy in Deletion 17p Myeloma Models.Authorship 10900137Authorship 10902911838439082Wang X, Shi Y, Shi H, Liu X, Liao A, Liu Z, Orlowski RZ, Zhang R, Wang HJournal of experimental & clinical cancer research : CRMUC20 regulated by extrachromosomal circular DNA attenuates proteasome inhibitor resistance of multiple myeloma by modulating cuproptosis. J Exp Clin Cancer Res. 2024 Mar 05; 43(1):68.J Exp Clin Cancer Res2024-03-05T00:00:002024MUC20 regulated by extrachromosomal circular DNA attenuates proteasome inhibitor resistance of multiple myeloma by modulating cuproptosis.38448009Alzahrani K, Pasvolsky O, Wang Z, Milton DR, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Lee HC, Patel KK, Manasanch EE, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin R, Qazilbash MHBritish journal of haematologyImpact of revised International Staging System 2 risk stratification on outcomes of patients with multiple myeloma receiving autologous haematopoietic stem cell transplantation. Br J Haematol. 2024 Mar 06.Br J Haematol2024-03-06T00:00:002024Impact of revised International Staging System 2 risk stratification on outcomes of patients with multiple myeloma receiving autologous haematopoietic stem cell transplantation.true1Assistant ProfessorAssistant Professortrue1ProfessorProfessortrue1Associate ProfessorAssociate Professortrue1Associate ProfessorAssociate Professortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessor